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Résumé 
La bursite infectieuse aviaire (IBD) est une des causes majeures de pertes 
économiques pour l’industrie  aviaire. La vaccination est le principal outil de contrôle de 
cette maladie et les oiseaux susceptibles doivent être vaccinés  aussitôt que le niveau des 
anticorps maternels (MA) anti-IBDV est suffisamment bas. L’estimation du moment de 
vaccination est habituellement déterminée par la formule de Deventer qui utilise le titre 
initial de MA anti-IBDV et la demi-vie des anticorps pour prédire l’évolution du titre. 
Dans la présente étude, l’effet du gain de poids sur la vitesse de disparition des MA a été 
étudié dans le but de l’utiliser pour prédire la détermination du moment de la 
vaccination. L’analyse des taux d’anticorps neutralisants par ELISA a montré que les 
poussins avec une forte croissance avaient un taux de disparition plus rapide des MA 
que ceux à faible croissance. Une formule pour la prédiction du moment de vaccination 
contre le IBDV, basée sur le gain de poids et le niveau des MA a été développée et 
vérifiée. La prédiction du moment de vaccination avec cette formule a montré une haute 
corrélation avec les titres de MA mesurés par ELISA. 
Le virus de l’anémie infectieuse aviaire (CIAV) est une cause importante 
d’immunosuppression chez le poulet augmentant la pathogénicité des infections 
secondaires et en entraînant une réponse humorale suboptimale et une forte mortalité. 
D’autre part, l’infections sub-clinique du au CIAV provoque une immunosuppression 
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qui facilite la coinfection par d’autre virus tel que le IBDV. Les effets de la coinfection à 
J1 avec une souche vaccinale de CIAV CAV-VAC® (Intervet) et à J14 avec une souche 
faiblement virulente de IBDV isolée au Québec, sur l’état de santé des poussins, sur la 
persistance virale et sur la réponse immunitaire ont été étudiés autant chez des poussins 
de 1 jour d’âge exempts d’agents pathogènes specifique (SPF) que ceux provenant 
d’élevages commerciaux. Les résultats ont montré que l’inoculation de la souche 
vaccinale du CIAV a entraîné une infection sub-clinique, une persistance virale dans la 
rate et le thymus, une altération de la thymopoièse et une réponse humorale temporaire 
chez  les poussins SPF. Ces effets ont aussi été mis en évidence chez des poussins 
d’élevage commerciaux malgré des taux élevés de MA. Lors de l’infection avec la 
souche de IBDV chez des poussins déjà vaccinés contre le CIAV, la persistance du 
CIAV dans les organes lymphoïdes a été aggravée par une présence de réponses 
humorales temporaires contre les deux virus et une altération des populations 
lymphocytaires dans les organes lymphoïdes. Par contre, la présence des MA contre le 
CIAV a limité temporairement ces effets. Ces travaux ont mis en évidence des désordres 
immunitaires cellulaires et humoraux et une persistance virale chez des poussins 
vaccinés contre le CIAV et co-infectés avec le IBDV. 
Mots-clés : Poulet, la bursite infectieuse aviaire, virus infectieux d'anémie de 
poulet, coinfection, persistance viral, immuno-désordres, CAV-VAC®, sous-populations 
de lymphocyte, anticorps maternel, temps de vaccination. 
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Abstract 
Infectious bursal disease (IBD) is one of the major causes of economic losses in 
the chicken industry. Vaccination is the main tool against the disease, and the 
susceptible birds should be vaccinated as soon as the maternal antibody (MA) becomes 
low enough to allow the vaccine to break through. Estimation of vaccination time is 
currently performed by Deventer formula which uses initial anti-IBDV titer and 
antibody half-life to predict the titer. Considering the increased growth rate of chicken in 
the last decades and the wide variations of MA, we have examined the effects of chick’s 
weight gain on MA decline and the use of weight in predicting IBD vaccination time. 
The virus neutralization test and ELISA results demonstrated that fast-growing birds had 
a faster rate of antibody decline whereas slow-growing birds demonstrated a slower rate. 
Based on the effect of weight-gain on maternal antibody decline, a new formula for 
predicting IBD vaccination time was introduced and tested. The predicted IBD 
vaccination time made by this weight formula showed higher correlation with the 
measured ELISA titers in the experiment. 
Chicken infectious anemia virus (CIAV) is another cause of immunosuppression 
in chicken which is characterized by increased pathogenicity of secondary infectious 
agents, sub-optimal antibody responses and mortality. CIAV subclinical infections can 
result in immunosuppression and enhancement of pathogenicity of co-infecting agents 
such as infectious bursal disease virus (IBDV). Effects of pathogenic CIAV and IBDV 
coinfection on chick’s health and immune responses are investigated in different studies. 
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In this study, newly hatched specific pathogen free (SPF) and commercial chicks were 
vaccinated with CAV-VAC® (Intervet) vaccine and /or inoculated with a low-virulent 
Québec isolate of IBDV at 14 days post CIAV vaccination. 
Inoculation of the CIAV vaccinal strain at hatch resulted in subclinical infection 
associated with viral persistency in spleen and thymus, alteration of thymopoiesis and 
transient humoral response in SPF chicks. Subclinical infection, viral persistency and 
lack of antibody responses were also shown in CIAV inoculated commercial chicks with 
high MA. Infection of the low-virulent IBDV in the CIAV vaccinated SPF chicks lead to 
extended viral persistence of CIAV in lymphoid organs, transient immune responses to 
both CIAV and IBDV, and alteration of lymphocytes subpopulation in the lymphoid 
organs. In the coinfected commercial chicks, presence the CIAV in the lymphoid organs 
was controlled by MA in the first 1-2 weeks after hatch. Thereafter, the immune 
disorders, viral persistence and lack of humoral responses almost similar to the 
coinfected SPF chicks were recorded. 
Keywords :  
Chicken, Infectious bursal disease, Chicken infectious anemia virus, Coinfection, 
Viral persistence, Immuno-disorders, CAV-VAC®, Lymphocyte subpopulations,  
Maternal antibody, Vaccination time. 
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 Introduction 
Infectious bursal disease (IBD) has been one of the most important avian viral 
diseases since its first appearance about 50 years ago, and continues to pose its threat to 
the poultry industry worldwide. It is well known as an acute and highly contagious viral 
infection of 3-6 weeks old chickens that induces lymphoid cell apoptosis and poor 
immune responses which results in immunosuppression. Clinical disease is generally 
observed in birds over 3 weeks of age while the subclinical form occurs at younger ages. 
The significance of disease is considered paramount not only because of the mortality 
and economic losses caused by the infection in the birds of 3 weeks and older, but also 
the induced immunosuppression in younger chicks which leads to compromised immune 
responses against other micro-organisms and vaccines.  
The degree of immunosuppression depends on the maternal antibody (MA) status, 
the age at the time of infection, and the virulence of virus strain. Vaccination is the main 
tool for the prevention and control of IBDV in the poultry industry. In the first days of 
life, chicks are protected by MA transferred from immunized hens, which should be 
followed by vaccination with live attenuated or killed vaccine to establish their active 
immunity and maintain the protective level of anti-IBDV antibody titers. High levels of 
neutralizing MA protect chicks against early infection and immunosuppression, but they 
can also interfere with the development of active immunity to vaccine virus. If the 
vaccine is administered too early, it will be neutralized by the residual MA, and if it is 
administered too late, the wild virus may infect the birds in advance. Therefore, the birds 
should be vaccinated as soon as the level of MA becomes low enough to allow the 
vaccine to break through. Since more than 2 decades, estimation of vaccination time and 
2 
 
 
the breakthrough titer is performed by Deventer formula, which uses initial anti-IBDV 
titer and antibody half-life to predict the titer at any given ages. Considering the 
increased growth rate of chicken in the last decades, the wide variations of antibody 
decline rates and observations based on 20 years regional flocks serology results 
perfromed in our laboratory, we hypothesized that there should be another important 
factor involved in the chicks antibody decline rate. 
The first experiment in this study, examines the effects of chick weight gain on MA 
decline and the use of weight rather than age in predicting Gumboro disease vaccination 
time. This was performed by comparison of MA decline rate in groups of experimental 
birds with different growth rate and initial anti-IBDV titers. 
Chicken infectious anemia virus (CIAV) was first isolated in 1979 by Yuasa et al. 
The virus is transmitted vertically and horizontally. The disease induced by CIAV is 
characterized by aplastic anemia, generalized lymphoid atrophy, skin lesion, 
haemorrhages, immunosuppression, increased pathogenicity of secondary infectious 
agents, sub-optimal antibody responses and mortality in chicks younger than 3 weeks. 
These clinical or subclinical features are the results of virus replication and apoptosis of 
hemacytoblasts in bone marrow and T cell precursors in thymus of infected chicks. Also, 
the negative impacts of CIAV infection in older birds, particularly on the generation of 
pathogen-specific cytotoxic T lymphocytes (CTL) to other pathogens, suggest that CIAV 
infection can facilitate the development of other diseases. After infection with CIAV, 
antibodies are produced in immunologically mature chickens which prevent lesions 
development. Because of the age-related resistance to clinical disease which is antibody-
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mediated, the birds of 3 weeks and older do not show clinical signs. However, subclinical 
infections can result in immunosuppression, reductions in immune response to vaccines 
and enhancement of pathogenicity of co-infecting agents such as infectious bursal disease 
virus (IBDV). The attenuated CIAV strains are commercially used as vaccine but some 
technical and practical problems affect the widespread use of vaccines. Considering 
ubiquitous and contagious nature of CIAV, infection of newly hatched chicks with CAV-
VAC® (Intervet, Delaware, USA) vaccine virus used in the industry or other attenuated 
strains of the virus is expected. However, it is not known if the commercial vaccinal 
strains have retained the ability to induce immune disorders which is seen with the 
pathogenic strain. 
Chicken infectious anemia and infectious bursal disease are both categorized as 
non-oncogenic immunosuppressive viral diseases that are of high economic importance. 
Different pathogenic and non-pathogenic strains of IBDV are circulating in the poultry 
farms. The effects of pathogenic CIAV and IBDV coinfection on chick’s health, immune 
responses, severity of the diseases and their recovery are investigated in different studies. 
Lower responses of lymphocytes to mitogens, prolong acute phase prior to recovery or 
mortality, increased CIAV’s infectivity and persistence, inhibition of virus neutralizing 
antibody production to CIAV, increased mortality rate, more severe tissue damage and 
lower weight gain are well documented as the consequences of pathogenic CIAV and 
IBDV coinfection. The non-pathogenic strains which do not cause clinical form of IBD 
may affect birds' immune responses in a non-visible degree. 
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In the second experiment of this study, specific pathogen free (SPF) chicks were 
vaccinated with CAV-VAC® at hatch. The presence of clinical signs and anemia, the 
vaccine virus distribution and persistence, lymphocyte subpopulations in lymphoid 
organs, antibody response and some blood parameters in groups of CIAV vaccinated and 
control birds were investigated at various times up to 28 days post-vaccination. 
In the third experiment, the effects of CAV-VAC® vaccine virus along with a low-
virulent strain of IBDV in the SPF chicks were investigated. By infection with live 
attenuated CIAV vaccine virus at hatch followed by a low-virulent IBDV inoculation at 
14 days post-hatch, possible accumulative effects of these immunosuppressive viruses 
are examined.  
Considering the importance of MA in the prevention of the disease and viral 
replication in very young chickens, the same experimental design and assay was planned 
and performed on commercial chicks. Experiments 4 and 5 of this study were performed 
on commercial chicks with MA to CIAV and IBDV, and the effects of early inoculation 
of CAV-VAC® vaccine, and infection of a low-virulent IBDV isolate on CAV-VAC® 
vaccinated birds were examined. 
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Chapter 1. Literature Review 
1.1. Infectious Bursal Disease 
1.1.1. History and Clinical Disease 
The first IBD cases were reported in the broiler flocks in Gumboro, in southern 
Delaware, USA in 1957 (Cosgrove, 1962). The disease was described as infectious and 
contagious and more apparent in young chickens. When first recognized, it caused high 
mortality in affected flocks and spread rapidly throughout the Delvarma peninsula and 
other broiler-producing areas (Snedeker, 1967). The disease was initially called; “avian 
nephrosis” because of the renal damage and signs which were very similar to the lesions 
caused by a nephropathic isolate of infectious bronchitis virus. The recurrence and 
persistence of the unknown agent in the affected farms in addition to the ineffectiveness 
of antibiotics in the disease control had raised the idea of a causative agent being a virus. 
Later, it was named “Gumboro disease” referring to its first description in the town of 
Gumboro. 
After the first isolation of the virus by Winterfield (Winterfield et al., 1962) it was 
known as a nephrosis inducing isolate of infectious bronchitis virus (IBV). Edgar and 
Cho designated the syndrome as "infectious bursal disease" in a paper for the first time. 
The term “infectious bursal disease” (IBD) was used again (Hitchner, 1970) and became 
popular thereafter due to pathological changes observed in the bursa of affected chickens. 
They determined that the causative agent was very different from the IBV agent, and also 
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suggested the proper route of inoculation in susceptible embryos for successful virus 
isolation. 
The IBDV is omnipresent in all chicken producing countries, very stable in the 
environment, and resistant to a variety of chemical and physical agents. Chicken is 
known as the only avian species susceptible to the disease and to show clinical symptoms 
while the serological evidences of infection have been documented in other species such 
as turkey, duck, guinea fowl and ostrich (McNulty M. S., 1979; Lukert and Saif, 1997, 
2003). 
The serotype one includes all pathogenic virus strains in chicken and serotype 2 
strains are avirulent (Saif, 1998). Different factors and elements are involved in the 
severity of the disease including age, breed and maternal or acquired immunity of the 
birds as well as the virus strain and dosage (Muller et al., 2003). Signs of depression, 
diarrhea, anorexia, ruffled feathers and mortality appear in the affected birds after a short 
incubation period. 
A wide range of mortality rate from 1 to 50% is reported in classical form of the 
outbreaks. In broilers, IBDV infection may result in high morbidity rates, but mortality is 
mostly less than 3% in 3-6 weeks old flocks (Muller et al., 2003). Therefore, clinical or 
subclinical disease may occur and infection at early age, or subclinical disease will be 
followed by immunosuppression which may depress both humoral and cell-mediated 
immune responses. With the emergence of acute IBD in Europe about 20 years ago, more 
severe form of the disease with higher mortality rates and economic losses were caused 
by the described very virulent (vv) infectious bursal disease viruses (vvIBDV) (Chettle et 
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al., 1989b; Van den berg et al., 1991). Even though the pathogenesis of the disease is not 
well understood, different investigations on lymphoid organs of infected birds revealed 
that some mechanisms such as more severe inflammatory responses, related cytokines 
secretion, apoptosis, and necrosis are involved in the severity of the vvIBD. So far, 
vvIBD caused by these very virulent strains has been reported in some European, Asian, 
South American and African countries. 
IBD viruses are able to infect lymphoid cells and produce clinical or subclinical 
disease in chicken.  The virus is ubiquitous and highly contagious and highly resistant to 
environmental exposure that spread by direct contact between infected and susceptible 
chickens mainly via the oral route. Indirect transmission of the agent may occur on 
fomites, through airborne dissemination of virus-laden feathers and poultry house dust 
(Lasher and Shane, 1994). Susceptibility of different breeds has been described with 
higher mortality rates in light than in heavier breeds (Bumstead et al., 1993; Van der 
berg, 2000). Nielson et al (1998) showed that the meat-type chicken line was more 
resistant to IBDV infection than the layer-type line, and differed in mortality rate, liver to 
body weight ratio and erythrocyte sedimentation rate (ESR) (Nielsen et al., 1998).  
1.1.2. IBDV Classification 
The causative agent which is called “infectious bursal disease virus” (IBDV) is a 
member of Avibirnavirus genus of the Birnaviridae family.  After the isolation of IBDV, 
intensive investigations were conducted to determine the virus properties and 
classification. Dobos et al (1979) showed that IBDV of chickens, infectious pancreatic 
necrosis virus of fish, and drosophila X virus consisted of naked icosahedral virus 
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particles and possess diameter of 58 to 60 nm and could not be classified as a reovirus or 
any other known virus genus at that time (Nick et al., 1976; Dobos et al., 1979). The 
genome of each of these new viruses is made of two segments of double-stranded RNA 
(Dobos et al., 1979; Muller et al., 1979; Macdonald, 1980). In 1986 and 2000, the 
International Committee on Taxonomy of Viruses (ICTV) reviewed the updated 
knowledge and designated 3 genera in the new recognized birnaviridae family; 
Avibirnavirus, Aquabirnavirus, and Entomobirnavirus which their host species are 
chicken, fish and Drosophila X (insect), respectively. Recent ICTV committee in 2009 
created the 4th genus, Blosnavirus (BSNV), in the Birnaviridae family (ICTV, 2009). 
Blosnavirus, an aquatic birnavirus, has been isolated from cultured cells originating from 
a tropical fish, the Blotched Snakehead fish (Channa lucius). BSNV is serologically 
unrelated to Infectious Pancreatic Necrosis Virus (IPNV), the type species of the genus 
Aquabirnavirus (Da Costa et al., 2003). 
1.1.3. Morphology and Chemical composition 
IBDV is a non-enveloped double-stranded RNA (dsRNA) virus with icosahedral 
symmetry and two segments designated A and B in the genome. The sedimentation rate 
of IBDV in sucrose gradients is 460S. The buoyant density of mature complete virus 
particles in caesium chloride gradients ranges from 1.31 to 1.33 g/ml. Incomplete virus 
particles have buoyant densities lower than 1.33 g/ml. Electron microscopy and SDS-
PAGE analysis have shown that the prominent band seen at 1.33 g/ml density contained 
the complete particle with typical appearance of IBDV. The 1.32 and 1.31 g/ml buoyant 
densities related bands contain particles with relatively small amount of dsRNA or no 
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RNA, respectively. The buoyant density of 1.29 g/ml which is commonly seen when the 
virus is grown in chicken embryo fibroblast (CEF) cultures demonstrates incomplete 
virus particle, irregular shape and poor assembly, different polypeptide pattern and 
unusual amount of dsRNA. Different polypeptide pattern and less related incomplete 
band are observed when the viruses are recovered from the bursa of Fabricius (Kibenge 
et al., 1988). 
The capsid is composed of 32 capsomers with a T=13 lattice and diameter of 60 to 
70 nm, in which its outer part has 780 subunits that are clustered in 260 trimers, and the 
inner layer of the capsid appears as 200 Y-shaped features. The outer trimers are made of 
the structural protein VP2, and contain the neutralizing epitopes. The inner trimers 
correspond to the viral protein VP3, which contains four group-specific antigenic 
determinants, two serotype-specific epitopes (Mahardika and Becht, 1995), a basic C-
terminal region that interacts with the viral RNA (VP1 binding domain), and a domain 
with capsid assembly function (Chevalier et al., 2004). The presence of four proteins 
VP1, VP2, VP3 and VP4 is needed for capsid morphogenesis of birnaviruses (Chevalier 
et al., 2004). 
1.1.4. Viral genome 
The larger segment A of IBDV has 3400 bp and contains one large and one small 
open reading frames (ORF) in which the larger monocistronic ORF encodes for a 
polyprotein VP243 in the order of NH2-pVP2-VP4-VP3-COOH that is later auto-
processed and cleaved into the precursor VP2 (pVP2) and VP3 capsid proteins by VP4 
(Muller and Becht, 1982; Azad et al., 1985), whereas the second ORF of segment A 
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which is a partially overlapping ORF encodes for a small protein, VP5, a non-structural 
protein (NSP) of 17 kD (Mundt et al., 1995). The 45-50 kD pVP2 is further processed at 
its C-terminus to become VP2 through the cleavage of three alanine-alanine bonds 
(positions 487 to 488, 494 to 495, and 501 to 502) and an alanine-phenylalanine bond 
(positions 441 to 442) (Da Costa et al., 2002). The controlling role of VP3 in correct 
assembly in final processing of pVP2 to VP2 is shown (Chevalier et al., 2002). The small 
segment B is composed of 2800 bp and encodes for VP1which is contained within the 
viral particle (van den Berg, 2000) and interacts with VP3 (Tacken et al., 2000). There 
are some non-coding regions in both segments of A and B which resemble other dsRNA 
viruses. Any possible role of these non-coding regions and highly conserved motifs 
which are found in both segments are not clearly understood (Mundt and Muller, 1995).  
It is shown that the IBDV RNA is RNase resistant and has a sedimentation 
coefficient of 14S and a buoyant density of 1.62 g/ml (Muller et al., 1979; Spies et al., 
1987). The purine/pyrimidine ratio is nearly 1; the guanine plus cytosine content is 
55.3%; the Tm is 95.5° C. The molecular weights of 2.2 x 106 and 1.93 x 106 were 
determined for two double-stranded segments (Muller and Nitschke, 1987). The same 
molecular weights of viral proteins are reported in serotype 1 and 2 isolates (Jackwood et 
al., 1984; Becht et al., 1988), therefore it is not possible to differentiate between strains 
of serotype 1 and 2 viruses based on differences in structural proteins. Later it was 
demonstrated that IBDV of both serotypes are able to bind to bursal as well as cultivated 
cells (Nieper and Muller, 1996). By generation of chimeras in genome segment A of the 
two serotypes, it is revealed that this binding does not seem to be sufficient for 
productive infection (Schroder et al., 2001). 
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1.1.4.1. VP1 
VP1 is a 90 kD viral protein encoded by the small segment (B) of the IBDV 
genome. Its RNA-dependent RNA polymerase activity and also its role in genome 
replication and mRNA synthesis have been demonstrated (Spies et al., 1987; Tacken et 
al., 2000). This multifunctional enzyme was shown to be linked to 5- end of the RNA 
genome and closely associated with transcription (Spies and Muller, 1990). The presence 
of the VP1-VP3 complex in IBDV-infected cells was confirmed by co-
immunoprecipitation studies that show the complex of VP1 and VP3 is formed in the 
cytoplasm and eventually is released into the cell-culture medium, indicating that VP1-
VP3 complexes are present in mature virions. Recently, the VP1 involvement in “in vivo 
modulation of virulence” and  the efficiency of viral replication was demonstrated (Liu 
and Vakharia, 2004). 
1.1.4.2. VP2 and VP3 
 In serotype 1 viruses, the VP2 and VP3 constitute 51% and 40% of the virus 
proteins, respectively; whereas VP1 (3%) and VP4 (6%) are minor proteins. The external 
and inner surfaces of the virion are built by trimeric sub-units of VP2 and VP3, 
respectively (Van den berg, 2000). Deletion mapping studies suggest that (Azad et al., 
1987) the conformational epitope recognized by the virus neutralizing monoclonal 
antibody is present within VP2. 
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There is evidence that the antigenic region responsible for the production of 
neutralizing antibodies is highly conformation-dependent. Passively administered 
neutralizing antibodies directed against the 40kD structural polypeptide (VP2) of Cu-1 
strain confer protective immunity to susceptible chickens, whereas antibodies directed 
against the 32kD structural protein (VP3) do not have any protective effect. The VP2 also 
has epitopes which do not induce neutralizing antibodies and which are common to both 
strains of serotype 1 and 2. The group specific antigens and serotype specific antigens are 
located in VP2 and VP3 proteins, respectively (Becht et al., 1988). The nucleotide 
sequence analysis of the large open reading frame (ORF) from segment A of three 
European and one Australian strains of IBDV determined a variable region in VP2 which 
corresponded to the region where binding of a neutralizing monoclonal antibody had 
previously been mapped (Bayliss et al., 1990). In a study of IBDV conformational 
epitopes, a random heptapeptide screened by monoclonal antibodies directed to the VP2 
protein identified two peptide motifs which are present on the N and C terminal 
sequences of the highly variable region (Wang et al., 2005). 
It was demonstrated that VP1 binds to VP3 through an internal domain, while VP3 
interacts with VP1 solely by its carboxy-terminal 10 amino acids. RNase treatments and 
reverse transcription-PCR analyses of the immunoprecipitates demonstrated that VP3 
interacts with dsRNA of both viral genome segments. This interaction is not mediated by 
the carboxyterminal domain of VP3 since C-terminal truncations of 1, 5, or 10 residues 
did not prevent formation of the VP3-dsRNA complexes. VP3 seems to be the key 
organizer of birnavirus structure, as it maintains critical interactions with all components 
of the viral particle: itself, VP2, VP1, and the two genomic dsRNAs (Tacken et al., 2002) 
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1.1.4.3. VP4 
The 28kD VP4 is a viral protease (Spies et al., 1987; Jagadish et al., 1988). Using 
cDNA fragments containing site-specific mutations monoclonal antibodies (Jagadish et 
al., 1988), and also deleting mapping studies of the large segment of the genome (Azad et 
al., 1987), it was demonstrated that the VP4 protein is involved in processing of the 
precursor polyprotein to generate VP2 and VP3. Therefore, the previous theory about the 
possibility of internal initiation for the generation of VP3 was excluded. 
1.1.4.4. VP5 
 VP5 is a 21kD non-structural protein of IBDV whose function is not clearly 
established, but it has been suggested that it might have a regulatory function playing a 
role in virus release and dissemination. Yao et al. (1998) created a mutant of IBDV, D78 
strain, with deleted VP5 using a reverse genetics system. The mutant induced apoptosis 
in a reduced number of infected CEF cells compared with the parental strain and 
replicated more slowly than the parental strain. They suggested that the 17kD NSP is 
dispensable for viral replication in vitro and in vivo and may play a role in viral 
pathogenesis (Yao et al., 1998). 
1.1.5. Antigenic Types of IBDV 
Since the discovery of IBDV, different classification systems based on phenotypic 
or molecular genetic procedures have been developed to classify the virus isolates. The 
phenotypic method of virus serotyping correlates successfully to the protection studies. 
Based on updated knowledge, Lukert and Saif (2003) well reviewed the important 
procedures used for strain classification of IBDV isolates, and described the antigenic, 
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immunogenicity or protective, and molecular genetic typing procedures. Three antigenic 
types of  IBDV are well known; serotype 1 classic (standard), serotype 1 variant, and 
serotype 2 viruses. 
The IBDV isolate from turkeys have been reported to be  essentially identical to the 
chicken strains, but the turkey isolates were not pathogenic and could be distinguished by 
neutralization (McNulty M. S., 1979; Jackwood et al., 1982); therefore, a second 
serotype was established (McFerran et al., 1980). McFerran et al (1980) studied a 
number of isolates and strains of infectious bursal disease (IBD) virus from fowl, turkeys 
and ducks and demonstrated the antigenic variations among IBDV isolates of European 
origin. Therefore, the isolates could be grouped into two serotypes using the 
neutralisation test. They presented evidence for the existence of two serotypes, 
designated 1 and 2, and showed only 30% relatedness between several strains of the two 
serotypes. This might attribute to the fact that immunization against serotype 2 does not 
protect against serotype 1. The reverse situation where immunized birds against serotype 
1 to be protected against serotype 2 viruses cannot be tested because no virulent serotype 
2 viruses are available for challenge. Virus-neutralization (VN) tests is used to 
differentiate 2 serotypes but other serological tests such as enzyme-linked 
immunosorbent assay (ELISA) and fluorescent antibody (FA) are applicable only for 
diagnosis purposes and not for serotyping.  
Variant type viruses were introduced based on cross-neutralization tests and the 
reports that new isolates are antigenically different from commercial vaccine strains. 
These isolates belonged to serotype 1, but the vaccines used against classic strains of 
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serotype 1 did not protect the infected birds. In the affected broiler or commercial layer 
chickens there were high levels of MA against the virus and bursal lesions at the same 
time (Ismail et al., 1990). Jackwood and Saif  studied 13 serotype 1 IBDV strains from 
vaccines or field strains using cross-neutralization test and determined 6 antigenic 
subtypes in which all variant strains included in the one subtype (Jackwood and Saif, 
1987(Jackwood and Saif, 1987). 
 In 1988, an outbreak of  acute IBD occurred in broilers in east of England (Chettle 
et al., 1989a). This was the first report of new emerging virulent virus strain which later 
spread rapidly in some other European and Asian countries and named very virulent 
IBDV which was difficult to control using available vaccines (Van den berg et al., 1991; 
Eterradossi et al., 1992; Wyeth et al., 1992; Tsukamoto et al., 1995). Different studies 
conducted on isolated strains from Europe demonstrated that these strains are similar and 
belong to classic serotype 1 viruses. 
Immunogenicity or protective typing is based on cross-protection studies in live 
birds. Cross-examination of challenge and VN tests on classic and/or variant viruses of 
serotype 1 is feasible, whereas this method of virus typing does not apply to serotype 2 
viruses due to lack of clinical signs. Therefore, there are only 2 protective types; classic 
and variant groups, both of which belong to serotype 1 viruses (Lukert and Saif, 2003). 
More investigation on IBDV revealed the pathogenesis, and also the morphological 
and histopathological changes left in BF, cecal tonsils, spleen, harderian glands and 
thymus of infected birds (Cheville et al., 1978; Dohms et al., 1981; Helmboldt, 1964; 
Okoye, 1990; Sharma et al., 1989; Survashe, 1979; Winterfield et al., 1972). In 1972, the 
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first report about the immunosuppressive nature of the virus was published (Allan et al, 
1972). In the late 1970, simultaneous research was conducted on different field isolates 
of the virus to produce an effective IBD vaccine. Winterfield modified a field isolate, 
which is called as Winterfield 2512, and used it for vaccine production. Moultrop and 
Snedeker team introduced the first licensed IBDV vaccine in 1967. It was made by 
adaptation of a field isolate in chicken embryo system which was commercialized and 
named Bursa Vac® (Snedeker, 1967). 
1.1.6. Pathogenesis and Immunosuppression 
The outcome of an IBDV infection largely depends on the strain and the amount of 
the infecting virus, the age and the breed of the birds, the route of inoculation, and the 
presence or absence of neutralizing antibodies (Muller et al., 2003). The virus targets and 
destroys IgM-bearing bursal cells (Ivanyi and Morris, 1976; Hirai and Calnek, 1979; 
Hirai et al., 1981) and causes an acute immunosuppressive disease in chicken. Surviving 
birds become more susceptible to other infectious agents with reduced ability to respond 
to the vaccines (Allan et al., 1972; Muller et al., 2003).  
The severity of the disease is directly related to the number of susceptible cells 
present in the BF; therefore, the highest age susceptibility is between 3 and 6 weeks, 
when the BF is at its maximum development. This age susceptibility is broader in the 
case of vvIBDV strains (Van der berg, 2000). The immunosuppression caused by the 
virus may be permanent at earlier ages close to hatch resulting in greater pathogenic and 
economic risks.  
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The IBDV replication leads to destruction of lymphoid cells in the BF and to a 
lesser extent in other lymphoid organs such as cecal tonsils and spleen (Van der berg, 
2000). Even though there is no evidence of IBDV replication in thymic cells, many 
pathologic changes, atrophy and apoptosis occur in the thymus of affected birds (Sharma 
et al., 2000). Classic and vvIBDV strains cause hemorrhagic inflammation of the BF, 
whereas variant strains (GLS and E/Del) cause rapid bursal atrophy without evoking an 
inflammation response, suggesting differences in the pathogenesis of the disease (Liu and 
Vakharia, 2006). 
It is noted that the macrophages could play a specific role in the IBDV pathology 
by  exacerbated release of cytokines such as tumor necrosis factor (TNF)-α and 
interleukin 6  (IL6), as it is observed in acute coccidiosis induced septic shock syndrome 
(Van der berg, 2000). The role of T helper (Th) cells and increased secretion of interferon 
(IFN)-α in the activation of macrophages are shown in vivo and in vitro after IBDV 
infection of live chicken, and chicken embryo culture, respectively.  
Histologic evidence of infection in the bursa was detected within 24 hours. In 
sequential studies of tissues from orally infected chickens using immunofluorescence, 
viral antigen was detected in macrophages and lymphoid cells in the cecum at 4 hours 
after inoculation; an hour later, virus was detected in lymphoid cells in the duodenum and 
jejunum (Saif and Eterradossi, 2008). After entry of the virus through the gut, it first 
reaches the liver, where it is detected 5 hours post-inoculation. It then enters the 
bloodstream, where it is distributed to other tissues including the bursa. By 13 h post-
inoculation, most of the bursal follicles are positive for the virus. The bursal infection is 
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followed by a second massive viremia by 16h post-inoculation which may result in 
disease and death. The virus infection will result in cytolysis, which leads to a dramatic 
reduction in circulating IgM+B cells, as the main IBDV target cells. Other cells, for 
instance monocytes and macrophages can play a role in dissemination of the virus 
(Khatri et al., 2005). A few hours after infection, the virus can be detected in the kidneys 
and liver, however, the primary viral replication takes place in BF (Kibenge et al., 1988; 
Sharma et al., 2000). The virus peak titer in the non-lymphoid organs is several log10 
lower than in the bursa and limited to the viremic period (Saif and Eterradossi, 2008). 
In a study performed by Peters et al (2006), the effects of IBDV polyprotein on 
suppression of bursal B lymphocyte growth and their capacity for proliferation was 
examined with either the classical STC or variant E strains of the virus. The polyprotein 
VP243 DNA construct induced suppression of proliferation for bursal lymphocytes 
independent of the virus infection. The expression of the mature viral proteins VP2, VP4 
or VP3 did not change the rate of cell proliferation or response of B cell cultures to 
mitogen. Their results suggested that IBDV polyprotein is a mediator of 
immunosuppression (Peters et al., 2006). 
Previous studies had shown that classic IBDV serotype 1 virus strains induce a 
transient viremia and infectious virus may be recovered from a variety of organs during 
7–10 days of viremic phase. However, infectious serotype 1 virus could be recovered 
from BF up to 16 days post-infection. Commercial broilers inoculated at 1 day of age 
with E/Del variant strain of IBDV had the recoverable virus in their bursa, bone marrow 
up to 4 weeks post-inoculation (Elankumaran et al., 2002). Furthermore, the persistence  
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of the virus in bursal tissue up to 3 weeks after experimental infection was shown in the 
absence of MA in SPF chicks (Abdel-Alim and Saif, 2001). These indicate that variant 
strains of IBDV may be present in commercial broilers longer than previously thought, 
and cecal tonsils and bone marrow may serve as non-bursal lymphoid tissues supporting 
virus replication at a later time after inoculation (Elankumaran et al., 2002). 
1.1.6.1. Molecular basis of Virulence 
There have been many studies that examine presence and location of IBDV 
receptor on susceptible cells. While it has become obvious that variable region of VP2 
contains amino acids that represent the molecular basis for antigenic variation, no 
definite hot spots or related sequences that determine pathogenicity has been identified 
(Van der berg, 2000). Binding studies performed on serotype 1 and 2 strains by Nieper 
and Müller (1996) showed that strains of both IBDV serotypes bind to lymphoid cells 
isolated from the bursa, thymus or spleen. This finding and the fact that apathogenic 
serotype 2 strains do not replicate in lymphoid bursa cells or in other lymphoid cell 
indicate that restriction of IBDV serotype 2 in lymphoid B cells is not determined by the 
presence of specific receptor sites. It was also revealed that chicken embryo fibroblasts 
(CEF) have common receptors to both serotypes and also specific ones for each serotype. 
Receptor sites common to both serotypes were also present on lymphoid cells. Strains of 
both serotypes specifically bound to proteins of 40 kD and 46 kD exposed on the surface 
of CEF and lymphoid cells (Nieper and Muller, 1996). 
In a flow cytometric assay, the binding of IBDV to its target cells on three chicken 
lymphoid cell lines was investigated. The chicken B lymphoblastoid cell line, LSCC-
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BK3, which is permissive for IBDV infection, bound high levels of the virus. Another B 
lymphoblastoid cell line, LSCC-1104-B1, bound low levels of the virus, although it was 
non-permissive. No virus binding was detected in non-permissive T lymphoblastoid cell 
lines. In the binding assay to heterogeneous cell populations of chicken lymphocytes, a 
highly virulent OKYM strain of IBDV bound to 94%, 37%, 3% and 21% of lymphocytes 
prepared from BF, spleen, thymus and blood, respectively. Most of the cells, which 
bound the virus, were surface immunoglobulin M (SIgM)-positive, but a small number of 
them were SIgM-negative. Additionally, the binding of IBDV to the LSCC-BK3 cells 
was affected by treatment of the cells with proteases and N-glycosylation inhibitors. 
Therefore, the IBDV host range may be mainly controlled by the presence of a virus 
receptor composed of N-glycosylated protein associated with the subtle differentiation 
stage of B-lymphocytes represented mostly by SIgM-bearing cells (Ogawa et al., 1998). 
It is known that passage of the virus in cell culture results in the loss of virulence, 
and the genetic basis responsible for the attenuation of IBDV at the molecular level have 
been investigated. Yamaguchi et al. (1996) investigated the IBDV genome segment 
encoding the precursor polyprotein (NH2-VP2-VP4-VP3-COOH) of a cell culture-
adapted OKYMT strain derived from highly virulent OKYM. Comparison of the 
identified nucleotide and deduced amino acid sequences of the attenuated strain with the 
parental virulent OKYM strain revealed only five amino acid differences: four in the VP2 
variable domain and one in the VP3. Two amino acid substitutions at positions 279 (Asp-
->Asn) and 284 (Ala-->Thr) in the VP2 variable domain were commonly predicted in 
another cell culture-adapted strain. These two amino acid changes resulted in reduced 
hydrophilia of this region and deletion of the alpha-helix which might alter the 
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conformation of the virion surface structures. Therefore, it is suggested that the amino 
acid residues at position 279 and 284 in VP2 variable domain contribute to virulence of 
IBDV (Yamaguchi et al., 1996). Other studies have shown possible presence of the 
correspondent ligand of cell receptor on VP2 (Ogawa et al., 1998; Setiyono et al., 2001a) 
which may be related to the presence of virulence factors in the capsid protein. 
Another study reported the identification of proteins of 110, 82 and 70 kD on the 
surface of chicken B lymphoblastoid cell line, (LSCC-BK3) by monoclonal antibodies 
that may be associated with the binding of virulent IBDV. The molecule that interact 
IBDV on the chicken B lymphoblastoid cell line, LSCC-BK3, which is permissive for 
virulent IBDV infection was identified. The IBDV specifically bound to two proteins in 
LSCC-BK3 plasma membrane with molecular weights of 70, 82 and 110 kD (Setiyono et 
al., 2001a; Setiyono et al., 2001b). 
Delgui et al (2009) suggested that the IBDV might use the alpha 4 beta 1 integrin 
as a specific binding receptor in avian cells. They identified a strictly conserved amino 
acid triplet matching the consensus sequence used by fibronectin to bind the alpha 4 beta 
1 integrin within the protruding domain of the IBDV capsid polypeptide. A single point 
mutation on this triplet abolishes the cell-binding activity of IBDV-derived subviral 
particles (SVP), and abrogates the recovering of infectious IBDV by reverse genetics 
without affecting the overall SVP architecture. Additionally, they demonstrated that the 
presence of the alpha 4 beta 1 heterodimer is a critical determinant for the susceptibility 
of murine BALB/c 3T3 cells to IBDV binding and infectivity (Delgui et al., 2009 ). 
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In 2002, the research performed by Yamaguchi et al (2002) raised more questions 
about the possible role of VP2 in target cell binding and infection. A polyclonal anti-
idiotypic antibodies was generated by the sequential immunization of a rabbit with a 
virus-neutralizing monoclonal antibody GI-11 which recognizes the capsid protein VP2 
hypervariable domain. The anti-idiotypic antibodies mimics the conformational epitope 
in the VP2 hypervariable domain. Despite the expectation,  the anti-idiotypic antibodies 
did not interfere with either the virus binding or the infection to the target cell indicating 
that the epitope recognized by GI-11 is not directly involved in the binding of the virus to 
the target cells (Yamaguchi et al., 2002). 
IFA and ELISA analyses of the NSP VP4 expression in pathogenic and non-
pathogenic IBDV infection confirmed serum anti-VP4 antibodies in pathogenic IBDV-
infected rather than non-pathogenic IBDV-infected chickens. Kinetic analysis of anti-
IBDV antibody shows that in the pathogenic IBDV-infected chickens, the antibody to 
VP4 was later detectable than anti-VP3 antibody and virus neutralizing antibody. 
Therefore, it is suggested that VP4 antibody may be used as an indicator discriminating 
pathogenic and non-pathogenic IBDV infection in chickens. They detected the VP4 
antigen mainly in the cortex of bursal follicles in pathogenic IBDV-infected chickens 
(Wang et al., 2009). Therefore, probably IBDV has several sites that will bind to the 
cellular receptors or not depending on unknown variables. 
1.1.6.2. IBDV dependent cytolysis 
IBDV infection also affects the potassium current properties of chicken embryo 
fibroblasts which may result in cytolysis and the death of the infected cells due to 
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alterations of membrane permeability and intracellular ion homeostasis (Repp, et 
al.,1998). Incubation of CEFs with Cu-1 strain of IBDV led to marked changes in their 
K+ outward current properties with respect to both the kinetics of activation and 
inactivation and the Ca2+ dependence of the activation. UV-treated noninfectious virions 
induced the same K+ current changes as live IBDV. When CEFs were inoculated with 
IBDV after pre-treatment with a neutralizing antibody, about 30% of the cells showed a 
normal K+ current, whereas the rest exhibited K+ current properties identical to or 
closely resembling those of IBDV-infected cells. The same effect is already known for 
some other viruses (Repp et al., 1998). It is suggested that the K+ changes are the results 
of attachment and/or penetration and possibly delay the apoptotic process on IBDV 
infected CEF cells. 
Galloux et al., (2007) studied the entry pathway of IBDV and identified a capsid 
associated peptide; pep46, that deforms and induces pores in the host cell membrane as 
visualized by electron microscopy. They also showed that IBD virus infectivity and its 
membrane activity (probably because of the release of pep46 from virions) are controlled 
by calcium concentration, suggesting that entry is performed in two steps, endocytosis 
(endosome formation) followed by alteration of endosome permeability due to the 
lowering of the calcium concentration which in turn promotes the release of pep46. This 
induces the formation of pores in the endosomal membrane in endosomes containing 
viruses (Galloux et al., 2007). 
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1.1.7. Apoptosis 
Apoptosis is the best-characterized form of programmed cell death (PCD). It is a 
crucial component for normal multicellular life, playing a key role in development and 
immunity. This type of cell death is important in lymphocyte development, regulation of 
lymphocyte responses to foreign antigens, and maintenance of tolerance to self-antigens 
(Abbas et al., 2000). It is characterized frequently by chromatin condensation, 
phosphatidylserine exposure, cytoplasmic shrinkage, membrane blebbing and caspase 
activation. As a defence mechanism in response to virus infection, infected host cells 
undergo apoptosis, which occurs at the early stage of viral infection, thus limiting viral 
propagation. Generally, a virus can benefit and may instigate either promotion or 
inhibition of apoptosis. In response to a virus infection, the host produces an array of 
proteins, including cytokines and proteases. Furthermore, the viruses may need to 
influence only a single point of the process to affect the onset or progress of the natural 
cell death program. There are, however, strategies other than simple biochemical 
manipulation that viruses use to overcome the hindering effects of apoptosis (Hay and 
Kannourakis, 2002 ). 
A virus may multiply rapidly to produce many virions before an effective immune 
response can be mounted. This approach is exhibited by most RNA viruses, including 
vesicular stomatitis virus and influenza virus. Another strategy available to viruses is that 
of a cryptic infection. In this situation, a virus may infect a cell and remain undetected, 
thus avoiding host cell destruction and allowing a productive infection. To overcome host 
resistance, many viruses carry anti-apoptotic factors to inhibit apoptosis. Although the 
benefits to a virus in avoiding the apoptotic process are obvious, the onset of PCD, in 
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some cases, provides a means for the dissemination of the virus without initiating a 
concomitant host response, which would follow the release of the progeny into the 
extracellular fluid (Murphy et al., 1999). 
In addition to B cell destruction in the bursa of IBDV infected birds; there is 
evidence of viral replication and associated cellular destruction in other lymphoid organs 
including the thymus, cecal tonsils, and spleen (Ivanyi and Morris, 1976; Hirai et al., 
1981; Rodenberg et al., 1994; Elankumaran et al., 2002). Destruction of the bursal and 
lymphoid cell depletion and even its relation with number of accessible cells is known as 
the main feature of the IBDV infection and pathogenesis (Kaufer and Weiss, 1980; Becht 
and Muller, 1991). On the other hand, IBDV infection of susceptible chickens results in 
the induction of apoptosis in bursal cells. Cell death due to apoptotic processes have been 
shown in IBDV-infected bursa cells (Lam, 1997), chicken peripheral blood lymphocytes, 
IBDV infected Vero cells and chicken embryo (CE) cells (Vasconcelos and Lam, 1994, 
1995; Tham and Moon, 1996). Vasconcelos and Lam (1994) performed In vitro studies 
on chicken peripheral blood lymphocytes and demonstrated the apoptosis of avian 
lymphocytes in IBDV infected samples (Vasconcelos and Lam, 1994). They also 
detected apoptotic nucleosomal DNA fragments in IBDV-infected CEFs that was 
independent of virus replication and occurred at an early stage following in vitro 
infection. The apoptotic signs were more intense in chicken embryo fibroblast than Vero 
cells (Tham and Moon, 1996). Light and electron microscopical examination of the 
IBDV-infected embryonic bursal cells revealed increased number of apoptotic and 
necrotic cells, condensation of nuclear chromatin, crescent formation, nuclear and 
cellular fragmentation, and death of lymphoid cells without surrounding inflammatory 
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reaction, which indicated the infection of chicken embryos with IBDV induced apoptosis 
in bursal lymphoid cells (Vasconcelos and Lam, 1995). 
Based on a surprising finding by Tanimura and Sharma (1998) apoptotic process is 
enhanced by IBDV infection even in antigen negative bursal and thymic cortical 
lymphocytes. They performed in vivo studies on BF and thymus in specific pathogen-free 
(SPF) chickens following inoculation with three strains of infectious bursal disease virus 
(IBDV), including a classical virulent, an antigenic variant-E and an attenuated vaccine 
strain. Appearance of large numbers of apoptotic bursal lymphocytes, both in IBDV 
antigen-positive and antigen-negative bursal follicles were seen in the classical variant 
strain IM-IBDV, and the attenuated vaccine virus B2-IBDV infected birds. This suggests 
that virulent strains and vaccine strains of IBDV enhance endogenous apoptosis of bursal 
lymphocytes that are even free of detectable IBDV antigen. Interestingly, infection of 
chickens with the virulent strain IM-IBDV caused a significant increase in apoptotic cells 
in the thymic cortical lymphocytes which were negative for IBDV antigen (Tanimura and 
Sharma, 1998). 
In recent studies, Jungmann et al (2001) suggested that various mechanisms might 
be involved in the pathogenesis of IBDV. Shortly after infection, cells expressing viral 
antigens seem to be protected from apoptosis to ensure virus replication. This suggests 
inhibition of apoptotic cell death in productively infected cells and might be favourable 
for the virus. Induction of apoptosis in cells in the vicinity of productively infected cells 
might be attributed to antiviral mechanisms of the organism to prevent virus spread. Later 
in infection, productively infected cells also undergo apoptosis which is induced by 
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IBDV replication to release the virus from infected cells (Jungmann et al., 2001). Liu and 
Vakharia (2006) investigated the kinetics of viral replication during a single round of 
viral replication and examined the mechanism of IBDV-induced apoptosis. It was shown 
that IBDV-induced apoptosis is caspase dependent and activates effector caspases 3 and 
9. It also requires nuclear factor kappa B (NF-κB) activation. The NF-κB inhibitor 
MG132, a proteasome inhibitor, completely inhibited IBDV-induced DNA 
fragmentation, caspase 3 activation, and NF-κB activation. In the same research, the 
recombinant rGLS virus and a NSP knockout mutant, rGLSNSΔ viruses were generated 
using reverse genetics. Comparisons of the replication kinetics and markers for virally 
induced apoptosis indicated that the NS knockout mutant virus induces earlier and 
increased DNA fragmentation, caspase activity, and NF-κB activation. These results 
suggest that the NSP has an anti-apoptotic function at the early stage of virus infection 
and apoptosis is detected in the late stage of a single round viral replication. The 
apoptosis occurs at a time when IBDV synthesis is complete and the progenies need to be 
released from infected cells (Liu and Vakharia, 2006). In a more recent study, Liu et al 
(2007) examined the interplay between IBDV replication and the ubiquitin-proteasome 
pathway in cultured cells. It was demonstrated that proteasome inhibitor reduces IBDV 
replication through inhibition of viral RNA transcription and protein synthesis, and thus 
preventing IBDV-induced apoptosis (Liu et al., 2007). 
1.1.8. Immune responses to IBDV infection 
The roles of humoral immune responses are shown in the IBDV infected or 
vaccinated chicks. Field exposure to the virus, or vaccination with either live or killed 
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vaccines stimulates active immunity and result in very high antibody levels (Vakharia et 
al., 1994; Juul-Madsen et al., 2006). Passive transfer of maternal antibodies and its 
effectiveness is also a strong evidence of humoral immunity contribution in IBDV 
protection. Adult birds are resistant to oral exposure to the virus but produce antibody 
after intramuscular or subcutaneous inoculation. The VP2 (40 kD) is known as serotype-
specific antigens that induce VN antibodies and the major antigens that induces 
protection (Bayliss et al., 1991) while antibodies against VP3 do not have any protective 
effect. Interestingly, inactivated and live vaccine made from variant strains protected 
chickens from disease caused by either variant or standard strains, whereas inactivated 
vaccines made from standard strains did not protect, or only partially protected, against 
challenge with variant strains. Based on the study performed on five different subtypes of 
serotype 1, it was suggested that all the subtypes of serotype 1 share a minor antigen(s) 
that elicits protective antibodies. The known immunosuppressive IBDV does not cause 
immunosuppression against its own antigens in chicken, and the response against IBDV 
itself is normal, even in very young chickens. There appears to be a selective stimulation 
of the proliferation of B cells committed to anti-IBDV antibody production (Schat and 
Woods, 2008). 
The effect of IBDV on cell-mediated immune (CMI) responses is transient and less 
obvious than that on humoral responses. However, delayed skin graft, suppression of 
cell-mediated responsiveness, suppression of T cell response to mitogens and transient 
suppression of peripheral blood and spleen lymphocytes from IBDV infected chicks are 
well documented. Peripheral lymphocytes responses to Phytohemagglutinin (PHA) were 
transiently suppressed in all the chickens infected with strains of different virulence i.e. 
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mild (Lukert strain), intermediate (Georgia strain) or invasive intermediate (IV-95 strain) 
(Poonia and Charan, 2004).  
Tanimura and Sharma (1997) demonstrated that infection with IBDV resulted in 
extensive viral replication in the bursa and the cecal tonsils with an associated 
accumulation of T cells. They observed the appearance of viral antigen in the bursa and 
the germinal centers of cecal tonsils accompanied by the presence of CD3+ cells in 
virulent IBDV-infected chickens (Tanimura and Sharma, 1997). Another study suggested 
T cells were needed to control the IBDV-antigen load in the acute phase of infection at 5 
days post-infection.  In the absence of T cell function, the IBDV-induced inflammatory 
responses, incidence of apoptotic bursa cells and expression of cytokines such as IL-2 
and IFN-γ were significantly reduced in comparison to T cell-intact birds. It is noted that 
T cells modulate IBDV pathogenesis in two ways; they limit viral replication in the bursa 
in the early phase of the disease, and promote bursal tissue damage and delay tissue 
recovery possibly through the release of cytokines and cytotoxic effects (Rautenschlein et 
al., 2002a). Pro-inflammatory cytokines such as IL-1β and IL-6, and the cytokines 
produced by T and natural killer (NK) cells, such as IFN-γ, could play a role in IBDV 
immune responses. IFN-γ mRNA was induced by two tested classical and very virulent 
strains, indicating that a cell-mediated response is induced (Eldaghayes et al., 2006). 
Rautenschlein and Sharma (2002b) examined the role of T cells using neonatal 
thymectomy and cyclosporin A treatment. The inactivated IBDV vaccine induced virus 
neutralizing (VN) and ELISA antibodies, respectively, in 65 and 5% of thymectomy and 
cyclosporin A treated, and in 100 and 58% of T cell-intact birds. Therefore, the presence 
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and stimulation of T helper cells is needed for the production of protective antibody 
levels in iIBDV-vaccinated chickens. Additionally, passive administration of VN anti-
IBDV antibodies inducing a circulating antibody level of log2 8 in chickens revealed that 
the levels of antibodies that protected T cell-intact chickens against virulent IBDV 
challenge were not protective for thymectomy and cyclosporin A treated chickens. They 
concluded that antibody alone was not adequate in inducing protection against IBDV in 
chickens and that T cell-involvement was critical for protection (Rautenschlein et al., 
2002b). Unexpectedly, in the presence of B cells destruction and atrophy, the cell-
mediated immunosuppression induced by two IBDV vaccines in SPF birds was not 
associated with altered helper (CT4+CT8-) or cytotoxic (CT8+CT4-) subpopulations of T 
lymphocytes (Corley and Giambrone, 2002). 
The key role of macrophages and its activation due to IBDV infection has been 
demonstrated in different studies. Khatri and Sharma (2006) showed that exposure of 
cultured spleen macrophages from SPF chickens to IBDV resulted in the production of 
nitric oxide (NO). In addition, there was up-regulation of mRNA expression of inducible 
nitric oxide synthase (iNOS), IL-8 and cycloxygenase-2 (COX-2) which is suggested to 
contribute to bursa inflammatory responses commonly seen during the acute IBDV 
infection. The signal transduction pathways involved in the infected macrophage 
activation was determined to be the p38 mitogen-activated protein kinases (MAPK), and 
NF-κB pathway. Production of IBDV-induced NO and mRNA expression of iNOS, IL-8 
and COX-2 were suppressed in the presence of p38 MAPK and NF-κB inhibitors. 
Presence of IBD viral genome and its replication in bursal macrophages were also shown 
in IBDV infection indicating that B cells are not the only target cells of IBD virus. 
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Macrophages have been proposed to serve as virus carriers from the site of infection in 
the gut to the bursa and other peripheral tissues (Khatri et al., 2005).  IBDV infection has 
been shown to stimulate production of IL-6, IL-1, IL-18, chicken myelomonocytic 
growth factor (cMGF) and iNOS in infected macrophages (Kim et al., 1998; Khatri et al., 
2005). Increased cytokine gene expression by macrophages during the acute phase of 
IBDV infection which coincided with in vitro inhibition of T cell mitogenic response of 
spleen cells was reported by Kim et al, (1998). Type I IFN, chicken myelomonocytic 
growth factor (cMGF), avian homologs of mammalian IL-6 and IL-8 genes were 
transiently over expressed following the infection.  
The study performed by Poonia and Charan (2004) on different virus strains 
indicates that substantial infiltration of CD4+ and CD8+ T-cells in the bursal follicles of 
virus-infected groups was observed from 4 days post-inoculation (dpi) onwards. The 
magnitude of T-cell responses in BF during IBDV infection is influenced more by the 
virulence of virus strain rather than the quantum of viral load in the bursa.  
1.1.8.1. Passive immunity and vaccination 
Control of IBD depends on different strategies including enforced sanitary and 
biosecurity measures, and scheduled vaccination of young and mature birds. IBD threats 
against birds’ health include chicks of very young ages in which their active immunity is 
not yet completely functional. Therefore, the onset of infections and damages may occur 
before production and appearance of vaccine induced neutralizing antibodies. The adult 
vaccination results in hen’s hyperimmunization and provides some levels of MA in their 
progeny preventing early clinical and subclinical infections. MA transferred via egg yolk 
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play an essential role in chicks protecting at susceptible ages. The combination of passive 
and active immunity can protect the birds of all ages and provide enough antibodies to be 
transferred to their progeny. Al-Natur et al (2004a) examined the effectiveness of 
different levels of MA against serotype 1 variant virus at one, two and four weeks of 
ages. They demonstrated that chicks with no MA were not protected at any ages while 
the medium levels of MA conferred chick’s protection only at one and two weeks of age. 
In addition, the higher levels of MA protected the chicks challenged at all the ages tested. 
Van Den Berg and Meulemans (1991) obtained different results from their experiments 
and concluded that, even after extensive live vaccination followed by inactivated oil 
emulsion of parent hens, it is not possible to protect the progeny, and prevent bursal 
damages during the whole growing period. 
MA has become an important factor in deciding vaccination policy in the poultry 
industry. Prime boost strategies, using live vaccines followed by inactivated vaccines, are 
utilized to protect the laying hen or breeder from disease throughout the laying period. A 
consequence of this is the transfer of high levels of antibody into the progeny. IgY is 
sequestered across the follicular epithelium of the ovary into the egg yolk by a receptor-
mediated transfer involving specific sequences found on IgY but not on IgM or IgA 
isotypes. The amount of transfer of IgY is correlated with the amount of IgY present in 
the maternal circulation with transfer being delayed for approximately 5–6 days in 
chicken, and 7–8 days in turkeys. IgY in the yolk sac continues to be transferred for at 
least 48 h after hatching, so peak levels of MA are not necessarily at 1 day of age (Schat 
and Skinner, 2008). 
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Since the late 1970s, medical prophylaxis of IBD has been largely based on the use 
of live attenuated vaccines to immunologically prime breeder pullets at an early age, 
followed by inactivated oil-adjuvant vaccines administered at around 10 and 18 wk of 
age. This vaccination protocol results in the generation of high antibody levels in the 
parent flocks, and at the same time, it provides MA to the progeny chicks to ensure their 
protection against IBDV (Box, 1989a; Lasher and Shane, 1994; Eterradossi et al., 1997) 
High levels of neutralizing MA can also interfere with the development of active 
immunity to vaccine virus (Muskett et al., 1979; Kibenge et al., 1988). The timing of 
vaccination in relation to MA levels is thus critical in ensuring adequate replication of the 
vaccine virus and efficacious protection of young chicks from disease (Knoblich et al., 
2000). If the vaccine is administered too early, it will be neutralized by the residual MAs, 
and if it is administered too late, the birds might have already been infected by wild virus. 
It should be noted that wide variation in the level of MA in newly hatched chicks and the 
variation in the rate of antibody decline are reported (Kumar et al., 2000), which makes 
the prediction more and more difficult. Since the appearance of variant strains and very 
virulent strains of the virus, it has become more difficult to formulate a successful 
vaccination program. Broiler chickens cannot be protected by MA during the whole 
growing period, therefore, they should be vaccinated as soon as the level of MA becomes 
low enough to allow the vaccine to break through (breakthrough titer) (Van der berg, 
2000).  
Several formulas for estimating the optimal vaccination time are used in poultry 
production. The first and most frequently used formula was developed by Kouwenhoven 
and revised and renamed as the Deventer formula (de Wit, 1998). The formulas are based 
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on the decline of antibody levels due to immunoglobulin half-life in the chicken. On the 
other hand, the decline of the level of MA varies between types of chicken, and the 
decrease is a factor of the metabolism and the growth rate. The measured half-life time, 
as measured by the VN test, is suggested to be 3 to 3.5 days for broilers, 4.5 days for 
breeders and about 5.5 days for layers (de Wit, 1998). Based on Deventer formula, the 
breakthrough titer can thus be predicted by measuring the level of MA at a young age, 
usually within the first week of life. Prediction of vaccination time can thus be made 
based on initial titer, immunoglobulin half-life, and breakthrough titer, depending on the 
vaccine strain used (de Wit, 1998). 
Because of Deventer formula’s flexibility, which is adjustable to all types of 
chicken, age of sampling, different percentage of flock and vaccines, it can be applied to 
every field situation compared to previous methods. In contrast to other methods, in the 
Deventer formula, the estimation is not based on the mean titer of the flock, but on the 
titer level when a certain percentage of the flock can be successfully vaccinated. This is 
determined to be 75%, as a default percentage, based on field experiences, and allows 
estimations for flocks with both uniform and non-uniform titer distributions. Also, it uses 
previously measured antibody half-life for each chicken type which may result in a better 
prediction of vaccination age (de Wit, 1998). 
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1.2. Chicken Infectious Anemia 
1.2.1. History and clinical disease 
Chicken infectious anemia virus (CIAV) was first isolated in 1979 by Yuasa et al.  
Yuasa group also determined some of the characteristics of the disease including being a 
virus-like agent, resistance to some disinfectants, triggering specific antibodies in 
inoculated chickens and its experimental egg transmission (Yuasa et al., 1979; Yuasa et 
al., 1983a). It was called ‘chicken anemia agent’ for years without knowing about the 
causative agent. Some years earlier, another unknown virus, porcine circovirus, had been 
described in 1974 as a picornavirus-like contaminant without being linked to a disease. 
This agent was named circovirus when it was shown that the genome consisted of 
circular, covalently linked single-stranded DNA. Porcine circovirus had no similarities to 
any other known animal virus, but similar physicochemical properties were found in 
plant pathogens belonging to the geminiviruses. A second serotype of porcine circovirus 
(porcine circovirus 2) has been described that is causing post-weaning multi-systemic 
wasting syndrome in piglets (Schat and Woods, 2008). 
Later, viruses with similar physicochemical characteristics were detected in 
chickens and several psittacine species during the 1980s, notable viruses include 
psittacine beak and feather disease virus (BFDV), CIAV and pigeon circovirus. In an 
outbreak of broiler flock in Japan with haemorrhagic lesions of the muscles, atrophic 
changes of the lymphoid organs and aplastic bone marrow, Yuasa et al (1987) isolated 
the virus and named the disease as haemorrhagic syndrome. In Germany, the disease was 
called as anaemia-dermatitis after observing gangrenous dermatitis, atrophy of thymus, 
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bursa and bone marrow, severe anaemia, and immunosuppression in the outbreaks 
(Vielitz and Landgraf, 1988).  
There were strong evidences of CIAV presence in Japan and United States before 
its first isolation. A retrospective serological survey to determine an approximate 
timeframe for first chicken exposure to CIAV in the south-eastern United States was 
performed in 2006 (Toro et al., 2006). The assessment of serum samples covering the 
time period of 1959 through 1979 resulted in most sera being positive for CIAV 
antibodies showing that CIAV must have been present in the United States long before its 
first isolation in 1989.  
During early years of the virus isolation, Yuasa group succeeded to isolate chicken 
anemia agent (CAA) from anemic chickens in the field by using MDCC - MSB1 cells, 
which was an established cell line derived from Marek's disease lymphoma. When 99 
chickens of 15 flocks were examined, CAA was isolated from 58 chickens of 12 flocks. 
The rate of CAA isolation with MDCC - MSB1 cells was almost the same as that 
determined by an in vivo method of chick inoculation (Yuasa, 1983; Yuasa et al., 1983a). 
The establishment of cell line for the isolation enhanced more research on virus 
characterization and purification, its molecular biology, pathogenesis and development of 
serological methods and vaccines. 
1.2.2. Classification and Characterization 
CIAV is a Gyrovirus belonging to the family Circoviridae. The agent is a non-
enveloped, spherical in outline with icosahedral symmetry. The diameters of 22, 23.5, 25 
and 26.5nm is reported for the virions in different preparations (Todd et al., 1990; 
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Murphy et al., 1999; Schat and Woods, 2008). The genome consists of a single molecule 
of circular (covalently closed end) single- stranded ambisense or positive sense DNA 
(Gelderblom et al., 1989; Murphy et al., 1999). Virus particles banded at a density of 
1.33 to 1-34 g/ml in caesium chloride gradients (Schat and Woods, 2008), while there are 
other findings of 1.35 to 1.36 (Goryo et al., 1987) and 1.36-1.37 g/cm3 (Gelderblom et 
al., 1989). Viral replication occurs in the nucleus and, similar to parvoviruses, probably 
depends on cellular proteins produced during the S phase of the cell cycle. The double 
stranded DNA replicative intermediates are infectious. Replication of the genome is 
believed to occur via a rolling circle that originates at a stem-loop structure. One product 
of CIAV translation is a polyprotein that is cleaved to form 3 mature proteins (Murphy et 
al., 1999). 
The agent is extremely resistant to most treatments (Schat and Woods, 2008), and 
can tolerate heating for 15 min. at 80°C (Schat and Skinner, 2008), 30 min at 60°C, 50% 
chloroform for 15 min at 4°C, and passed through a 25 nm membrane filter. However, it 
was completely inactivated after heating for 30 min at 70°C or more (Goryo et al., 1987). 
Due to its ubiquitous presence in chicken flocks, small size, and resistance to physical 
and chemical treatments, it can be present as a contaminant in other viruses especially if 
these agents are propagated in embryonated chicken eggs. As such it can become a 
confounding factor in studies on immunosuppressive properties of other pathogens (Schat 
and Skinner, 2008). 
Other viruses with similar physicochemical characteristics were detected in 
chickens and several psittacine species later. Psittacine beak and feather disease virus 
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that is associated with feather dystrophy and loss, malformations of the beak and 
immunosuppression, also ClAV, and pigeon circovirus are the most important viruses of 
circoviridae family that infect psittacine, chicken and pigeon, respectively. Although 
these animal circoviruses have similar characteristicstics, there are major differences 
between ClAV on the one hand and psittacine beak and feather disease virus  and 
porcine circoviruses on the other hand. Based on the lack of DNA sequence similarities 
or common antigenic epitopes, replication strategies, and morphological differences, it 
was suggested that ClAV belongs to a separate virus group (Schat and Woods, 2008). 
In the International Congresses of Virology in 1999 and 2009, the taxonomy of the 
Circoviridae was reviewed and changed.  CIAV is assigned as the only member to a new 
genus, Gyrovirus, while porcine circovirus 1, porcine circovirus 2, beak and feather 
disease virus remained as the recognized members of the genus Circovirus. Since then, 
canary, duck, finch, starling, swan and goose Circoviruses are also recognized as species 
in the genus Circovirus (ICTV, 2009). 
1.2.3. Viral genome 
The CIAV DNA sequence has three partially overlapping major reading frames that 
are called ORF1, ORF2 and ORF3 coding for putative peptides of 51.6 (VP1), 24(VP2), 
and 13.6 (VP3) kD, respectively. The CIAV genome contains only one promoter region 
and only one poly(A) addition signal. Southern blot analysis using oligomers derived 
from the CIAV DNA sequence showed that infected cells contained double- and single-
stranded CIAV DNAs, whereas purified virus contained only the minus strand (Noteborn 
et al., 1991). The single promoter region in the cloned genome in chicken T cells was 
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analyzed by Noteborn et al (1994). A unique region containing four or five near-perfect 
direct repeats (DR) of 21 bp with one 12-bp insert was proven to be the main 
transcription-activation element, with enhancer-like characteristics. PCR studies revealed 
that CIAV isolates from across the world all contained this promoter sequence. They 
showed that individual DR units, as well as the 12-bp insert, could bind to nuclear factors 
of chicken T-cells. However, the DR units may bind to factors other than the 12-bp insert 
(Noteborn et al., 1994). 
Miller et al (2005) demonstrated that the single promoter-enhancer region of CIAV 
containing four consensus cyclic AMP response element sequences (AGCTCA), are 
similar to the estrogen response element (ERE) consensus half-sites (AGGTCA). These 
sequences are arranged as direct repeats, an arrangement that can be recognized by 
members of the nuclear receptor superfamily. Their analysis suggests that estrogen 
receptor and other members of the nuclear receptor superfamily may provide a 
mechanism to regulate CIAV activity in situations of low virus copy number (Miller et 
al., 2005). 
Viral genes of CIAV codes for only 3 proteins which are briefly described as 
follow: 
1.2.3.1. VP1 
Only the VP1, a 50 kD capsid protein, is present in purified virus. Alignments of 
the VP1 sequences of some isolates of CIAV revealed a previously unreported 
hypervariable region spanning amino acid positions 139 to 151. Transfer of a 316 bp 
region of CUX-1 strain open reading frame 1 into CIA-1 strain produced a virus with a 
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cytopathogenic profile typical of CUX-1, indicating that one or both of the amino acid 
differences at positions 139 and 144 affect the rate of replication or the spread of 
infection. However, transfection experiments with additional chimeras indicated that the 
inability of CIA-1 to replicate in MDCC-MSB1 cells is mediated by a larger region of the 
genome which contains the hypervariable region in addition to upstream amino acid 
differences (Renshaw et al., 1996). 
Recently, Wang et al (2009) studied the driving force in CIAV evolution; they 
detected positive selection in the structural protein gene VP1 by using maximum-
likelihood models. Evidence was found that the VP1 protein was subjected to the high 
rates of positive selection, and eight sites were identified to be under positive selection in 
which four selected sites (amino acids 75, 125, 141, and 144) might be responsible for 
the attenuation exhibited and one selected site (amino acid 287) was connected with the 
virulence of CIAV (Wang et al., 2009 ). Some of these sites are located in the same 
hypervariable region discussed by Renshaw et al (Renshaw et al., 1996). 
1.2.3.2. VP2 
Similarity of CIAV VP2 amino acid sequence to a number of eukaryotic, receptor, 
protein-tyrosine phosphatase-α  proteins as well as to a cluster of human TT viruses was 
shown by Peters et al (2002). It was also demonstrated that the circoviruses, CIAV and 
TT-like minivirus encode ‘dual specificity protein phosphatases’ with an unusual 
signature motif that may play a role in intracellular signaling during viral replication. 
This was the first dual specificity protein phosphatases gene to be identified in a small 
viral genome (Peters et al., 2002). 
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In a study of immunogenic properties of the CIAV proteins, the coding information 
for three putative proteins (VP1, VP2, VP3) inserted into a baculovirus vector and 
expressed in insect cells. Only lysates of insect cells which included all three 
recombinant CIAV proteins, or mainly VP1 plus VP2 induced neutralizing antibodies 
directed against CIAV in inoculated chickens. Therefore, at least two CIAV proteins, 
VP1 plus VP2, is required to obtain sufficient protection in chickens (Koch et al., 1995). 
Noteborn et al (1998) showed that VP1 and VP2 interact directly with each other, which 
indicates the NSP VP2 might act as a scaffold protein in virion assembly (Noteborn et 
al., 1998 ). 
1.2.3.3. VP3 
The VP3, a NSP, is a CIAV protein of 121 amino acids and contains two proline-
rich stretches and two positively charged regions. It is associated with nuclei in infected 
cells, but not with highly purified virus particles. It is well known that VP3 is a strong 
inducer of apoptosis in chicken lymphoblastoid T cells and myeloid cells, which are 
susceptible to CIAV infection. The results of the immunoassays revealed that VP3 is 
strictly located within the cellular chromatin structures. By immunogold electron 
microscopy, VP3 was shown to be associated with apoptotic structures. In vitro 
expression of VP3 induced apoptosis in chicken lymphoblastoid T cells and myeloid 
cells, but not in chicken embryo fibroblasts, which are not susceptible to CIAV. 
Interestingly, expression of a C-terminally truncated VP3 induced much less pronounced 
apoptosis in the chicken lymphoblastoid T cells (Noteborn et al., 1994). 
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1.2.4. Pathogenesis and Immunosuppression 
The small genome coding for only 3 proteins requires the infection of dividing cells 
in order to use the cellular machinery for viral DNA replication. Dividing cells that are 
susceptible to infection are hemocytoblasts in the bone marrow, T cell precursors in the 
thymus and dividing T cells in response to antigenic stimulation (Schat and Skinner, 
2008). CAA infection in young chickens can produce a dramatic decrease in immune 
competence, which, although transitory, is likely to seriously compromise the ability of 
birds to mount a successful immune response to invading pathogens (Adair et al., 1991). 
The T lymphocyte progenitor cells in the thymus are particularly susceptible to 
CIAV infection and appear to be a major target for the virus. In the thymus, the cortical 
lymphocytes were among the first cells to be destroyed, whereas non-lymphoid 
leukocytes and stromal cells were unaffected (Adair, 2000). The way in which the T cells 
in the spleen are infected is not known. The cells may become infected as precursor T 
cells in the thymus, subsequently moving to the spleen when they migrate as mature 
cells, or infection of mature cells may be initiated in the spleen (Adair, 2000). In a 
sequential study, presence of CIAV was shown 4 days after infection in the spleen and 
thymus, simultaneously. It indicates an independent CIAV infection in thymus and 
spleen since virus infected cells appear in spleen and thymus at the same time following 
infection at 1 day of age (Smyth et al., 1993 ; Adair, 2000). 
B cells and their precursors are not susceptible to infection and no substantial 
depletion of B cell numbers comparable to the dramatic depletion in numbers of T cells is 
observed following CIAV infection. Any effects on the BF appear to result from an 
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indirect effect of CIAV infection mediated by disruption of cytokine networks resulting 
from destruction of other effector populations, or enhanced pathogenicity of other agents, 
which adversely affect the bursa by direct means. The fact that no substantial depletion of 
B cells, comparable to the destruction of T cell populations, is observed following 
infection indicates that the common lymphoid progenitor cell in the bone marrow, which 
provides progenitor cells for seeding of the thymus and bursa, is probably not susceptible 
to CIAV (Adair, 2000). 
Cardona et al (2000) detected CIAV in ovaries, infundibula, vas deferentia, testis 
and spleens of seroconverted SPF flocks. The ovaries were often the only positive 
tissues, while a few hens had only positive spleens. This was an important finding about 
the pathogenesis of infection with CIAV that shows 2 surprising points; firstly, the virus 
can persist in chickens long after seroconversion, secondly, CIAV can persist in 
reproductive tissues (Cardona et al., 2000). It was generally believed that clearance of 
CIAV and subsequent life-long resistance to infection coincides with the development of 
neutralizing antibodies. Cardona’s findings were also supported by another study that 
examined the presence of CIAV in the gonads and spleens of hens from commercial 
broiler breeder flocks by nested PCR. The results demonstrated that CIAV genome can 
remain present in the gonads of hens in commercial broiler breeder flocks even in the 
presence of high neutralizing antibody titers that have been associated with protection 
against CIAV vertical transmission. It also suggests that transmission to the progeny may 
occur irrespectively of the level of the humoral immune response in the hens (Brentano et 
al., 2005 ). Maternal antibodies prevent the clinical signs but do not prevent infection, 
transmission of the virus, or immunosuppression (Sommer and Cardona, 2003). The 
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presence of CIAV in intrathecal cells in ovaries and epithelial cells in the infundibulum 
suggests that CIAV, although lymphotrophic during the early pathogenesis, can infect 
other cell types (Cardona et al., 2000).  
In many studies, a greater destruction and decrease of CD8+ cells compared to the 
CD4+ cells were observed following experimental infection (Cloud et al., 1992a; Adair 
et al., 1993). Later, Markowski-Grimsrud and Schat demonstrated the negative impact of 
CIAV infection in older birds on the generation of pathogen-specific cytotoxic T 
lymphocytes (CTL) to other pathogens such as reticuloendotheliosis virus (REV), 
suggesting that CIAV infection can facilitate the development of other diseases (Adair et 
al., 1993; Markowski-Grimsrud and Schat, 2003). In contrast, Calnek et al (2000) 
showed that the susceptibility of T cell lines to CIAV infection is not related to their 
phenotype such as CD4, CD8 and TCRαβ2 surface molecules (Calnek et al., 2000). 
Decrease in lymphocyte transformation responses (Adair et al., 1991) and down 
regulation of several macrophage functions including; cytokine secretion, FC receptor 
expression and phagocytosis are among other crucial CIAV infection consequences 
(McConnell et al., 1993). 
As chickens get older, they rapidly develop a resistance to the experimentally 
induced disease although they remain susceptible to infection. This resistance is virtually 
complete by the time the birds reach 2 weeks of age (Adair, 2000). Jeurissen et al (1992) 
suggested the absence of clinical and microscopic signs of CIAV infection in older 
chickens may be caused by a lack of susceptible thymocytes. Many infected cells were 
observed in the thymus of birds infected at 1, 3, or 7 days post-hatch. In chickens 
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inoculated at days 14 and 21, only few CIAV-infected cells were detected in the thymus, 
whereas these cells were not detected in thymus of 28-day-old inoculated chickens. 
Depletion of the thymic cortex was only detected in chickens inoculated from day 16 of 
embryonic development till day 21 after hatching (Jeurissen et al., 1992). The results 
obtained by Hu et al (1993) challenged this idea showing that embryonally 
bursectomized chickens developed signs and lesions typical of CIA when infected with 
CIA-1 isolate of CIAV at 21 or even 38 days of age. In both cases, the chickens had low 
hematocrit values after the 14th day of inoculation, and the percentage of CD4+ and 
CD8+ cells in the thymus was markedly reduced at 21 days post-inoculation. Even 
though intact chickens became infected, they never developed low hematocrit values. 
Their data support the hypothesis that age-related resistance to CIAV is antibody-
mediated and is not due to disappearance of the CIAV target cell (Hu et al., 1993a).  
Until recently, all strains belonged to the same serotype, but recently a second 
serotype has been described. However, the clinical importance of this serotype is not 
clear at this time (Miller and Schat, 2004). 
In an infection model developed in embryos, it was shown that mutations in the 
VP2 gene can reduce the virulence of CIAV. Attenuation of the ability to produce lesions 
was found consistently for the thymus, spleen and bone marrow, thymic and splenic 
weights, and for CIAV-induced haemorrhage. CIAVs mutated in the VP2 gene were 
infectious for embryos, but were highly attenuated with respect to growth depression and 
CIAV-specific pathology compared to wild-type CIAV infection (Peters et al., 2006). 
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The role of VP1 in CIAV pathogenicity is also shown. It was demonstrated that 
residue 394 of VP1 was crucial for the pathogenicity of CIAV. All of the cloned viruses 
with glutamine at this position were highly pathogenic, whereas those with histidine had 
low pathogenicity. There may be many genetic determinants of pathogenicity in the 
CIAV genome, and the amino acid at VP1 residue 394 maybe a crucial one (Yamaguchi 
et al., 2001). It is also possible that the hypervariable region in the coding region for VP1 
(nt 1192–1508) is important for interactions with the putative receptor because this 
fragment was important for the differences between CUX-1 and CIA-1 in infection and 
replication in two sub-lines of MDCC-MSB-1 cells (Miller and Schat, 2004).  
The effects on CIAV on lymphopoietic and hematopoietic organs, and immune 
cells are closely related to its pathogenesis and immunosuppression. The current 
knowledge on these effects are well reviewed (Adair, 2000; Miller and Schat, 2004; 
Balamurugan and Kataria, 2006; Schat and Woods, 2008). Based on these reviews, the 
CIAV pathogenesis in different stages which may result in clinical or sub-clinical 
infections are briefly mentioned in the followings: 
- Apoptosis and destructive effect on both primary and secondary lymphoid tissues  
- Marked damage to haematopoietic and lymphopoietic tissues  
- Depletion of lymphoid cells in thymus, bursa, spleen and other lymphoid organs  
- Destruction of erythroid progenitors in bone marrow that results in severe anemia 
and depletion of granulocytes and thrombocytes 
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- Decreased T and B cell proliferation activities resulting in a significant decrease 
in immunoglobulin (IgG, IgM and IgA) levels in all body fluids 
- Poor antibody response in the early phase of CIAV infection as a consequence of 
depressed T-helper responses, precursor T cells destruction, mature cytotoxic and T-
helper cells depletion and other effects of the infection 
- Reduced levels of lymphocyte transformation responses of splenic, thymic and 
blood lymphocytes to T-cell mitogens and adverse effects on lymphokine production (IL-
2, TGF, IFN-γ) 
- Increased susceptibility and enhancement of the pathogenicity of secondary 
infections 
- Decreased ratio between the weight of lymphoid organs including; thymus, bursa 
and spleen, and the whole-body weights  
- Substantial reduction in macrophage functions such as bactericidal activity, 
phagocytosis, cytokine (IL-1) production and Fc receptor expression   
- Inhibition of IL-1, IL-2, and IFN-γ production and reduction of cytotoxic 
activities of macrophages, cytotoxic T-lymphocytes and natural killer (NK) cells and 
expression of surface receptors 
Co-infection of birds with CIAV and some other infectious diseases reveal other 
features of CIAV immunosuppression. As expected, the coinfection of CIAV with other 
immunosuppressive viruses such as IBDV, reticuloendotheliosis virus (REV) and 
48 
 
 
Marek’s disease virus (MDV) has a synergetic effect in the pathogenesis, clinical signs 
and the induced immunosuppression. Morbidity and mortality are considerably enhanced 
if chicks are dually infected with CIAV and MDV, or IBDV, probably due to virus-
induced immunosuppression (Schat and Woods, 2008). 
Early studies by Cloud et al (1992b) well demonstrated some features of CIAV and 
IBDV coinfection. Lymphocytes harvested from birds inoculated simultaneously with 
CIAV and IBDV had significantly lower responses to mitogens. Also, vaccination of 
birds 2 weeks following CIAV infection at 1 day of age resulted in decreased protection 
against Newcastle disease virus (NDV), and infectious laryngotracheitis virus (ILTV) 
challenge compared with control birds (Cloud et al., 1992b). Chickens inoculated 
simultaneously with CIAV and IBDV experienced a prolonged acute phase prior to 
recovery or mortality (Cloud et al., 1992a). When SPF chickens were infected with 
IBDV at 1 day of age, they remained susceptible to CIAV up to at least 21 days, whereas 
birds inoculated with CIAV alone were susceptible only at 1 day of age. IBDV also 
increased the susceptibility of birds to infection with CIAV and resulted in increased 
mortality rate in CIAV inoculates. The effects of CIAV infection varied following 
exposure at 1 day of age to two different strains of IBDV (STC and Variant-E) 
(Rosenberger and Cloud, 1989). 
 Imai et al (1999) studied the effect of highly virulent IBDV infection on CIAV's 
infectivity and persistence. They dually infected 35 and 40 days old chicken with very 
virulent IBDV and CIAV strains, respectively. It was found that vvIBDV infection had 
inhibited production of VN antibody to CIAV, and that it was possible to recover CIAV 
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from plasma and blood cells of these chickens at high titers which was a result of IBDV 
caused immunosuppression (Imai et al., 1999). Chicks dually infected with CIAV and the 
reovirus strain had significantly (P < 0.05) lower weight gain and more severe tissue 
damage than chicks inoculated with either virus alone. In addition, a significant (P < 
0.05) reduction in the mean PCV was seen in these dually infected chicks when 
compared with chicks inoculated with CIAV alone (McNeilly et al., 1995 ).  
CIAV is noted as the most important confounding pathogen in MDV infection. 
CIAV coinfection increased ICP4 expression, which is the MDV immediate early gene, 
in the spleens of chickens infected with a vvMDV pathotype. Coinfection with CIAV 
exacerbated vvMDV strain RB1B infection. The extent of this exacerbation varied when 
the coinfection was investigated with different strains of vvMDV (Miles et al., 2001). 
Recently, the effect of CIAV coinfection at 4 weeks of age after inoculation of virulent 
MDV (vMDV, KS strain) or very virulent MDV (vvMDV, Md/5 strain) in 1-day-old 
chicks was investigated by pathological and immunohistochemical studies. It was 
concluded that CIAV was responsible for bone marrow hypoplasia, severe anemia and 
hindrance of lymphoid organ regeneration in MDV-CIAV co-infection (Haridy et al., 
2009 ).  
Toro et al (2000) performed a simultaneous and/or a subsequent coinfection with 
CIAV and fowl adenovirus (FAV) isolates  in SPF chicks and suggested that the 
susceptibility of chickens to FAV oral infection resulting in inclusion body 
hepatitis/hydropericardium syndrome, IBH/HPS, varies throughout the course of CIAV 
infection (Toro et al., 2000 ). Coinfection of CIAV and Salmonella enterica serovar 
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Enteritidis and its effects on immune responses to salmonella infection was also 
examined. It was shown that CIAV infection depressed these immune responses, 
especially the mucosal immune responses to Salmonella infection (Sheela et al., 2003). 
The synergistic effect of CIAV and Cryptosporidium baileyi infection on each other and 
increased reproductive potential of C. baileyi in chickens coinfected with CIAV is also 
demonstrated (Hornok et al., 1998). 
1.2.5. Apoptin 
CIAV causes cytopathogenic effects in chicken thymocytes and cultured 
transformed mononuclear cells via apoptosis. The depletion of thymocytes observed after 
CIAV infection is caused by apoptosis, as DNA isolated from the thymus of infected 
chickens shows an apoptosis-specific laddering pattern (Noteborn, 2004). Other studies 
have confirmed the role of VP3 in the apoptosis, thus the VP3 was renamed as apoptin 
because of the fact that it can induce CIAV-specific apoptosis. The VP2 protein also has 
some apoptotic activity, although much weaker than that of apoptin, whereas VP1 was 
shown not to harbor apoptotic activity (Noteborn, 2004). 
The amino acid sequence of VP3 does not show any distinct homology with the 
sequences of the common receptors that mediate apoptosis, or of c-myc and p53 
oncogene products, known to induce apoptosis. So, it is unlikely that VP3 mimics the 
activity of one of these cellular proteins (Noteborn et al., 1994). In order to induce 
apoptosis, VP3 must be phosphorylated on a specific threonine residue near the carboxy 
terminus by a cellular kinase, resulting in a predominantly nuclear location of VP3 which 
is necessary but not sufficient for induction of apoptosis (Schat and Woods, 2008). The 
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association of VP3 with apoptotic structures was shown by immunogold electron 
microscopy (Noteborn et al., 1994). Furthermore, in vitro expression of VP3 induced 
apoptosis in chicken lymphoblastoid T cells and myeloid cells, which are susceptible to 
CIAV infection, but not in chicken embryo fibroblasts, which are not susceptible to 
CIAV. Expression of a C-terminally truncated VP3 induced much less pronounced 
apoptosis in the chicken lymphoblastoid T cells (Noteborn et al., 1994). 
Considerable evidence has accumulated suggesting that VP3 triggers apoptosis via 
the intrinsic mitochondrial death pathway. Thus, VP3 triggers loss of mitochondrial 
membrane potential and release of cytochrome c and apoptosis-inducing factor from 
mitochondria (Schat and Woods, 2008). Most of the findings in the last 2 decades of 
research on CIAV-induced apoptosis support this idea. Apoptosis induced by apoptin 
required apoptosis protease activating factor-1 (Apaf-1). The cytoplasmic protein, Apaf-
1, forms one of the central hubs in the apoptosis regulatory network. Upon binding 
cytochrome c, it forms an oligomeric apoptosome. The apoptosome binds and cleaves 
caspase 9 preproprotein, which is released following apoptotic stimuli from the 
mitochondria, leading to produce its mature, activated form. Caspase-9 is an initiator of 
the intrinsic apoptotic cell death pathway and is an important activator of downstream 
effector proteases such as caspase-3. Application of a broad spectrum caspase inhibitor 
was highly protective against apoptin-induced cell death showing a caspase dependent 
pattern. It is also shown that Bcl-2 and Bcl-xL inhibit apoptin-induced cell death in 
several tumor cell lines (Burek et al., 2006 ). The Bcl-2 proteins family is known to 
inhibit apoptosis. Further results confirmed the implication of mitochondrial death 
pathway elements in the apoptin induced apoptosis. Apoptin triggers the processing and 
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activation of caspase-3, and the cytoplasmic translocation of Nur77. Translocation of this 
protein from the nucleus to mitochondria induces apoptosis, and the inhibition of Nur77 
expression by siRNA significantly protects MCF7 cells from apoptin-triggered cell death 
(Maddika et al., 2005). It is demonstrated that apoptin induces apoptosis even faster in 
transformed blood cells with a normal level of Bcl-2. In fact, apoptin induced cell death 
benefits a tumorogenic background and is p53-independent (Zhuang et al., 1995; Danen-
Van Oorschot et al., 1997 ; Noteborn, 2004). This is important and so promising in the 
anti-cancer therapy because a large number of tumors are mutated in the p53 gene and 
irresponsive to the induction of apoptosis by this protein (Zhuang et al., 1995).  
1.2.6. Immunity 
After infection with CIAV, antibodies are produced in immunologically mature 
chickens that prevent lesions development. Antibody responses are the major arm of 
protective immunity to ClAV, but neutralizing antibodies cannot be detected until 3 
weeks pi of susceptible one-day-old chicks. Also, it is observed that higher antibody 
levels were a result of greater stimulation by the virus. The age-related resistance to CIA 
is antibody-mediated and is not due to disappearance of the CIAV target cell. Infection of 
chicks may result in clinical disease by vertical transmission, which occurs when hens 
first become infected during egg production or horizontal transmission during the first 
few weeks of age. However, most chicks are protected against early infection by 
maternal antibodies and clinical disease is not frequently seen. Infection after 3 weeks of 
age is mostly subclinical but may result in significant immunosuppression. The 
development of virus-neutralizing (VN) antibodies is essential to curtail virus replication, 
53 
 
 
and immunosuppression caused by IBDV, e.g., has been implicated in prolonged 
replication of  CIAV (Schat and Skinner, 2008). Studies using neutralizing MAb on 
Western blots suggested that the neutralizing epitope(s) are conformational in nature and 
may consist of VPI and VP2 components (Schat and Woods, 2008) 
Koch et al (1995) studied immunogenic properties of the CIAV proteins, produced 
separately or together in insect-cell cultures, by inoculating them into chickens. The 
coding information for three putative proteins (VP1, VP2 and VP3) inserted into a 
baculovirus vector and expressed in insect cells. Only lysates of insect cells which 
included all three recombinant CIAV proteins, or mainly VP1 plus VP2 induced 
neutralising antibodies directed against CIAV in inoculated chickens. Their results 
indicate that expression at least two CIAV proteins, VP1 plus VP2, in the same cell is 
required to obtain sufficient protection in chickens (Koch et al., 1995). The results 
obtained with baculovirus-encoded synthesis of recombinant VP1 and/or VP2 proteins 
indicate that formation of the CIAV -neutralizing epitopes of both VP1 and VP2 have to 
be synthesized synchronously. Furthermore, immune precipitation assays show that VP1 
and VP2 interact directly with each other, which indicates that the NSP VP2 might act as 
a scaffold protein in virion assembly (Noteborn et al., 1998 ). The anti VP3 is also 
produced in vaccinated chicks, but with  poor immunogenic properties, low antibody 
concentration and non-specific reaction (Cunningham et al., 2001 ). 
MA protects young chicks against CIAV-induced anemia and persist for 3 weeks. 
Presence of other agents especially IBDV can abrogate this protection affecting the 
humoral immune response. It is shown that there is a direct correlation between the 
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outbreak of CIA in the field and absence of CIAV antibody in the parent flocks (Schat 
and Woods, 2008). 
1.3. Objectives 
1.3.1. A. Effects of weight gain on anti-IBDV MA decline. 
IBDV causes clinical disease and acute infection in young chicks which results in 
damage to immune tissue, particularly the bursa of Fabricius and bursa-derived 
lymphocytes, compromising the host’s ability to mount effective responses upon 
subsequent infection by other pathogens (Schat and Skinner, 2008). Immunosuppression 
induced by  CIAV, and IBDV depend on the age of challenge (Schat and Skinner, 2008). 
The MA of the chicks has an important role in the infection prevention during the first 
weeks of age, and in deciding vaccination policy in the poultry industry. 
High levels of neutralizing MA protect chicks against early infection and 
immunosuppression, but it can also interfere with the development of active immunity to 
vaccine virus (Muskett et al., 1979; Kibenge et al., 1988). If the vaccine is administered 
too early, it will be neutralized by the residual MA, and if it is administered too late, the 
birds might have already been infected by wild virus at this time. Therefore, vaccination 
should be done as soon as the level of MA becomes low enough to allow the vaccine to 
break through (breakthrough titer). 
The currently used method of vaccination time prediction is based on decline of 
antibody levels due to immunoglobulin half-life and breakthrough titer depending on the 
vaccine strain used (de Wit, 1998). It should be noted that wide variation in the level of 
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maternal antibody in newly hatched chicks and the variation in the rate of antibody 
decline are reported (Kumar et al., 2000). Considering the rapid improvements in 
genetics, feed and vaccine formulations and management that has resulted in the 
increased growth rate in the last decades, and also the observations in our laboratory, we 
hypothesized that there should be some differences in the MA decline of the chicken with 
slow and rapid growth rate. In the other word, the faster growth may lead to a faster 
decline in MA levels due to a dilution effect. In addition, if these effects exist, it can 
affect the rapidity of MA decline and should be applied in the prediction of vaccination 
time. To examine this hypothesis, the following two objectives were examined: 
1- Effects of weight gain on infectious bursal disease maternal antibody decline 
rate in broiler chicks 
2- Prediction of optimal vaccination timing for infectious bursal disease based on 
chick weight rather than age. 
These two objectives are studied in the first experiment of this work. 
1.3.2. B. CIAV and low-virulent IBDV coinfection. 
Infection of chicks by CIAV may result in clinical disease by vertical transmission, 
which occurs when hens first become infected during egg production or horizontal 
transmission during the first few weeks of age. However, most chicks are protected 
against early infection by MA and clinical disease is not frequently seen.  
Broiler chicks become infected in the absence of non-protective levels of MA 
which is usually around 2-3 weeks of age (Daniel, 2000). Infection after 3 weeks of age 
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is mostly subclinical but may result in significant immunosuppression, reduction in 
immune response to vaccines and enhancement of pathogenicity of coinfecting agents, 
such as IBDV (Schat and Skinner, 2008). Although live vaccines have been shown to be 
very efficacious against a variety of diseases, two consequences of concurrent 
vaccinating with several vaccines are immunosuppression and vaccine interference 
(Meeusen et al., 2007). Immunosuppression has been associated with the use of live 
MDV, IBDV, haemorrhagic enteritis virus and CIAV vaccines as these viruses replicate 
in cells associated with immune responses. In addition, vaccines that have similar 
tropisms are known to interfere with the immune response to each other (Schat and 
Skinner, 2008). On the other hand, the current CIAV vaccines, which use live attenuated 
viruses, are not acceptable for vaccination of young susceptible birds because of residual 
pathogenicity in 1-day-old chicks (Miller and Schat, 2004). 
 Considering ubiquitous and contagious nature of CIAV, infection of newly 
hatched chicks with CAV-VAC®  (Intervet, Delaware, USA) vaccine virus used in the 
industry or other attenuated strains of the virus is expected that can lead to some effects 
on chicks immune responses. Furthermore, synergetic effects of virulent IBDV and 
CIAV coinfection which results in more severe clinical signs and immunosuppression, 
have already been shown (Imai et al., 1999). 
After infection of young unprotected chicks with the CIA vaccine virus, coinfection 
of low-virulent IBD viruses which are circulating in the poultry farms may occur. The 
invisible effects of these low-virulent viruses on immune system may accumulate in the 
coinfected chicks. Based on these facts, the following objectives are studied: 
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1- The effects of early infection of CAV-VAC® vaccine virus on lymphoid cell 
subpopulations, viral persistence and humoral immune responses of SPF chicks. 
2- The effects of a low-virulent strain of IBDV infection on lymphoid cell 
subpopulations, viral persistency and humoral immune responses of CAV-VAC® 
vaccinated SPF chicks. 
3- The effects of early infection of CAV-VAC® vaccine virus on lymphoid cell 
subpopulations, viral persistence and humoral immune responses of commercial chicks. 
4- The effects of a low-virulent IBDV infection on lymphoid cell subpopulations, 
viral persistency and humoral immune responses of CAV-VAC® vaccinated commercial 
chicks. 
To examine these objectives, five separate experiments were conducted which are 
described in the following chapters.  
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Chapter 2. Materials & Methods 
Five separate experiments were planned and performed to examine the objectives 
of this study. In the first experiment, effects of weight gain on anti-IBDV MA decline 
and prediction of IBD vaccination time were evaluated, whereas the experiments 2 to 5 
investigate the effects of early inoculation of CAV-VAC®, alone, or along with a low-
virulent IBDV in SPF and commercial chicks.  
2.1. Experiment 1. Effects of weight gain on anti-IBDV MA decline and 
prediction of vaccination time. 
2.1.1. Experimental birds 
 Two groups of 500 Hubbard/Ross one-day old male broilers were used in this 
experiment. The chicks in group A, with an average initial ELISA titer of 5333 originated 
from 27 week-old breeders while those in group B with a titer of 3799 derived from 60 
week-old breeders. Each group was equally subdivided into two groups. Birds in group 
A1 and group B1 were kept on broiler feed ration while those in group A2 and group B2  
were fed breeder ration, which normally has lower protein and energy contents. 
At 1, 4, 8, 12, 16, 22, 29 and 36 days of age, 22 chicks from each group were 
weighed and blood was collected from the heart or wing-vein puncture. Birds sampled at 
1, 4 and 8 days of age were sacrificed during blood collection. Sera samples were 
prepared from clotted blood by centrifugation, labelled and frozen at -20˚C until used. 
The serum samples from each group were tested for antibodies to IBDV using enzyme-
linked immunosorbent assay (ELISA) and virus neutralization (VN) test.  
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2.1.2. ELISA procedure 
Titration of MA in chick sera was carried out using commercial IBD kits provided 
by Synbiotics Corporation (San Diego, CA) according to the manufacturer’s protocol. 
Regular titers and sample to positive (SP) values calculated by Synbiotics software were 
used for statistical analyses and prediction of vaccination age. 
2.1.3. Virus Neutralization test 
VN test using constant-virus, dilute-serum (ß method) was conducted in VERO cell 
cultures. Serum was inactivated at 56˚C for 30 min and serially diluted in two-folds 
directly in 96-well tissue-culture microtiter plates. VERO cell adapted D78 strain of 
IBDV was added at 100 tissue culture infectious dose (TCID50) to the serially diluted 
serum samples in triplicates and incubated at 37°C for 1 hour. After the first incubation, 
VERO cells were added to each well and the cultures were incubated at 37°C for 5 days 
in a humid chamber and the results, based on the absence of cytopathic effects, were 
recorded. Appropriate cell and virus controls were included in each test plate. Antibody 
titers were calculated based on the average of triplicate wells, determined after 5 days of 
incubation. The VN titer was expressed as a two-fold serum dilution (e.g. 1/256 serum 
dilution was expressed as 256) and their geometric means (GMT) were calculated for age 
groups. 
2.1.4. Comparison of vaccination times: age vs weight 
 For ELISA results, the averages of the measured MA titers were plotted out 
against corresponding bird ages and also against bird weights. VN titers were also plotted 
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against bird ages and bird weights. To determine the most suitable moment for 
vaccination of young birds based on the decline in MA titers, a target titer was considered 
for ELISA and VN. This target titer or breakthrough titer is determined by vaccine 
manufacturers and varies according to vaccine types (mild, intermediate, hot) and ELISA 
kit manufacturers. A breakthrough titer of 100 for VN, and 500 for IBD ELISA 
(Synbiotics) was considered for the analysis of the results. Based on the measured titers, 
the time at which a breakthrough titer occurs was determined by comparing MA decline 
versus age and versus weight. 
2.1.5. Prediction of vaccination age using ELISA titer and bird weight 
 ELISA titer was used to establish a new IBD vaccination prediction formula. Birds 
weights and titers measured at 4 days of age were used to predict residual titer at any 
given targeted weight. The number of times the average chick weight increased 
compared to the weight at day 4 was used in calculating the effect of weight gain on the 
decreasing titer. Therefore, the following formula was devised to predict the residual MA 
titers at different chick weights: 
 
TiterghBreakthrou
DayatWeightDayatTiterTimenVaccinatioatWeight )4()4( ×=
 
The average of 75% lowest bird titers was used for vaccination prediction by the 
formula. This was done by eliminating 25% highest titer in computing the average titer of 
day 4 used for prediction. 
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This formula was then used to predict the vaccination time for chicks using bird 
weight and the titers measured at day four and the results were compared to the 
prediction made by current Deventer formula (de Wit, 1998). 
2.1.6. Total antibody content (TAC) 
In this analysis, the effects of weight on the decline of MA and the decline due to 
normal catabolic rate were studied. Total antibody content in birds at different ages post-
hatch were calculated by multiplying the average VN titer by respective bird weight. The 
value was assumed to represent the entire amount of antibody remaining in the bird at the 
specified age (TAC = Titer x Weight). The TACs were then plotted in a graph against 
bird ages. 
2.1.7. Statistical analyses 
The averages of body weights, ELISA titers and VN titers, and correlation analysis 
were performed using Excel Microsoft Office software. Linear model analysis, with 
groups and time were performed using SAS statistical software for windows, version 9.1 
(SAS Institute Inc. Cary, NC). 
2.2. Experiments 2 to 5. Effects of a low-virulent IBDV infection in 
CAV-VAC® vaccinated SPF and commercial young Chicks 
2.2.1. Chicken and experimental design 
In experiment 2, embryonated pathogen free (SPF) eggs were incubated and reared 
at Faculty of Veterinary Medicine facilities (Université de Montréal, St-Hyacinthe, 
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Québec, Canada). Fifty four 1-day-old SPF chicks were divided into two groups and 
housed separately in sterile condition with air filtered under negative pressure. Thirty six 
chicks received 5 μl of CIAV vaccine (CAV-VAC®, Intervet, Delaware, USA) by 
intraperitoneal injection while the chicks in control groups were inoculated with PBS. At 
7, 14 and 28 days post-vaccination, six chicks from each group were weighed, blood-
sampled by cardiac puncture and euthanized in CO2 chamber. Samples of blood, sera, 
liver, thymus, spleen, cecal tonsils, bone marrow and bursa were used in different tests. 
Another eighteen chicks reared in the vaccinated group were euthanized at 18, 21 and 28 
dpv and used only for antibody assay and virus genome detection by PCR. 
In experiment 3, fifty four 1-day-old SPF chicks were divided into 3 groups and 
housed separately in sterile condition with air filtered under negative pressure. At hatch, 
eighteen chicks in group 1 and eighteen chicks in group 2 received 5 microliter of CIAV 
vaccine via intra-peritoneal route while the chicks in the group 3 were inoculated with 
PBS. At 14 dpv, chicks in the groups 2 and 3 were inoculated by 100 μL (100 TCID50 
/μL) of IBDV-QT1 via intra-peritoneal route. At 18, 21 and 28 dpv, six chicks from each 
group were weighed, blood-sampled by cardiac puncture and euthanized in CO2 
chamber. The same samples as experiment 2 were collected and were used in different 
tests. 
In experiment 4, fifty four Hubbard/Ross one-day old male broilers were provided 
by a commercial source, divided into two groups and housed separately in sterile 
condition with air filtered under negative pressure. Thirty six chicks received 5 μl of 
CIAV vaccine via intraperitoneal route while the chicks in control groups were 
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inoculated with PBS. At 7, 14, and 28 dpv, six chicks from each group were weighed, 
blood-sampled by cardiac puncture and euthanized in CO2 chamber. Another eighteen 
chicks reared with the vaccinated group were euthanized at 18, 21 and 28 dpv and used 
only for antibody assay and virus genome detection by PCR. The samples of all birds 
were subjected to the same sampling procedure as performed on SPF chicks in the 
experiment 2. Fourteen more chicks from the same commercial source were sacrificed at 
hatch and their sera were collected to measure the maternal anti-CIAV and IBDV ELISA 
titers. 
In experiment 5, fifty four one-day-old chicks obtained from commercial source 
were subjected to the same rearing condition, inoculation schedule, experimental design 
and sampling as described in experiment 3.  
2.2.2. Sampling and cell extractions 
The blood samples were collected directly into heparinized microhematocrit tubes 
for packed cell volume (PCV) determinations and also used for white blood cells counts 
(WBC) and differential analyses. Thymus, spleen and bursa were collected under sterile 
conditions and subjected to lymphocyte extraction procedure. Samples of sera, liver, and 
cecal tonsils were also collected and frozen till tested. 
Extraction of lymphocytes from spleen, thymus and bursa were conducted by 
mincing each tissue into fragments and then pushing it through a 70 µm cell strainer 
(Falcon Scientific Co, Montreal, Québec, Canada). The lymphocytes then recovered in 
RPMI 1640 media (GIBCO, Laboratories, Grand Island, NY) supplemented with 20% 
fetal bovine serum (FBS) and antibiotic-antimycotic solution (GIBCO Laboratories).  
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Spleen and thymus cell suspensions were placed gently on Lymphoprep gradient 
(Cedarlane, Hornby, Ontario, Canada) in tubes and centrifuged at 1500 RCF for 20 min. 
The recovered lymphocyte layer from spleen and thymus, also the original cell 
suspension from bursa samples were washed in fresh media with 20% FBS by 
centrifugation at 450 RCF for 10 min. Bone marrow cells were collected from femur in 
RPMI 1640 with 5% FBS after cutting the 2 epiphysis and pushing the media through the 
medular cavity using a one ml insulin syringe. The suspensions were placed on FBS 
cushion and incubated on ice for 10 min to remove the debris. The superior layer from 
each bone marrow cell suspension was recovered in a fresh tube. After cell counting in a 
hemacytometer with trypan blue, the cell concentrations of thymus, spleen, bursa and 
bone marrow suspensions were adjusted at 106 viable cells/ml and used for different 
assays. 
2.2.3. Immunolabelings of lymphocytes subsets 
The phenotype of lymphocyte subpopulations was determined by double 
immunolabeling using fluorescein isothiocyanate (FITC)-conjugated, conjugated with 
anti-CD4, anti-IgM, anti-CD3, or anti-TCR-γδ, and phycoerythrine (PE)-conjugated anti-
CD8a or CD3 monoclonal antibodies (mAb) (Southern Biotech, Anaheim, CA). Thymic, 
splenic and bursal lymphocytes were prepared in a concentration of 106 cells per ml of 
RPMI-1640 with 20% FCS. Cells were incubated with the optimal concentration of 
mAbs (1 μg) for 30 min at 4oC. Cells were then washed in RPMI-1640 and fixed 
overnight at 4oC in PBS, pH 7.2, containing 1% formaldehyde (Fischer Scientific, 
Montréal, Québec, Canada). Cytofluorometric analysis was performed on a FACScan 
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cytofluorometer (Becton Dickinson, Mountain View, CA) using CellQuest software 
(Becton Dickinson, San Jose, CA). Analysis was done on 10,000 events and discrete 
lymphoid cell populations were gated according to forward scatter (FSC) versus 90o 
angle scatter (SSC) parameters. Percentages of different lymphoid cell subpopulations in 
thymus, spleen and bursa, were determined by multiparametric analyses. 
2.2.4. CIAV genome detection by PCR 
Viral DNA was extracted from thymus, spleen, bursa, bone marrow cell 
suspensions, and also sera samples using Trizol_LS Reagent (Life Technologies, Grand 
Island, NY) according to the manufacturer instruction. Bursa tissues were first 
homogenized by glass beads and then viral genomes were extracted by Trizol Reagent 
(Life Technologies, Grand Island, NY). To detect the viral genome in the samples, 
fragments of 374 bp situated between nucleotides 472 and 846, and 203 bp situated 
between nucleotides 588 and 791, were targeted to be amplified in conventional and 
nested PCR respectively. A set of primers were designated and used as follow: Forward 
(ctctccaagaagatactccac), Reverse (gctcgtcttgccatcttac), Forward nested 
(atcactctatcgctgtgtgg) and Reverse nested (ggagtagtggtaatcaagc). 
PCR program consisted of an initial denaturation at 94˚C for 5 min, and 35 cycles 
of 94˚C for 35 sec., 58˚C for 55 sec., and 72˚C for 1 min followed by a final extension at 
72˚C for 5 min. PCR products were analyzed by electrophoresis on 1.4% agarose gel in 
TAE buffer (40 mM of Tris and 2 mM of EDTA, with a pH value of 8.0) containing 0.5l 
g/ml of ethidium bromide for 60 min at 100 volts and visualized under an ultraviolet light 
transilluminator.  
66 
 
 
2.2.5. IBDV genome detection by RT-PCR 
 Viral RNA was extracted from thymus, spleen, bursa, cecal tonsils, and sera 
samples using Trizol_LS Reagent (Life Technologies, Grand Island, NY) according to 
the manufacturer instruction. Bursa tissues were first homogenized by glass beads and 
then extracted by Trizol Reagent (Life Technologies, Grand Island, NY). To detect the 
IBD viral genome in the lymphoid organs samples, a 604 base pair (bp) product, in the 
VP2 gene, was amplified by a 2 step RT-PCR. In the first step, the cDNA was produced 
in 25µL reaction volume using SuperScript® II Reverse Transcriptase (Invitrogen, Life 
Technology, Grand Island, NY) using the forward primer, U3-IBDV ; 
tgtaaaacgacggccagtgcatgcggtatgtgaggcttggtgac. In the second step, the cDNA was used 
as a template for amplification in the IBDV PCR with the same forward primer and the 
reverse primer, L3-IBDV; caggaaacagctatgaccgaattcgatcctgttgccactctttc (OIE, 2004). 
PCR program consisted of an initial denaturation at 95˚ C for 5 min, and 35 cycles of; 
95˚C for 30 sec., 64˚C for 45 sec., and 70˚C for 1 min followed by a final extension at 
72˚C for 10 min. The PCR products were analyzed on 1.2% agarose gels and visualized 
under UV light after staining with ethidium bromide (Figure 2-1). 
2.2.6. Specific anti-CIAV antibody and cytokine assays 
Specific anti-CIAV antibodies were quantified by an ELISA procedure by the 
IDEXX FlockChek CAV test Kit, as described by the manufacturer (IDEXX 
Laboratories, Inc., Westbrook, Maine, USA). IFN-γ and TGF-β were quantified by 
ELISA. For the cytokine assays, prepared cell suspensions from bone marrow were 
adjusted at concentration of 106 cells per ml in RPMI 1640, with 20% FBS and 
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antibiotic-antimycotic solution (Gibco Laboratories, Grand Island, NY) in triplicates and 
transferred to 96 well flat-bottomed plates. Wells from each group contained, 240 μl of 
cells, 30 μl of LPS (5 μg/ml) and 30 μl of GM-CSF (0.2 μg/ml). After 3 hours of 
incubation at 37oC in 5% CO2, the media containing non-adherent cells were changed 
with fresh media, LPS and GM-CSF and incubated for another 20 hours, then the 
supernatant were recovered and frozen until tested. INF-γ and TGF-β levels in spleen cell 
culture supernatants were determined by a sandwich enzyme-linked immunosorbent 
assay (ELISA), CytosetsTM, according to the manufacturer instruction (BioSource, CA, 
USA). 
2.2.7. Hematology 
Hematocrit (PCV) were determined by centrifugation in micro-hematocrit tubes, 
and peripheral leukocyte analyses such as percentage of white blood cells (WBC) and 
differential percentages of heterophils, monocytes, lymphocytes,eosinophils, and 
basophils were performed by May-Grunwald's staining and light microscopic 
examination. 
2.2.8. Statistical analyses 
 Percentages of blood cells and lymphocytes subsets in lymphoid organs from 
CIAV vaccinated young birds were compared to those from sham birds using Student’s t 
test. Values of P≤ 0.05 were considered significant. 
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Figure 2-1 - Gel electrophoresis of amplified CIAV and IBDV genome fragments. 
CIAV vaccination performed at hatch, followed by IBDV inoculation in a group of 
vaccinated chicks at 14 days post-vaccination. The PCR and RT-PCR were conducted to 
detect CIAV and IBDV genome respectively. 
A- Detection of CIAV genome in the 3 spleen samples of CIAV vaccinated chicks 
by PCR at 21 days post-vaccination. 
B- Detection of IBDV genome in the 2 bursa samples of CIAV+IBDV coinfected 
chicks by RT-PCR at 21 days post CIAV vaccination 
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Chapter 3. Results 
3.1. Experiment 1. Effects of weight gain on anti-IBDV MA decline and 
prediction of vaccination time. 
3.1.1. Weight gains 
Significant differences in weights between groups A1 and A2, and groups B1 and 
B2 were observed starting from day 12 (P < 0.005) and persisted throughout the 
experiment (P < 0.0001). As expected, fast-growing birds in groups A1 and B1 had 
similar growth curves even though they originated from two breeder flocks of different 
ages and the chicks differed in initial average weights (39.5g vs 44.8g). Likewise, chicks 
from slow-growing groups A2 and B2 had similar growth curves (Figure 3-1). 
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Figure 3-1 - Growth curves of broiler chicks treated with broiler or breeder feed. 
Groups A1 and B1 received broiler feed (21.8% protein and 4.4% fat), groups A2 and 
B2; received breeder feed (18% protein and 2.4 % fat). 
3.1.2. MA titers and ages 
 Antibody titers monitored by ELISA (Figure 3-2) and VN (Figure 3-3) at 
different ages post-hatch showed different decline patterns for each group. Among the 
chicks with higher initial MA titers, birds in group A1, with a faster growth, also had a 
faster antibody decline pattern compared to those in slow-growing group A2. Likewise, 
in the groups with lower initial titers, the faster growing group B1 showed a faster 
decline in MA titer compared to the slow-growing group B2. Based on the ELISA 
results, the antibody half-life for fast-growing chicks in groups A1 and B1 were thus 4.35 
and 2.84 days respectively, while slow-growing chicks in group A2 and B2 showed 
higher half-life of 6.91 and 4.02 days respectively. 
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Figure 3-2 - Decline of maternal antibody titers measured by ELISA. 
Decline of maternal antibody titers at different ages post-hatch measured by; ELISA. 
Groups A1 and B1were given broiler feed and groups A2 and B2 were given breeder 
feed. 
0
500
1000
1500
2000
0 4 8 12 16 20 24 28 32 36
Age
 (days)
VN titer
A1 A2 B1 B2  
Figure 3-3 - Decline of maternal antibody titers measured by VN test. 
Decline of maternal antibody titers at different ages post-hatch measured by Virus 
Neutralization test. Groups A1 and B1were given broiler feed and groups A2 and B2 
were given breeder feed. 
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3.1.3. MA titers and weights 
MA titers showed two decline patterns when titers were plotted against weights. Chicks 
in fast-growing group A1 and slow-growing group A2 shared the same MA decline curve 
at the same given weights while those in groups B1 and B2 also had a similar titer curve 
(Figure 3-4, Figure 3-5).  
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Figure 3-4 - Decline of maternal antibody titers at different weights (ELISA). 
Decline of maternal antibody titers at different weights post-hatch measured by; ELISA. 
Groups A1 and B1were given broiler feed and groups A2 and B2 were given breeder 
feed. 
 
73 
 
 
0
500
1000
1500
2000
0 200 400 600 800
Weight
(gram)
VN titer
A1 A2 B1 B2
 
Figure 3-5 - Decline of maternal antibody titers at different weights (VN). 
Decline of maternal antibody titers at different weights post-hatch measured by virus 
neutralization test. Groups A1 and B1were given broiler feed and groups A2 and B2 were 
given breeder feed 
.
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3.1.4. Comparison of vaccination times: age vs weight 
 When a breakthrough ELISA titer of 500 was chosen as an ideal vaccination titer 
for an intermediate IBD vaccine, four different vaccination ages were predicted: 19 days 
for group A1, 24 days for group A2, 13 days for group B1 and 17 days for group B2 
(Figure 3-6). When the same titer was chosen and plotted against weight rather than age, 
630±20g was determined to be the ideal vaccination weight for groups A1 and A2, 
whereas 380 ±20g was the most appropriate vaccination weight for groups B1 and B2 
(Figure 3-7). In VN studies using the same serum samples, a titer of 100 was detected at 
18, 22, 12 and 15 days of age in groups A1, A2, B1 and B2 respectively (Figure 3-8). 
The same breakthrough titer was detected in chicks in groups A1 and A2 at 530 ±70g of 
weight, and in the groups B1 and B2 at 260 ±25g of the mean weight (Figure 3-9). 
75 
 
 
 
0
500
1000
1500
2000
1 4 8 12 16 23 29 37
Age
(days)
ELISA iter
A1 A2 B1 B2  
Figure 3-6 - Real vaccination times for a breakthrough ELISA titer of 500. 
Arrows indicate the breakthrough titers at which point birds can be vaccinated.  The Fig. 
shows breakthrough titers for each group according to chick’s age. 
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Figure 3-7 - Real vaccination times (weight) for a breakthrough ELISA titer of 500. 
Arrows indicate the breakthrough titers at which point birds can be vaccinated. The Fig. 
shows breakthrough titers for each group based on chick’s weight. 
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Figure 3-8 - Real vaccination times for a breakthrough VN titer of 100. 
Arrows indicate the breakthrough titers at which point birds can be vaccinated. The Fig. 
shows breakthrough titers for each group according to chick’s age. 
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Figure 3- 9 - Real vaccination times (weight) for a breakthrough VN titer of 100. 
Arrows indicate the breakthrough titers at which point birds can be vaccinated. The Fig. 
shows breakthrough titers for each group based on chick’s weight.
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3.1.5. Predicting vaccination time by the weight formula 
An ELISA titer of 500 was assumed to be the breakthrough titer used in predicting 
vaccination time based on weight rather than age. The targeted weight for vaccination 
was then calculated as follows: 
 
500
)4()4*( DayatWeightDayatTiternVaccinatioatWeight ×=
 
* The average of lowest 75% birds titer tested at day 4 was applied as the titer at 
day 4. 
The predicted vaccination weight for birds in groups A1 and A2 were 484g and 
433g respectively, and for groups B1 and B2 they were 305g and 313g respectively 
(Table I). For comparison purpose, prediction of vaccination time based on age was also 
calculated using Deventer formula (de Wit, 1998) and the results were compared to the 
measured real titers. While a breakthrough of 500 ELISA was targeted using both 
formulas, the birds weight predicted by weight formula were corresponding to the ELISA 
titer of 700, 725, 300 and 500 for the groups A1, A2, B1, and B2 respectively. The 
vaccination ages predicted by Deventer formula were corresponding to the titers of 850, 
1400, 490 and 1050 for the groups A1, A2, B1, and B2 respectively. When the predicted 
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times by weight formula were compared to the real measured titers in the experiment, a 
strong correlation between them was observed (R = 0.9889). The results indicated a 
lower correlation between real ELISA titers and the titers predicted by Deventer formula 
(R = 0.8355) (Figure 3-10). 
 
 
Breakthrough titer measured by 
ELISA at different weights and 
their corresponding age in days 
Predicted vaccination time by the weight 
formula and its corresponding age and 
titer 
Predicted vaccination age by the 
Deventer formula and its corresponding 
weight and titer  
 
Groups 
Targeted 
break-
through 
titer 
Weight at 
break-
through 
titer 
Age at 
break-
through 
titer* 
Titer at 
predicted 
weight 
Predicted 
vaccination 
Weight 
Age at 
corresponding 
vaccination 
weight 
Titer at 
predicted 
age 
Weight at 
corresponding 
vaccination 
age 
Predicted 
vaccination 
age* 
A1 500 590 18 700 484 17 850 340 14 
A2 500 510 22 725 433 20 1400 200 14 
B1 500 250 11 300 305 12 490 240 11 
B2 500 310 17 500 313 17 1050 180 11 
 
Table I - Vaccination time predicted by chick’s weight or the Deventer formulas. 
Vaccination time predicted by the two formulas was compared to the real measured 
weights and age of vaccination for a breakthrough ELISA titer of 500. For prediction by 
weight formula, the highest 25% titers measured at 4 days of age were eliminated and the 
average titers were based on the remained 75% of birds. In the Deventer formula, the bird 
titer next to the 75th percentile was used in the prediction. Corresponding weight, titer 
and ages were determined by regression model analysis of the measured  and predicted 
results. 
* Vaccination ages were rounded up to the nearest day. 
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Figure 3-10 - Prediction of IBDV vaccination time by Deventer and weight-based 
formula. 
IBDV vaccination time was predicted using current Deventer formula and weight-based 
formula for a break-through titer of 500. The predicted vaccination times by two methods 
were compared to vaccination time based on real titers measured by ELISA at different 
ages in the experiment.  
- Correlation between vaccination time determined by real ELISA titers, and predicted 
by Deventer formula; R=0.8355 
- Correlation between vaccination time determined by real ELISA titers, and predicted 
by weight-based formula; R= 0.9889 
 
3.1.6. Total antibody content. 
 Figure 3-11 represents the TAC and its decline based on VN titers and measured 
bird weights. The four curves are parallel and show a similar steady, declining pattern. 
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Figure 3-11 - Total maternal antibody content (TAC). 
Total maternal antibody content (TAC) of the chicks at various time post-hatch 
calculated multiplying virus neutralization titers by correspondent chick weight. Values 
represent the mean TAC of 22 chicks tested at each occasion. Groups A1 and B1were 
given broiler feed and groups A2 and B2 were given breeder feed 
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3.2. Experiment 2. Chicken infectious anemia vaccinal strain persists in 
the thymus and spleen of young SPF chicks and induces immune 
disorders 
3.2.1. Clinical signs and hematologic evaluation of CIAV-vaccinated SPF chicks 
Thirty-six SPF birds of one-day old CIAV-vaccinated or controls were euthanized 
at 7, 14 and 28 dpv. Birds in both CIAV-vaccinated and control groups did not show any 
clinical signs and anemia following vaccination. No weight loss or thymic atrophy, as 
revealed by gross examination, was observed in vaccinated chicks at various times. Bone 
marrow cell numbers were not altered in vaccinated chicks (results not shown). The 
hematocrit, WBC count and percentages of lymphocytes in blood of CIAV-vaccinated 
birds did not show significant variations up to 28 dpv when compared with chicks in 
control groups (Figure 3-12; A, B and D). However, percentage of blood heterophils 
slightly decreased at 14 dpv only (p≤ 0.05) (Figure 3-12, C). 
3.2.2. Presence of CIAV vaccinal strain in lymphoid organs 
The presence of the CIAV vaccinal strain in thymus, spleen, bursa, cecal tonsil, 
bone marrow, liver and sera was evaluated by detection of viral VP3 gene by PCR. As 
shown in Table II, CIAV DNA fragment was detected in the thymus of 5 (out of 6) 
vaccinated birds at day 7 pv. There were not any CIAV DNA positive cases in the 
thymus samples at 14, 18 and 21 dpv, whereas presence of CIAV genome in thymus was 
detected at 28 dpv in 2 of the 12 tested vaccinated chick. In the spleen, the vaccine virus 
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was detected in few chicks at 7 dpv and persisted in vaccinated birds until 28 dpv. All 
other specimens collected from, bursa, bone marrow, sera and liver were negative by 
nested-PCR. 
 
 
Figure 3-12 - Hematological examination of CIAV-vaccinated SPF chicks. 
 Hematocrit (PCV) (A), white blood cell count (WBC) (B), percentages of heterophils 
(C) and percentages of lymphocytes (D) in the blood of CIAV-vaccinated () and 
control birds () were determined at 7, 14 and 28 days post-vaccination. The mean of 
each value for vaccinated and control birds (n=6) were calculated and compared. * p≤ 
0.05 
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Table II - Detection of CIAV vaccine virus genome in lymphoid organs of commercial 
CIAV-vaccinated and control chicks. 
 
Days post-vaccination  
28 dpv 21 dpv 18 dpv 14 dpv 7 dpv  
CIAV Ctrl CIAV Ctrl CIAV Ctrl CIAV Ctrl CIAV Ctrl  
2/12 - - - - - - - 5/62 -1 Thymus 
3/12 - 3/6 - 2/6 - 1/6 - 1/6 - Spleen 
0/12 - - - - - - - - - Bursa 
0/12 - - - - - - - - - Cecal tonsil 
 
1- The dash reoresents no positive results 
2- Number of positives / Number tested 
Groups of 6 SPF chicks were inoculated by CAV-VAC® or PBS at hatch, euthanized at 
7, 14, 18, 21, and 28 (12 chicks at 28 dpv) days post-vaccination and organs were 
sampled. Viral genome was detected by polymerase chain reaction (PCR). 
 
3.2.3. Analyses of thymic cell subpopulations 
To verify whether the viral persistency of CIAV genome of vaccinal strain induces 
immunodisorders in lymphoid cells populations, percentages of the different lymphoid 
subsets in thymus, spleen and bursa from CIAV-vaccinated chicks were compared with 
control birds at various time pv. The isolated lymphoid cells from these three organs 
were double or triple immunolabelled with fluorescent antibodies against CD4, CD8, 
CD3, TCR-γδ and IgM, and analyzed by cytofluorometry.  
84 
 
 
As shown in Figure 3-13, percentages of thymic CD4+CD8-, CD4-CD8+ or TCR-
γδ+ cells were not modified in vaccinated chicks and the values were similar to those 
from unvaccinated birds (Figure 3-13, A, B and D). The percentages of CD4+CD8+ 
thymic cells, however, slightly decreased after 14 and 28 days in CAIV-vaccinated group 
(p<0.05) (Figure 3-13, C). No significant modification in percentages of thymic CD3-
CD8+ cells was detected in vaccinated chicks (results not shown). 
Separation of smaller (G1) and larger (G2) thymocytes was performed by more 
analysis of FSC/SSC parameters, as shown in the Figure 3-14. The G1/G2 ratio of 
thymic cells did not significantly differ between CIAV-vaccinated or control birds. The 
multiparametric analyses of cells in G1 area revealed that these cells contains both 
CD4+CD8-, CD4+CD8+ and CD4-CD8+ cell subsets (Figure 3-14- sect. I, B and E) 
whereas the cells located in G2 area were mostly double positive (CD4+CD8+) cells 
(Figure 3-14- sect. I, C and F). However, percentages of smaller CD4+CD8+ cells (in G1 
area) decreased at 14 and 28 days pv in thymus of CIAV-vaccinated birds (p<0.05) 
(Figure 3-14- sect. II-A). In contrast, the larger CD4+CD8+ cells increased only at 7 dpv 
(p<0.05) (Figure 3-14- sect. II-B). 
An example of flow cytometric analysis (Figure 3-15, A and B) and the results 
comparison of CD4 and CD8 molecules expression on thymocytes is presented in Figure 
3-15. The result revealed that, due to CIAV vaccination, the CD4 expression on 
thymocytes increased at 7 dpv (p≤0.01) while it decreased at 28 dpv (p≤0.05) (Figure 3-
15, C). The CD8 expression on the thymocytes surface, however, strongly increased in 
CIAV-vaccinated group at 7 dpv (p≤0.01) and remained variable until 28 dpv in the. 
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group of CIAV-vaccinated chicks (Figure 3-15, D) 
 
 
 
 
Figure 3-13 - Percentages of lymphocytes subpopulations in thymus of CIAV-vaccinated 
commercial chicks. 
SPF chicks were inoculated by CAV-VAC® or PBS at hatch. At 7, 14 and 28 dpv, 
thymocytes from CIAV-vaccinated () and control birds () were double or triple 
labeled with anti-CD4, anti-CD8, anti-TCRγδ conjugated to FITC or PE and analyzed in 
cytofluorometry.  The mean percentage of thymic CD4+CD8- (A), CD4-CD8+ (B), 
CD4+CD8+ (C) and TCRγδ+ (D) subpopulations for CIAV-vaccinated and control 
groups (n=6) were calculated and compared.  * p≤ 0.05. 
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Figure 3-14 - Analyses of small and large lymphocytes subpopulations in thymus of SPF 
chicks at 7, 14 and 28 days following CIAV-vaccination at hatch. 
 Thymocytes from CIAV-vaccinated and control birds were double or triple labeled with 
anti-CD4, anti-CD8, anti-TCRγδ conjugated to FITC or PE and analyzed in 
cytofluorometry. I- Thymocytes extracted from control (A) and CIAV-vaccinated (D) 
birds were separated in small (G1 area) and large (G2 area) cells according to FSC/SSC 
parameters. Multiparametric analyses of small (B and E) and larger (C and F) CD4/CD8 
cell subpopulations is also shown for control and vaccinated groups. II- Percentages of 
small (A) and large (B) lymphocyte subpopulations in thymus from control and CIAV-
vaccinated groups at various days post-vaccination. * p≤ 0.05. 
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Figure 3-15 - Analyses of relative expression of CD4 and CD8 molecules on thymocytes 
from CIAV-vaccinated and control groups at various times post-vaccination. 
The lines illustrate the intensity of CD4 (A) or CD8 (B) molecules on thymocytes of one 
control and one CIAV-vaccinated bird. Thymocytes from CIAV-vaccinated () and 
control birds () were double labeled with anti-CD4 and anti-CD8, conjugated to FITC 
or PE, and analyzed in cytofluorometry. The relative expression levels of CD4 (C) and 
CD8 (D) in thymocytes from control the group (n=6) were compared at 7, 14 and 28 days 
post-vaccination. * p≤ 0.05, ** p≤ 0.01. 
88 
 
 
 
3.2.4. Analyses of splenic and bursal lymphocyte subpopulations 
In spleen, the percentage of CD4-CD8+ cells increased at 28 dpv (p<0.05) (Figure 
3-16, A) while CD4+CD8-cells decreased simultaneously (p<0.05) (Figure 3-16, B) in 
CIAV-vaccinated chicks. Subpopulation of CD4+CD8+ labelled spleen cells exhibited a 
paramount elevation only 7 days after vaccination (p<0.05) (Figure 3-16, C). The IgM-
bearing and TCRγδ spleen cells were not significantly altered following CIAV 
vaccination (Figure 3-16, D and F). The vaccinated chicks also exhibited higher number 
of CD3-CD8+ cells (corresponding to NK cells) in their spleen at 7 and 14 dpv (p<0.05) 
(Figure 3-16, E). Therefore, at 28 days pv, the number of NK cells were less in CIAV-
vaccinated birds than that of control group (p<0.05) (Figure 3-16, E).  
In bursa of Fabricius, percentages of CD4-CD8+ cells increased at 7 and 28 dpv 
(p<0.05) while CD4+CD8- cells simultaneously decreased (p<0.05) (Figure 3-17, A, B). 
The number of double positive (CD4+CD8+) bursal cells were slightly lowered in CIAV-
vaccinated group only at 28 dpv (p<0.05) (Figure 3-17, C). Percentages of IgM+ bursal 
lymphocytes were relatively steady until day 28 when the percentage of these cells was 
lower in CIAV-vaccinated chicks (p<0.05) (Figure 3-17, D).  
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Figure 3-16 - Percentages of lymphocytes subpopulations in spleen of CIAV-vaccinated 
SPF chicks. 
SPF chicks were inoculated by CAV-VAC® or PBS at hatch. At 7, 14 and 28 dpv, spleen 
cells from CIAV-vaccinated () and control birds () were double or labeled with anti-
CD4, anti-CD8, anti-TCRγδ, anti-IgM, and anti-CD3 conjugated to FITC or PE and 
analyzed in cytofluorometry.  The mean percentage of thymic CD4-CD8+ (A), 
CD4+CD8- (B), CD4+CD8+ (C), IgM + (D), CD3-CD8+ (E) and TCRγδ+ (F) 
subpopulations for CIAV-vaccinated and control groups (n=6) were calculated and 
compared. * p≤ 0.05. 
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Figure 3-17 - Percentages of lymphocytes subpopulations in bursa of CIAV-vaccinated 
SPF chicks. 
SPF chicks were inoculated by CAV-VAC® or PBS at hatch. At 7, 14 and 28 days pi, 
bursal lymphocytes from CIAV-vaccinated () and control birds () were double 
labeled with anti-CD4, anti-CD8, anti-IgM conjugated to FITC or PE and analyzed in 
cytofluorometry.  The mean percentage of thymic CD4-CD8+ (A), CD4+CD8- (B), 
CD4+CD8+ (C) and IgM+ (D) subpopulations for CIAV-vaccinated and control groups 
(n=6) were calculated and compared.* p≤ 0.05. * * p≤ 0.01 
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3.2.5. Levels of anti-CIAV antibodies 
The efficiency of the vaccine virus to induce anti-CIAV antibodies in 1-day old 
SPF chicks was then monitored by ELISA assay. As shown in Figure 3-18, the 
vaccination with the CAV-VAC® did not produce a notable humoral response in majority 
of vaccinated chicks when administered at hatch. Among the 36 vaccinated birds 
sampled at 5 different times pi, the anti-CIAV titers were detected in 1, 2 and 1 chicks at 
7, 14 and 18 dpi respectively. The anti-CIAV antibodies did not persist up to 18 dpv in 
seropositive chicks. 
3.2.6. Cytokines assays 
The ELISA performed on bone marrow cells extracted from vaccinated and control 
groups demonstrated no significant differences in the TGF-β and IFN-γ production at 
various times pv (data not shown). 
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Figure 3-18 - Anti-CIAV ELISA titer of CAV-VAC® vaccinated SPF chicks. 
Chicks were inoculated by CIAV-VAC® or PBS at hatch. Sera samples of CIAV-
vaccinated and control group were tested for anti-CIAV antibodies by ELISA at 7, 14, 
18, 21 and 28 dpv by ELISA. Each column represents the ELISA titer of individual chick 
that tested positive in each group. The mean titer of each group is shown above the 
related column. 
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3.3. Experiment 3. Effects of a low-virulent strain of IBDV infection on 
lymphoid cell subpopulations, viral persistency and humoral immune 
responses of CAV-VAC® vaccinated SPF chicks. 
3.3.1. Clinical signs and Hematologic evaluation 
Fifty four SPF chicks of the CIAV, CIAV+IBDV, and IBDV infected groups did 
not show any clinical signs and anemia during the experiment. No weight loss or thymic 
atrophy, as revealed by gross examination, was observed in the experimental birds at 
various times pi. Bone marrow cell numbers were not altered in vaccinated chicks 
(results not shown). The PCV and WBC count of CIAV+IBDV and IBDV inoculated 
birds did not show significant variations at various dpv when compared with chicks in 
vaccinated groups (Figure 3-19, A, and B). There were not any significant differences in 
the WBC numbers between the coinfected and CIAV vaccinated group while counted 
WBC of IBDV inoculated birds at 18 dpv demonstrated dramatic increase in compare to 
CIAV vaccinated chicks (p≤ 0.01). In addition, significant decrease in blood 
lymphocytes, and increase in the heterophil percentages (p≤ 0.05) were shown in the 
blood of IBDV inoculated chicks at 28 days pi (p< 0.005) (Figure 3-19, C and D). 
3.3.2. Presence of CIAV and IBDV in lymphoid organs 
The presence of the CIAV vaccinal strain in thymus, spleen, bursa and cecal tonsil 
was evaluated by detection of viral VP3 gene by PCR, as shown in Table III. 
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In CIAV vaccinated group, there were no IBDV or CIAV DNA positive cases in 
the thymus samples at 18 and 21 days pi, whereas presence of CIAV genome in thymus 
was documented at 28 dpv in 1 of the 6 tested vaccinated chicks. In the spleen, the 
vaccine virus persisted in vaccinated birds and was detected in 2, 3 and 3 chicks at 18, 
21, and 28 days pi respectively. All other specimens collected from, bursa, bone marrow, 
sera and liver of CIAV vaccinated chicks were negative by nested-PCR. 
In the CIAV vaccinated and IBDV infected groups, the CIA vaccinal strain 
persisted in both thymus and spleen of inoculated birds throughout the experiment. In 
thymus, 1, 2, and 2 chicks were CIAV-DNA positive at 18, 21, and 28 days pi 
respectively. The same trend was observed in the spleen of these birds in which 2, 3 and 
3 birds had the CIAV viral genome in their spleen. Also, the CIAV was detected in the 
bursa of 3 out of 6 tested birds at 28 days pi. Other bursa samples from the coinfected 
group, and the cecal tonsil, sera and liver samples were negative in nested-PCR.  
As expected, in the IBDV inoculated SPF chicks the CIAV were not detected in 
any of the tested organs. The RT-PCR at 18, 21 and 28 dpi demonstrated that the 
lymphoid organs, sera and liver samples of all tested SPF chicks in CIAV vaccinated 
group were free of IBD virus. The thymus and spleen samples of CIAV and IBDV 
coinfected groups also were negative in the RT-PCR for IBDV. The presence of IBDV 
was only documented in the bursa of 3 and 4 birds at 21 and 28 dpv respectively. 
Interestingly, in 2 of the 3 IBDV positive birds simultaneous presence of CIAV was 
documented. In addition, presence of IBDV in 1 coinfected chick was detected at 21 dpv. 
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Figure 3-19 - Hematological examination of blood from CIAV and/or IBDV inoculated 
SPF chicks. 
 Hematocrit (PCV) (A), white blood cell count (WBC) (B), percentages of 
heterophils (C) and percentages of lymphocytes (D) in the blood of  CIAV (), 
CIAV+IBDV (), and IBDV () inoculated birds were determined at 18, 21 and 28 days 
post-vaccination. The mean of each value for coinfected and IBDV inoculated groups 
were compared to CIAV vaccinated groups (n=6). * p≤ 0.05,  ** p≤ 0.01  
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Table III- Detection of CIAV and IBDV genome in lymphoid organs of the CIAV and 
/or IBDV infected groups at 18, 21 and 28 dpi. 
 .
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3.3.3. Analyses of thymic cell subpopulations 
To verify whether the coinfection of CIAV vaccinal strain and IBDV induces 
immune disorders in lymphoid cells populations, percentages of different lymphoid 
subsets in thymus, spleen and bursa from CIAV-vaccinated, CIAV+IBDV, and IBDV 
inoculated chicks were compared at various time pi. The isolated lymphoid cells were 
isolated from these three organs were double immunolabelled with fluorescent antibodies 
against CD4, CD8, CD3, TCR-γδ and IgM, and analyzed by cytofluorometry.  
As shown in Figure 3-20. A, percentages of thymic CD4+CD8- cells were 
significantly lower in the CIAV vaccinated and CIAV+ IBDV inoculated group in 
various time pv in compare to those who received IBDV alone (p≤ 0.001). Thymic CD4-
CD8+ cells were also lower in CIAV group (p≤ 0.001) at 18 dpv, whereas the adverse 
trend was observed at 28 dpv in which elevated percentage of CD4-CD8+ cells in the 
CIAV vaccinated group was concurrent with significant reduction of these cells in IBDV 
infected birds.  Effects of IBDV+CIAV coinfection in thymic CD4-CD8+ cells were not 
significant, but a variation in the percentages among the chicks was observed (Figure 3-
20. B). The same variation was obvious in thymic CD4+CD8+ cells in which addition of 
IBDV to vaccinated chicks increased the percentage of these cells in a non-significant 
level at various time pv. However, significant decrease in the percentage of CD4+CD8+ 
cells in IBDV group were shown at 18 (p≤ 0.01) and 21 dpv (p≤ 0.05) (Figure 3-20. C). 
TCRγδ+ cells were not modified in CIAV+IBDV chicks and the values were 
similar to those from vaccinated birds (Figure 3-20. D). The percentages of TCR-γδ+ 
98 
 
 
thymic cells were obviously lower in IBDV inoculated birds when compared to the two 
other groups at 18, 21 (p≤ 0.05), and 28 dpv (p<0.001).  
There were not any significant changes in the expression level of CD4 and CD8 
molecules between the CIAV, CIAV+IBDV and IBDV inoculated groups (data not 
shown).  
3.3.4. Analyses of splenic and bursal lymphocyte subpopulations 
In spleen, an analysis of lymphocytes surface molecules shows that both CIAV 
vaccinated, and CIAV+IBDV coinfected group had higher CD4-CD8+, CD4+CD8+ 
(except for 28 dpi), and CD3-CD8+ NK cell percentages compared to the IBDV 
inoculated group (Figure 3-21, A, B, and E). In contrast,  the percentage of CD4+CD8- 
cells were significantly lower  in the CIAV vaccinated and coinfected chicks when 
compared to IBDV group at various time pv (p≤0.05) (Figure 3-21, C). Coinfection of 
CIAV and IBDV viruses lowered the IgM-bearing spleen cells at 21 dpv (p≤0.05) 
whereas the coinfection, and also CIAV vaccination exhibited a paramount elevation of 
these cells percentages at 28 dpv (p≤0.001) (Figure 3-21, D). The splenic TCRγδ cells 
were not different among the 3 groups at 18 and 21 dpv, while its percentage was 
significantly higher in the IBDV inoculated birds at 28 days of age (Figure 3-21, F). 
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Figure 3-20 - Percentages of lymphocytes subpopulations in thymus of SPF chicks at 18, 
21 and 28 days following CIAV-vaccination at hatch. 
Thymocytes from CIAV (), CIAV+IBDV () and IBDV () inoculated birds were 
double labelled with anti-CD4, anti-CD8, anti-TCRγδ conjugated to FITC, PE or PerCP 
and analyzed in cytofluorometry. The mean of each value for coinfected and IBDV 
inoculated groups were compared to CIAV vaccinated groups (n=6). * p≤ 0.05, ** p≤ 
0.01, *** p≤ 0.001 
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In bursa of Fabricius, percentages of CD4-CD8+ cells were clearly higher in the 
IBDV infected birds at various dpv in comparison to the other groups. The CIAV+IBDV 
coinfection caused more reduction of these T cytotoxic lymphocytes in the bursa 
compared to administration of CIAV vaccine alone (p<0.001) (Figure 3-22, A). The 
main feature of the experimental treatments effects on the bursa CD4+ CD8- was 
contrary to the results obtained in the spleen in which higher percentages of the bursal T 
helper cells in the CIAV vaccinated and CIAV+IBDV coinfected groups were detected 
especially at 21 and 28 dpv (Figure 3-22, B). This was concurrent with reduction of the 
IgM+ bursa cells by CIAV+IBDV co-administration at 21 dpv which was followed by a 
recovery and even a significantly higher level than the IBDV infected birds at 28 dpv 
(Figure 3-22, C). The immune disorders induced by CIAV and/or IBDV viruses were 
also observed in bursal CD4+CD8+ cells in which the elevation of these cells in the 
coinfected group at 18 dpv was reversed at 21 dpv with the lowest percentages among the 
three groups. The percentages of these cells in the coinfected birds were also significantly 
higher than the control CIAV, and also the coinfected group at 28 dpi (Figure 3-22, D). 
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Figure 3-21 - Percentages of lymphocytes subpopulations in spleen of SPF chicks at 18, 
21 and 28 days following CIAV inoculation at hatch. 
Spleen cells from CIAV (), CIAV+IBDV () and IBDV () inoculated birds were 
double or triple labeled with anti; CD4, CD8, CD3, IgM and anti-TCRγδ conjugated to 
FITC or PE and analyzed in cytofluorometry.  The mean of splenic CD4-CD8+ (A), 
CD4+CD8+ (B), CD4+CD8-(C), IgM+ (D), CD3-CD8+ NK cells (E),  and TCRγδ+ (F) 
subpopulations for coinfected  and IBDV inoculated groups were compared to CIAV 
vaccinated groups (n=6). * p≤ 0.05,  ** p≤ 0.01,  *** p≤ 0.001 
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Figure 3-22 - Percentages of lymphocytes subpopulations in bursa of SPF chicks at 18, 
21 and 28 days following CIAV inoculation at hatch. 
Bursa cells from CIAV-vaccinated (), CIAV+IBDV inoculated () and IBDV infected 
() birds were double labeled with anti; CD4, CD8 and IgM conjugated to FITC or PE 
and analyzed in cytofluorometry. The mean percentage of bursal CD4-CD8+ (A), 
CD4+CD8- (B), IgM+ (C) and CD4+CD8+ (D) subpopulations for coinfected  and IBDV 
inoculated groups were compared to CIAV vaccinated groups (n=6). * p≤ 0.05,  ** p≤ 
0.01,  *** p≤ 0.001 
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3.3.5. Levels of anti-CIAV antibodies 
The SPF chick’s humoral response to the CIAV and/or IBDV inoculation was 
monitored by ELISA. Vaccination with the CAV-VAC® did not produce a notable 
humoral response in majority of vaccinated chicks when administered at hatch. Measured 
anti-CIAV antibodies revealed that there were only 2 antibody positive chicks (out of 36 
birds) at 18 and 21 dpi, in CIAV and coinfected groups respectively.  The anti-CIAV 
antibodies were not produced in majority of the chicks and did not persist up to 28 days 
pv. The anti-IBDV antibodies were only detected in IBDV inoculated group in 1 and 3 
chicks at 21 and 28 dpi respectively (Figure 3-23).  
3.3.6. TGF-β and IFN-γ production 
There were no significant differences in the levels of TGF-β and IFN-γ production 
of bone marrow cells obtained from CIAV, CIAV+IBDV, and IBDV inoculated birds as 
performed by ELISA at various times pi (data not shown). 
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Figure 3-23 - Anti-CIAV and IBDV antibody levels of coinfected SPF chicks. 
After CAV-VAC® vaccination  at hatch and/or IBDV inoculation at 14 days of age in 
SPF chicks, sera samples of the three groups were tested for anti-CIAV and IBDV 
antibodies by ELISA at 18, 21 and 28 days post-vaccination. The numbers on the data 
column represent the number of antibody positive chicks out of 6 chicks tested in the 
related group. 
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3.4. Experiment 4. Effects of early infection of CAV-VAC® vaccine virus 
on lymphoid cell subpopulations, viral persistence and humoral immune 
responses of commercial chicks 
3.4.1. Clinical signs and hematologic study results 
The commercial chicks inoculated by CIAV at hatch, and also the chicks in control 
group did not show any clinical signs or anemia throughout the experiment. No weight 
loss or thymic atrophy, as revealed by gross examination, was observed in vaccinated 
chicks at various times pv. Bone marrow cell numbers also were not altered in vaccinated 
chicks (data not shown). Reduction of PCV at 14 dpv in the CIAV inoculated birds was 
the only significant differences (p≤0.05) observed in hematologic studies of the 
commercial chicks. The WBC count, and percentages of heterophils and lymphocytes in 
blood of CIAV-vaccinated birds did not show any significant variations throughout the 
experiment when compared with control group (Figure 3-24). 
3.4.2. Presence of CIAV vaccinal strain in lymphoid organs 
The presence of the CIA vaccine virus in thymus, spleen, bursa, cecal tonsil, bone 
marrow, liver and sera was evaluated by detection of viral VP3 gene by PCR. As shown 
in Table IV, CIAV DNA fragment was detected in the thymus of 1, 3 and 3 (out of 6 
tested) and 7 (out of 12) vaccinated birds at 7, 14, 21, and 28 dpv respectively. Also, 
presence of CIAV genome in the spleen of 1 (out of 12) tested vaccinated chick, was 
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documented at 28 dpv. All other specimens collected from, bursa, cecal tonsil, bone 
marrow, sera and liver were negative in the carried out nested-PCR. 
3.4.3. Analyses of thymic cell subpopulations 
Percentages of the different lymphoid subsets in thymus, spleen and bursa from 
CIAV-vaccinated chicks were compared with control group birds at various time pv. The 
extracted lymphoid cells from these three organs were double immunolabeled with 
fluorescent antibodies against CD4, CD8, CD3, TCR-γδ and IgM, and analyzed by 
cytofluorometry.  
As shown in Figure 3-25, percentages of thymic CD4+CD8-, CD4-CD8+, 
CD4+CD8+ or TCR-γδ+ cells were not modified in vaccinated chicks and the values 
remained similar to those from unvaccinated group (Figure 3-25, A, B, C, D). No 
significant modification in percentages of thymic CD3-CD8+ cells was also detected in 
vaccinated chicks (data not shown). 
Separation of smaller (G1) and larger (G2) thymocytes performed by more analyses 
of FSC/SSC parameters did not significantly differ between CIAV-vaccinated or control 
birds (data not shown).  
3.4.4. Analyses of splenic and bursal lymphocyte subpopulations 
The percentage of all the cell subsets including CD4-CD8+ T cytotoxic cells, CD4-
CD8+ helper cells, CD4+CD8+, IgM-bearing and TCRγδ cells were not significantly 
altered following CIAV vaccination (Figure 3-26, A, B, C, D, F). The number of CD3-
CD8+ cells in the spleen was also not affected by CIAV vaccination till 14 dpv. The 
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reduction in the percentage of CD3-CD8+ (NK) cells at 28 dpv was the sole significant 
changes observed in spleen of CIAV-vaccinated commercial birds in the 
immunolabeleing assays (p≤0.05) (Figure 3-26, E).  
In fabricius bursa, labeling of lymphocytes surface molecules did not show any 
significant differences between the vaccinated and control group. The percentages of 
CD4-CD8+, CD4+CD8-, CD4+CD8+ and IgM+ bursal lymphocytes were relatively 
similar between the two groups of commercial chicks at various time pv  (Figure 3-27, 
A, B, C, D).  
3.4.5. Levels of anti-CIAV antibody 
The ELISA results of anti-CIAV and anti-IBDV antibody monitoring in 
commercial chicks is shown in Figure 3-28. Vaccination of 1-day old commercial chicks 
with the CAV-VAC® did not produce a humoral response in vaccinated chicks. At 7 dpv, 
the decreasing level of maternal antibody which was detected in all of the tested chicks at 
hatch, was only detectable in 4 of non-inoculated control birds but not in vaccinated 
chicks. Except for 2 individual antibody positive cases at 18 and 21 dpv, all the chicken 
at 14, 18, 21 and 28 dpv were anti-CIAV  negative in ELISA. 
Anti-IBDV maternal antibodies were detected in all the tested chicks at 7 and 14 
dpv. It was also detectable in 4 control and 4 CIAV vaccinated birds at 18 dpi. At 21 dpv, 
most of the chickens, and at 28 dpv all of them in the control and vaccinated groups 
didn’t have any anti-CIAV antibodies as shown by ELISA.  
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3.4.6. Cytokines assays 
The ELISA performed on bone marrow cells extracted from vaccinated and control 
groups demonstrated no significant differences in the TGF-β and IFN-γ production at 
various times pv (data not shown). 
 
Figure 3-24 - Hematological examination of CIAV-vaccinated commercial chicks. 
 Hematocrit (PCV) (A), white blood cell (WBC) count (B), percentages of heterophils 
(C) and lymphocytes (D) in the blood of  CIAV-vaccinated () and control birds () 
were determined at 7, 14 and 28 days post-vaccination. The mean of each value for 
vaccinated and control birds (n=6) were calculated and compared. * p≤ 0.05 
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Table IV - Detection of CIA vaccine virus genome in lymphoid organs of commercial 
CIAV-vaccinated and control chicks. 
 
Days post-vaccination  
28 dpv21 dpv 18 dpv14 dpv7 dpv  
CIAV Ctrl CIAV Ctrl CIAV Ctrl CIAV Ctrl CIAV Ctrl  
7/12- 3/6 - - - 3/6 - 1/62 -1         Thymus 
1/12- - - - - - - - -         Spleen 
0/12- - - - - - - - -         Bursa 
0/12- - - - - - - - - Cecal 
tonsil 
 
1- The dash reoresents no positive results 
2- Number of positives / Number tested 
Groups of 6 commercial chicks were inoculated by CAV-VAC® or PBS at hatch, 
euthanized at 7, 14, 18, 21, and 28 (12 chicks at 28 dpv) days post-vaccination and 
organs were sampled. Viral genome was detected by polymerase chain reaction (PCR). 
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Figure 3-25 - Percentages of lymphocytes subpopulations in thymus of CIAV-vaccinated 
commercial chicks. 
Commercial chicks were inoculated by CAV-VAC® or PBS at hatch. At 7, 14 and 28 
days pv, thymocytes from CIAV-vaccinated () and control birds () were double 
labeled with anti-CD4, anti-CD8 and anti-TCRγδ conjugated to FITC or PE and analyzed 
in cytofluorometry. The mean percentage of thymic CD4+CD8- (A), CD4+CD8+ (B), 
CD4-CD8+ (C) and TCRγδ+ (D) subpopulations for CIAV-vaccinated and control 
groups (n=6) were calculated and compared.  
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Figure 3-26 - Percentages of lymphocytes subpopulations in spleen of CIAV-vaccinated 
commercial chicks. 
Commercial chicks were inoculated by CAV-VAC® or PBS at hatch. At 7, 14 and 28 
days pv, spleen cells from CIAV-vaccinated () and control birds () were double 
labeled with anti-CD4, anti-CD8, anti-TCRγδ, anti-IgM, and anti-CD3 conjugated to 
FITC or PE and analyzed in cytofluorometry. The mean percentage of thymic CD4-
CD8+ (A), CD4+CD8+ (B), CD4+CD8- (C), IgM+ (D), CD3-CD8+ (E) and TCRγδ+ (F) 
subpopulations for CIAV-vaccinated and control groups (n=6) were calculated and 
compared.* p≤ 0.05. 
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Figure 3-27 - Percentages of lymphocytes subpopulations in bursa of CIAV-vaccinated 
commercial chicks. 
Commercial chicks were inoculated by CAV-VAC® or PBS at hatch. At 7, 14 and 28 
dpv, bursal lymphocytes from CIAV-vaccinated () and control birds () were double 
labeled with anti-CD4, anti-CD8, anti-IgM conjugated to FITC or PE and analyzed in 
cytofluorometry. The mean percentage of thymic CD4-CD8+ (A), CD4+CD8- (B), IgM+ 
(C) and CD4+CD8+ (D) subpopulations for CIAV-vaccinated and control groups (n=6) 
were calculated and compared. 
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Figure 3-28 - Anti-CIAV and IBDV ELISA titer of CAV-VAC® vaccinated commercial 
chicks. 
Commercial chicks were inoculated by CAV-VAC® or PBS at hatch. Sera samples of 
CIAV-vaccinated and control group were tested for anti-CIAV (A) and IBDV (B) 
antibodies by ELISA at 7, 14, 18, 21 and 28 days post-vaccination by ELISA. The initial 
titers (maternal anti-CIAV and anti-IBDV antibodies) were determined at hatch (n=14). 
Each column represents the ELISA titer of one positive chick tested. 
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3.5. Experiment 5. Effects of a low-virulent strain of IBDV infection on 
lymphoid cell subpopulations, viral persistency and humoral immune 
responses of CAV-VAC® vaccinated commercial chicks 
3.5.1. Clinical signs and hematologic evaluation 
Fifty four commercial chicks of the three groups did not show any clinical signs 
and anemia during the experiment. No weight loss or thymic atrophy, as revealed by 
gross examination, was observed in the experimental birds at various times pv. Bone 
marrow cell numbers were not altered in vaccinated chicks (data not shown). 
The PCV and WBC count of all birds from CIAV, CIAV+IBDV, and IBDV 
inoculated group were almost similar without significant differences (Figure 3-29, A, B). 
The notable effects of our treatments on measured blood parameters were observed in the 
percentages of blood heterophils and lymphocytes in which the highest differences were 
recorded between the CIAV and IBDV inoculated groups. The average percentage of 
heterophils in CIAV group was clearly less than those in IBDV inoculated birds at 18 
(p≤0.001), 21 (p≤0.01) and 28 (p≤ 0.001) days of pv. In contrast, significant increase in 
the blood lymphocytes of CIAV chicks  were shown compared with IBDV inoculated 
birds  at all three sampling times pi (p≤ 0.01) (Figure 3-29, C, D). 
3.5.2. Presence of CIAV and IBDV in lymphoid organs 
The presence of the CIAV vaccinal strain and IBDV in thymus, spleen, bursa and 
cecal tonsil of inoculated birds were evaluated by PCR and RT-PCR.  
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In the group of CIAV inoculated chicks, the vaccine virus was only detected in 
thymus, in which 3 CIAV thymus positive chicks were detected at 21 and also 28 dpv. 
All other samples of CIAV group including sera and liver (data not shown), spleen, bursa 
and cecal tonsil were negative in the detection assays (Table V). 
In the CIAV+ IBDV coinfected group, the vaccine virus was detected in thymus, 
spleen and bursa starting from 18 dpv and persisted till 28 dpv. Presence of CIAV 
genome in thymus was documented in three, two, and four birds (n=6) at 18, 21 and  28 
days pv respectively. The similar trend was observed in the spleen of these birds in which 
persistence of the vaccine virus was shown in the spleen of four, four and two birds at 18, 
21 and 28 dpi respectively. In the bursa samples, CIAV detection assays resulted in 1 
positive chicks at 18 dpv, with no more detection at 21 dpv and two positive cases at 28 
dpv (Table V). All other specimens collected from cecal tonsil, sera and liver of CIAV 
inoculated birds, and also all the samples collected from IBDV inoculated group were 
negative in the carried out nested-PCR. 
The RT-PCR results at 18, 21 and 28 dpv demonstrated that the lymphoid organs, 
sera and liver samples of all tested commercial chicks in CIAV vaccinated group were 
free of IBD virus. The thymus and spleen samples of CIAV + IBDV coinfected groups 
were also negative in the RT-PCR. The presence of IBDV in this group was only 
documented in the bursa of two and four birds at 18 and 28 dpv respectively. In the 
IBDV group, IBDV genome was detected in the bursa of two chicks at 28 dpv. The sole 
cecal tonsil positive case was documented in this group at 21 dpi (Table V). 
116 
 
 
3.5.3. Analyses of thymic cell subpopulations 
The isolated lymphoid cells from thymus were double immunolabeled with 
fluorescent antibodies against CD4, CD8, CD3, TCR-γδ and IgM, and analyzed by 
cytofluorometry. Percentages of the different lymphoid subsets in thymus of CIAV-
vaccinated, CIAV+IBDV, and IBDV inoculated chicks were compared at various time 
pv. Percentages of thymic CD4+CD8- cells were significantly lower in the IBDV  
inoculated group at 21 dpv  campared to those who received CIAV+ IBDV (p≤ 0.05), or 
CIAV alone ( p≤ 0.01). Thymic CD4-CD8+ cells were also higher in IBDV group (p≤ 
0.05) at 18 dpv, whereas the adverse trend was observed at 21 and 28 dpv in which lower 
percentage of CD4-CD8+ was observed in IBDV infected birds (Figure 3-30, A, B).  
The CD4+CD8+ cells also were significantly higher in the IBDV inoculated birds 
at 21 dpv compared to both CIAV, and CIAV + IBDV coinfected groups (p≤ 0.01). 
However, inoculation of IBDV in the CIAV vaccinated group didn’t change the 
percentages of these thymocyte subpopulations at various time pv (Figure 3-30, D). 
TCRγδ+ cells were significantly modified in CIAV, and CIAV+IBDV chicks 
compared to those from IBDV inoculated birds (Figure 3-30, D). Percentages of TCR-
γδ+ thymic cells were obviously lower in IBDV inoculated birds when compared to the 
CIAV vaccinated group at 18 (p≤ 0.01), 21 (p<0.001) and 28 (p<0.001) days pv. 
Inoculation of IBDV in the CIAV vaccinated birds reduced the percentages of TCR-γδ+ 
thymic cells at 18 dpv whereas the higher percentages of these cells were recorded at 28 
dpv in the coinfected group (p≤ 0.05). 
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The expression level of thymic CD4 and CD8 molecules between the CIAV, CIAV 
+ IBDV and IBDV inoculated groups were not significant changed (results not shown). 
3.5.4. Analyses of splenic and bursal lymphocyte subpopulations 
In spleen, significant differences among the three groups of chicks were observed 
in all of the tested subpopulation. The CD4-CD8+ of IBDV infected group was higher 
than those from CIAV+IBDV and CIAV groups at the three sampling times. The 
percentages of splenic cytotoxic T cells were significantly lower in both CIAV and 
CIAV+IBDV inoculated birds at 18, 21 and 28 dpv compared to IBDV infected birds 
(Figure 3-31, A). The CD4+CD8+ cells of vaccinated chicks also were affected by the 
IBDV infection only at 21 dpv in which lower percentages of these cells were observed 
in the coinfected group. In addition, both CIAV and CIAV+IBDV group had higher 
averages of splenic CD4+CD8+ cells in compare to IBDV infected birds (Figure 3-31, 
B). The percentage of CD4+CD8- spleen cells in CIAV vaccinated birds was almost 
similar to the coinfected chicks with no significant differences. Percentage of these 
helper T cells was slightly reduced in the IBDV group at 18 dpv compared to CIAV 
vaccinated chicks (Figure 3-31, C). The IgM+ and CD3-CD8+ cells in the spleen were 
not different among the CIAV vaccinated and coinfected chicks, whereas the average 
percentages of IgM+ cells were significantly lower in the spleen of IBDV inoculated 
birds at 21 and 28 dpv (p≤ 0.01). The CD3-CD8+ splenic NK cells were also 
significantly higher in the IBDV inoculated group at 18 and 21 dpv. This was followed 
by lower percentage of NK cells in the IBDV received group compared to the two other 
groups who had inoculated by CIAV, or CIAV+IBDV (Figure 3-31, E). 
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Dual infection of CIAV+IBDV viruses, and also inoculation of IBDV alone caused 
elevation of TCRγδ+ spleen cells percentages at 18 dpv (p<0.05), whereas the differences 
between the groups values were non-significant at 21 and 28 dpv (Figure 3-31, F). 
In the BF, percentages of CD4-CD8+ cells were obviously reduced by IBDV 
inoculation of CIAV vaccinated birds only at 18 dpi. The value was also significantly 
less than that of IBDV inoculated group (Figure 3-32, A) (p≤0.01). Inoculation of IBDV 
significantly reduced the percentages of CD4+CD8- and CD4+CD8+ subpopulation 
bursa when compared to CIAV vaccinated group. These cell percentages were also 
lowered by inoculation of IBDV in the CIAV vaccinated chicks at 28 dpv (p<0.05). 
IBDV inoculation, also reduced the average of CD4+CD8+ bursa cell percentages in the 
CIAV vaccinated group at 18 (p≤0.01) and 28 dpv (p≤0.05) (Figure 3-32, B, D). The 
IgM-bearing bursa lymphocytes subpopulation was also significantly decreased by IBDV 
inoculation of vaccinated chicks at 18 and 21days post- CIAV vaccination which 
corresponds to 4 and 7 days post- IBDV inoculation respectively. At 21 dpv, the number 
of IgM+ bursa cells in the IBDV inoculated birds was surprisingly more than the two 
other groups (Figure 3-32, C). 
3.5.5. Levels of anti-CIAV and anti- IBDV antibodies 
As it was observed in the SPF chicks (experiment 3), vaccination with the CAV-
VAC® did not produce a notable humoral response in majority of vaccinated chicks 
when administered at hatch. Notable maternal antibodies against both CIAV and IBDV 
were detected at hatch. Measured anti-CIAV antibodies reveals that there were only one 
antibody positive chick, out of 36 birds tested, in the CIAV vaccinated group which was 
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detected at 18 dpv. In the CIAV+IBDV infected chicks, the anti-CIAV antibodies were 
detected in one, three, and one chicks at 18, 21 and 28 days post- CIAV vaccination. 
Low level anti- IBDV antibodies were detectable only in some chicks in the CIAV 
and coinfected groups until 21 dpv. The 28 day old IBDV inoculated birds were the only 
anti-IBDV positive group in which two out of 6 chicks in the group were positive in 
ELISA. This might be the only detected non-maternal antibodies in this experiment 
(Figure 3-33).  
3.5.6. TGF-β and IFN-γ production 
There were no significant differences in the levels of TGF-β and IFN-γ production 
of bone marrow obtained from CIAV, CIAV+IBDV, and IBDV inoculated birds as 
shown by ELISA at various times pv (data not shown). 
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Figure 3-29 - Hematological examination of blood from CIAV and/or IBDV inoculated 
commercial chicks. 
Hematocrit (PCV) (A), white blood cell (WBC) count (B), percentages of heterophils (C) 
and percentages of lymphocytes (D) in the blood of  CIAV (), CIAV+IBDV (), and 
IBDV () inoculated birds were determined at 18, 21 and 28 days post-vaccination. The 
mean of each value for coinfected and IBDV inoculated groups were compared to CIAV 
vaccinated groups (n=6).  * p≤ 0.05, **p≤ 0.01, ***p≤ 0.001  
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Table V - Detection of CIAV and IBDV genomes in lymphoid organs of the CIAV and 
/or IBDV infected commercial chicks at 18, 21 and 28 dpv. 
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Figure 3-30 - Percentages of lymphocytes subpopulations in thymus of commercial 
chicks at 18, 21 and 28 days following CIAV-vaccination at hatch. 
 Thymocytes from CIAV (), CIAV+IBDV () and IBDV () inoculated birds were 
double labeled with anti-CD4, anti-CD8, anti-TCRγδ conjugated to FITC or PE and 
analyzed in cytofluorometry.  The mean percentage of thymic CD4+CD8- (A), CD4-
CD8+ (B), CD4+CD8+ (C) and TCRγδ+ (D) subpopulations for coinfected  and IBDV 
inoculated groups were compared to CIAV vaccinated groups (n=6).  
* p≤ 0.05,   ** p≤ 0.01,  *** p≤ 0.001 
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Figure 3-31 - Percentages of lymphocytes subpopulations in spleen of commercial 
chicks at 18, 21 and 28 days following CIAV vaccination at hatch.  
The caption of Figure 3-31 continues in the following page. 
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Figure 3-31- Continues from previous page. 
 Spleen cells from CIAV (), CIAV+IBDV () and IBDV () inoculated birds were 
double labeled with anti; CD4, CD8, CD3, IgM and anti-TCRγδ conjugated to FITC or 
PE and analyzed in cytofluorometry.  The mean percentage of splenic CD4-CD8+ (A), 
CD4+CD8+ (B), CD4+CD8-(C), IgM+ (D), CD3-CD8+ (E),  and TCRγδ+ (F) 
subpopulations for coinfected  and IBDV inoculated groups were compared to CIAV 
vaccinated groups (n=6). * p≤ 0.05,   ** p≤ 0.01,  *** p≤ 0.001 
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Figure 3-32 - Percentages of lymphocytes subpopulations in bursa of commercial chicks 
at 18, 21 and 28 days following CIAV inoculation at hatch. 
Bursa cells from CIAV (), CIAV+IBDV () and IBDV () inoculated birds were 
double labeled with anti; CD4, CD8 and IgM conjugated to FITC or PE and analyzed in 
cytofluorometry. The mean percentage of bursal CD4-CD8+ (A), CD4+CD8- (B), 
CD4+CD8+ (C) and IgM+ (D) subpopulations for coinfected  and IBDV inoculated 
groups were compared to CIAV vaccinated groups (n=6).   * p≤ 0.05,   ** p≤ 0.01,  
 *** p≤ 0.001 
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Figure 3-33 - Anti-CIAV and IBDV antibody levels of coinfected commercial chicks. 
After CAV-VAC® vaccination  at hatch and/or IBDV inoculation at 14 days of age in 
commercial chicks, sera samples of the three groups were tested for anti-CIAV and anti-
IBDV antibodies by ELISA at 18, 21 and 28 days post-vaccination. The initial titers 
(maternal anti-CIAV and anti-IBDV antibodies) were determined at hatch (n=14). The 
numbers on the data column represent the number of antibody positive chicks out of 6 
chicks tested in the related group.  
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Chapter 4. Discussion 
4.1. Anti-IBDV maternal antibody decline rate and weight gain 
Success in genetic selection and improvement in feed quality have resulted in at 
least the doubling of the chicken growth rate and overall performance over the past 
decades (Julian, 1998). A one-day per year decrease in chicken marketing age was 
reported over the 35 year period ending in 1991 (Havenstein et al., 1994a) and the same 
trend has continued, albeit at a different rate until now (Havenstein et al., 2003). As a 
result, a shorter growing period is now required to produce the broiler chicken of a given 
body weight, and many management methods should be applied at an earlier stage of 
broiler growth (Antony, 1998). The increase in growth rate has also been accompanied 
by changes in body composition and yield (Havenstein et al., 1994b), which in turn 
negatively influences adaptive immune responses (Qureshi and Havenstein, 1994). Since 
the appearance of variant strains and very virulent strains of the IBD virus (vvIBDV), it 
has become more difficult to formulate a successful vaccination program (van den Berg 
and Meulemans, 1991). Broiler chickens cannot be protected by MA during the whole 
growing period and should therefore be vaccinated as soon as the level of MA becomes 
low enough to allow the vaccine to break through (breakthrough titer) (van den Berg and 
Meulemans, 1991). Maternal antibody, which has always been assumed to decline 
according the chick age, may also be affected by the dilution of blood serum due to rapid 
weight gain. 
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In order to avoid IBDV infection, vaccination timing and vaccine choice are 
important factors in initiating active immunity in the chick (Kouwenhoven and Van der 
berg, 1994; Lasher and Shane, 1994). The timing is predicted based on MA decline rate, 
which is currently based on immunoglobulin half-life. It is generally accepted that flocks 
represent a mosaic of passive immunity, thus, the wider the coefficient of variation in 
mean antibody titer, the greater will be the possibility of infection. Differences in the MA 
decline rates have been reported (Kouwenhoven and Van der berg, 1994; Lasher and 
Shane, 1994; Kumar et al., 2000). In studies on passive immunity and MA decline in 
chicks, greater rates of decline were observed in rapidly growing broiler chicks compared 
to slow growing layer chicks (Fahey et al., 1987; Box, 1989b; van den Berg and 
Meulemans, 1991). On the other hand, different maternal antibody half-life for IBDV in 
chickens were reported as 3 days (Skeeles et al., 1979), 4 days (Wyeth and Cullin, 1976), 
5.5 days (Al-Natour et al., 2004), 6.7 days (Fahey et al., 1987) and 6-8 days (Wood et al., 
1981). These differences in the calculated immunoglobulin half-life of the same chicken 
breed are not normal and indicate that there should be another important factor in 
calculation of antibody half-life.  
In the experiment 1 of this study, in addition to initial antibody titer and age of the 
birds, their weight was taken into consideration and studied as another influencing factor 
in MA decline rate. This was then used to calculate the amount of residual maternal 
antibodies. The differences seen in the MA decline curves were minimized when the 
results were plotted out according to the chick weight. The initial titer and the chick 
weight determined the antibody decline pattern regardless of their age. In other words, 
chicks of the same weight had the same level of residual MA even at different ages. The 
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ELISA results, validated by VN showed the effects of weight gain on the waning MA, 
thus demonstrating the same antibody decline pattern for the groups with the same initial 
titers when they were plotted out against bird weight. Analysis performed on the ELISA 
SP values also showed similar pattern as regular ELISA titer and VN titer. Uniformity of 
the TAC curves, which are obtained by multiplying titer by weight, shows the same 
linear antibody decline pattern and half-life, regardless of feed used. Because of the 
direct effects of weight in this index, its application in calculation of maternal antibody 
half-life is suggested.  
 The results obtained by vaccination weight formula, and its comparison to 
measured breakthrough titer in chicks confirmed the importance of growth rate and body 
weight on residual anti-IBDV MA. The vaccination times predicted by weight formula 
were closer to the targeted breakthrough titer under different growth conditions, more 
significantly so in slow-growing birds. The formula may also be used to calculate 
targeted weights for different vaccine types using appropriate breakthrough titer for each 
vaccine. In field conditions, it is common that there are some high to very high titers in 
some chicks within a commercial broiler flock. These high titers can affect the overall 
average of the group while the majority of birds in the group are MA negative or close to 
negative. The titer variation effects on vaccination prediction may be reduced by the 
formula. The prediction results obtained by the average of 75% lowest titers as the 
representative titer to be used in the formula, were more realistic and closest to the 
measured breakthrough titer compared to the average titers of all samples tested. This 
was also true when compared to the Deventer which uses only one titer as the 
representative titer that is the titer equal to or next above the 75th percentile which in our 
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case this was the 6th highest titer out of 22 samples tested. The application of the average 
of 75% lowest birds titers in the formula decreases the effects of high titers on the 
prediction value and targets mid-range and lower titers birds within a flock. The chickens 
with higher MA titer that are missed by the vaccination will be contaminated by the 
others as the vaccine virus spreads for several days after the vaccination (de Wit, 1998). 
These findings strongly demonstrate the effects of weight gain rate on decline rate 
of MA to IBDV in chicken and introduce the application of bird weight as an influencing 
factor in timing of IBD vaccination. 
4.2. Effects of early CIAV vaccination on SPF chicks 
The findings in the experiment 2 demonstrate that commercial CIAV-vaccinal 
strain induce a subclinical infection in 1-day old chicks associated with viral persistency 
in spleen and thymus, transient humoral response and  alterations of  thymopoiesis. 
CIAV infection is highly prevalent worldwide as determined by serological testing 
(Miles et al., 2001; Todd, 2004 ). Clinical signs occurred in very young chicken after 7 to 
14 days while the disease remains subclinical in older birds. Clinical signs are 
characterized by anorexia; depression, pallor, and decrease of weight gain, hematocrit 
and white blood cells especially blood lymphocytes and heterophils. Pale bone marrow 
and atrophy of thymus, spleen and bursal reflect depletion of T and B cells predisposing 
the birds to secondary infections (Todd, 2004 ). Experimental CIAV-infection in 1-day-
old SPF chicks rendered them anemic (lower hematocrit) with depleted bone marrow and 
thymus at 14 days post-infection (Yuasa and Imai, 1986). 
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The attenuated CIAV strains are commercially used as vaccine but some technical 
and practical problems affect the widespread use of vaccines (Schat, 2009). However, it 
is not known if the commercial vaccinal strains have retained the ability to induce 
immune disorders which is seen with the pathogenic strain. Such pathological features 
support the attenuating phenotype of the commercial viral strain under study. The present 
study reveals that a commercial attenuated CIAV strain did not induce clinical signs in 1-
day old chicks, did not decrease white blood cells, except for heterophils, and induced no 
significant cell depletion in thymus, spleen, bursa and bone marrow. Hemocytoblasts, the 
precursors of erythrocytes, thrombocytes and heterophils are known as target cells for 
CIAV infection (Taniguchi et al., 1983). The light decrease in percentages of heterophils 
may suggest that vaccinal virus has retained the ability to infect hemocytoblast, but 
neither anemia, nor presence of VP3 gene and cell depletion were found in bone marrow 
cells. The decrease in heterophils was transient at 14 dpv only and may rather reflect the 
non significant increase of lymphocytes at the same time. These observations are 
comparable to a previous finding in which some attenuated CIAV strain induced 
subclinical infection with no anemia, or mild lesion (McKenna et al., 2003).  Presence of 
moderate thymic depletion, however, suggests that attenuated viral strain have kept their 
ability to alter thymopoiesis.  
Replication of the vaccinal viral strain tested in the present work was detected in 
thymus in most of the vaccinated chicks, at 7 dpv only. This indicates viral vaccinal 
replication rapidly aborted in the thymus. It is demonstrated that pathogenic CIAV was 
produced in many organs, both in 1 day old or 6 week-old infected chicks, up to day 18 
post- inoculation and reached a peak in the thymus, spleen and liver at 18 or 20 days pi 
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(Kaffashi et al., 2006). The vaccinal strain used in our work is attenuated since viral 
replication became undetectable after 7 dpv. At 28 dpv, however, VP3 gene was 
observed in thymus in some of the experimental birds, suggesting a viral persistency in 
this organ. Hu et al (1993) showed that persistent viremia occur in CIAV infected birds 
in the absence of antibody production. The viral persistency of pathogenic CIAV was 
confirmed by Imai et al (1999) who suggested that CIAV can induce persistent infection 
in infected birds. 
The replication of vaccinal strain in thymus and its persistency in some birds 
suggest the occurrence of thymopoiesis disorders, as seen in thymus from pathogenic 
CIAV-infected birds (Jeurissen et al., 1989; Kuscu and Gurel, 2008). The viral 
replication in thymus remains certainly low since no significant depletion of thymocytes 
was observed after vaccination. The cytofluorometric analysis of thymocytes subsets 
from CIAV-vaccinated birds revealed two different time-dependent steps, the first, at 7 
days pv and the second, up to14 dpv. At 7 dpv, percentage of larger CD4+CD8+ thymic 
cells and expression levels of CD4 and CD8 on thymocytes increased, suggesting a 
stimulation of thymic maturation.   
At 14 and 28 dpv, percentage of CD4+CD8+ cells decreased in the thymus of 
CIAV-vaccinated one-day-old chicks in spite of no significant decrease in total thymic 
cells, suggesting that replication of vaccinal strain slightly alter the thymocyte maturation 
process or mature antiviral CD4 and CD8 cells were recruited from blood and spleen. 
The decrease of the thymic CD4+CD8+ subset did not result from a compensatory 
increase of other thymic subsets, since there was no significant changes in percentages of 
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CD4+CD8- or TCR-γδ cells and a slight increase of CD4-CD8+ cells. However, the 
discrimination between dividing cells and resting cells by the FSS/SCC parameters 
revealed that smaller thymic CD4+CD8+ cells were depleted in vaccinated chicks, 
suggesting that resting cells are more susceptible to viral infection and apoptosis or the 
viral infection blocks the cell mitosis. Infection of T cell precursor in the thymus, and 
inhibition of anaphase-promoting complex/cyclosome by the viral apoptin which leads to 
G2/M arrest and apoptosis has been reported in pathogenic CIAV infection (Teodoro et 
al., 2004 ). The intensity analysis of CD4 and CD8 surface cell markers revealed that 
CD4 expression was diminished on thymocytes but not the CD8 expression. This 
observation suggests that vaccinal strain of CIAV may specifically interfere with CD4+ 
expression or maturation of CD4+ CD8- thymic cells, explaining thus the lower 
percentage of small CD4+CD8+ cells. The specific decrease of CD4 expression in 
thymocytes by CIAV viral infection has not been reported previously. However, the 
target cells in spleen for the CIAV are the T helper subset (Adair et al., 1993). It is 
demonstrated that percentage of both CD4+ and CD8+ thymic cells similarly decreased 
in thymus from 1-day-old chicks infected with pathogenic CIAV (CIA-1 strain)  due to 
cell destruction by viral infection or interference with CD4+ and CD8+ expression (Hu et 
al., 1993b). The CD4+CD8+ cell subset, however, represents the most important cell 
subset in thymus, and decrease of CD4+ cells may involve a decrease in CD8+ cells. The 
decrease of CD4 expression in thymic cells induced by attenuated vaccinal CIAV strain 
revealed rather discrimination between the thymocytes subsets expressing CD4 and/or 
CD8. We hypothesize, thus, that vaccinal CIAV strain does not inhibit specifically the 
CD4 expression but may affect the thymocyte development steps. It is well-known that 
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the thymic CD4-CD8+ cell subset occurred earlier than the CD4+CD8- or CD4+CD8+ 
cell subsets during the avian thymopoiesis (Davidson et al., 1992 ). In consequence, the 
lower expression of CD4+ in presence of higher expression of CD8 may reflect the 
accumulation of mature CD4-CD8+ cells rather than a differential decrease in CD4+ 
expressing thymocytes. On the other hand, the infection of T cell precursor expressing 
CD3 by the pathogenic CIAV involved a decrease of CD4+CD8+ thymic cells (reviewed 
in Schat, 2009). The decreases in CD4+CD8+ cells observed at 14 and 28 dpv indicate 
that thymocyte precursors can support replication of  CIAV vaccinal strain, as confirmed 
by VP3 gene detection in thymus from some birds at 28 days pv. 
Contrary to that seen in thymus, VP3 gene in spleen was detected in one chick at 7 
dpv, but the number of positive chicks increased with time. The percentages of splenic 
CD4-CD8+ cells increased while CD4+ CD8- cells decreased at 28 dpv only, which is 
similar trend as in the thymus. The increase of splenic CD4-CD8+ cells, however, at 28 
dpv suggests the occurrence of a cytotoxic T lymphocytes (CTL) immune response. The 
late increase of CD8+ cells raises also the possibility that vaccinal CIAV infection induce 
a delay in the CTL response or that this responses is not sufficient for viral elimination. 
Markowski-Grimsrud and Schat (2003) demonstrated that CIAV-infected chicks without 
anti-CIAV maternal antibodies have lost the ability to mount a CTL response at 7 days pi 
against secondary viral infections, suggesting that CIAV can impair the CTL functions. 
In another study, IFN-γ production increased at 8 days pi but decreased after up to 43 
days pi indicating a suppression of CTL response (Adair et al., 1991). We have observed 
no increase in the IFN-γ production in CIAV-vaccinated chicks, suggesting that CD8+ 
dependent cytotoxic function is not strongly stimulated by viral vaccination.  
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In addition, no significant stimulation of lymphocytes to ConA was detected in 
thymic or splenic cells from CIAV-vaccinated chicks (results not shown); supporting the 
idea that vaccination did not strongly stimulate the lymphocyte activity. Depressed 
responsiveness of lymphocytes to mitogens following CIAV infection has rather been 
well-documented (Otaki et al., 1988; Adair et al., 1991; McConnell et al., 1993; Bounous 
et al., 1995). 
The concurrent increase of splenic CD4+CD8+ and CD3-CD8+ (NK cells) which 
is seen only at 7 dpv suggests the occurrence of an innate antiviral immune response by 
CIAV vaccinal strain. It was previously demonstrated that pathogenic CIAV did not alter 
the NK cell activity (Markowsi-Grimsrud & Schat, 2001). 
Finally, the percentage increases of CD4-CD8+ cells in the BF at 7 and 28 dpv 
correlated with concurrent decreases of CD4+CD8- cells suggesting that these 
modifications reflect the thymus disorders rather than a specific viral replication. The 
VP3 gene was not found in bursa or cecal tonsils of experimental chicks. However, the 
decrease of IgM-bearing cells at 28 dpv suggests disorders in bursal B cell production. 
The CIAV-VAC® administration did not induce a strong and persistent humoral 
response when administered at susceptible young birds, as demonstrated by transient low 
anti-CIAV antibody titers detected in some of the birds only. The infection with 
pathogenic CIAV strain triggers antibody production in immunologically mature chicken 
which mediates the age-related resistance to the virus (Hu et al., 1993a). In our study, 
incompetent immune system of the very young chicks, decrease of the CD4+ cells in the 
thymus and spleen, decrease in percentage of IgM-bearing cells and persistency of 
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vaccinal strain in thymus and spleen up to 28 dpv might result in inability of the 
inoculated birds to produce proper high levels of anti-CIAV antibodies. Presence of the 
virus genome in the spleen until 28 dpv coexisted with lack of functional humoral 
immunity in the inoculated birds. It was previously reported that pathogenic CIAV was 
recovered from blood cells or lymphoid organs of infected birds at different days pi even 
in the presence of low or high viral neutralizing antibodies (Yuasa et al., 1983b; Imai et 
al., 1999). 
The virus persistence and the immune disorders induced by the CIAV vaccine virus 
lead to practical consequences, and it is likely to play an important role in the sub-clinical 
infections and decreased responsiveness to other avian pathogens in the poultry industry. 
4.3. Effects of IBDV on CIAV vaccinated SPF chicks 
Experiment 3 investigates the effects of the CIAV vaccinal strain on infection of 
young chicks with a low-virulent strain of IBDV. The infection of IBDV in the CIAV 
vaccinated chicks lead to viral persistence in thymus, spleen, bursa and cecal tonsil, 
transient immune responses to both CIAV and IBDV, and alteration of lymphocytes 
subpopulation in the chicks lymphoid organs. 
IBDV serotype 1 viruses are ubiquitous and highly contagious with ability to infect 
and produce clinical or subclinical disease in chicken. The virus targets and destroys 
IgM-bearing bursal cells (Ivanyi and Morris, 1976; Hirai and Calnek, 1979; Hirai et al., 
1981) and causes an acute immunosuppressive disease in chicken.  
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The IBDV replication leads to destruction of lymphoid cells in the BF and to a 
lesser extent in other lymphoid organs such as cecal tonsils and spleen (Van der berg, 
2000). Even though there is no evidence of IBDV replication in thymic cells, many 
pathologic changes, atrophy and apoptosis occur in the thymus of affected birds (Sharma 
et al., 2000). Classic and very virulent IBDV strains cause hemorrhagic inflammation of 
the BF, whereas variant strains (GLS and E/Del) cause rapid bursal atrophy without 
evoking an inflammation response, suggesting differences in the apoptotic processes and 
pathogenesis of the disease (Liu and Vakharia, 2006). IBDV also increased the 
susceptibility of birds to contact infection with CIAV and resulted in increased mortality 
rate in CIAV inoculates. The effects of CIAV infection varied following exposure at 1 
day of age to two different strains of IBDV (STC and Variant-E) (Rosenberger and 
Cloud, 1989). Surviving birds become more susceptible to other infectious agents with 
reduced ability to respond to the vaccines (Allan et al., 1972; Muller et al., 2003). 
Co-infection of birds with CIAV and some other infectious diseases revealed more 
features of CIAV immunosuppression. The coinfection of pathogenic CIAV with IBDV 
has a synergetic effect in the pathogenesis, clinical signs and the induced 
immunosuppression. Morbidity and mortality are considerably enhanced if chicks are 
dually infected with CIAV and IBDV, probably due to virus-induced immunosuppression 
(Schat and Woods, 2008). In the present study, neither clinical signs nor anemia were 
observed in the coinfected birds. The IBDV infection in vaccinated birds with CAV-
VAC® did not result in appearance of clinical signs or hematological changes in the 
coinfected birds suggesting that possible synergetic effects of the two non-pathogenic 
strains are not so strong to make symptoms in a clinical level. However, considering the 
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ubiquitious nature of these two viruses, and our finding about the immune disorders 
induced by CIAV alone, subclinical infections and viral persistency are not to be ignored. 
Infection of young vaccinated chicks with IBDV at 14 day after CIAV vaccination 
resulted in more prolonged presence and excessive numbers of CIAV and also IBDV 
genome detection in lymphoid organs of infected birds, including thymus, spleen, bursa 
and cecal tonsil. In fact, the IBDV infection of CIAV vaccinated birds did not correct the 
immune disorders and viral persistency induced by CIAV vaccine, whereas more 
extended presence of the vaccine virus till 28 dpv was recorded in thymus, spleen and 
bursa. On the other hand, more cases of IBDV positive bursas and cecal tonsils were 
recorded till 28 days post-vaccination which is correspondent to 14 days after IBDV 
inoculation. Therefore, the coinfection resulted in inability of the chick’s immune 
responses to clear both low-virulent IBDV and vaccinal strain of CIAV from lymphoid 
organs, and resulted in their persistency. In our knowledge, the coinfection of low-
virulent strains of CIAV and IBDV has not been investigated before.  However, it is 
shown that chickens inoculated simultaneously with pathogenic CIAV and IBDV 
experienced a prolonged acute phase prior to recovery or mortality (Cloud et al., 1992a). 
When SPF chickens were infected with IBDV at 1 day of age, they remained susceptible 
to CIAV up to at least 21 days, whereas birds inoculated with CIAV alone were 
susceptible only at 1 day of age. 
IBDV induced immunosuppression has been associated with the use of live MDV, 
IBDV, haemorrhagic enteritis virus and chicken infectious anaemia virus vaccines as 
these viruses replicate in cells associated with immune responses. In addition, vaccines 
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that have similar tropisms are known to interfere with the immune response to each other 
(Schat and Skinner, 2008). 
The decreased percentages of CD4+CD8+ cells in the thymus of vaccinated birds 
that was seen from 14 to 28 days pv, compared to the non-infected control group in 
experiment 2, was not significantly altered by IBDV inoculation. However, the values 
were reduced by the coinfection in a non-significant level at the three sampling times pv. 
The values were the least in the IBDV inoculated birds which may be related to the 
dramatic increase of CD4+CD8- subset in these birds at 18, 21 and 28 dpi. The same 
trend was observed in the thymic TCRγδ, CD4+CD8-, and  splenic CD4+CD8+, CD3-
CD8+, and IgM bearing cell subsets in which the CIAV results resembled CIAV+IBDV 
average cell percentages in most cases, but significantly different from the IBDV 
recorded subpopulation at various times pv. The CD4+CD8- and CD4-CD8+ spleen cell 
percentages were also similar between the CIAV and CIAV+IBDV infected groups at 18 
and 21 days pv. These observations suggest that the CIAV effects on lymphocytes 
subpopulations in lymphoid organs are more obvious than the effects related to the 
addition of IBDV. 
In the IBDV inoculated group, higher percentages of thymic and splenic 
CD4+CD8- T helper cells, less percentages of TCRγδ thymic cells, and lower 
percentages of CD3-CD8+ NK cells indicate that more elements of an acquired immunity 
are triggered in the lymphoid organs of these birds compared to the CIAV and 
CIAV+IBDV inoculated birds. The results of ELISA performed on the sera also confirms 
the stimulation of acquired humoral immunity in the IBDV inoculated birds in which 
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they were the only anti-IBDV antibody-positive chicks  at 7 and 14 days post- IBDV 
inoculation. In contrast, the CIAV and CIAV+IBDV groups with lower T helper cells in 
their thymus and spleen, more TCRγδ thymic cells, and higher percentages of cytotoxic T 
cells and NK cells in the spleen showed a characteristics of a transient anti-virus cellular 
and also innate immune responses. The cellular immune response of these chicks was not 
competent, and did not result in prevention of IBDV and/or CIAV persistence. In 
majority of these chicks, genomes of one or both of these viruses were present as long as 
28 dpv. In addition to ineffectiveness of the cellular and innate responses in the 
elimination of these viruses, lack of humoral immune responses is to be counted for the 
subclinical infection and lymphoid organs viral persistency. 
4.4. Effects of early CIAV vaccination on commercial chicks 
Subclinical infection, viral persistency and lack of antibody responses were the 
main consequences of early administration of CIAV vaccine virus in commercial broiler 
chicks. 
The results indicate that presence of MA in the CIAV inoculated chicks prevented 
the immune disorders induced by the vaccine virus in the lymphoid organs. However, the 
subclinical infection of thymus, and in a lesser extent in the spleen of vaccinated chicks, 
was demonstrated.  
In the previous studies, it is shown that virus may be present in the organs of 
infected birds even in the presence of low or high antibodies (Imai et al., 1999). The 
presence of the attenuated vaccinal strain used in our experiment was limited in the 
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lymphoid organs of vaccinated chicks during the first week following inoculation which 
is a result of high level of maternal antibody. At 14, 18 and particularly 28 dpv more 
cases of virus genome detection were recorded in the thymus of experimental birds. This 
suggests that the virus replication and persistence were limited by the MA, at least during 
the first week, but not completely eliminated in the lymphoid organs of vaccinated birds.  
In addition, high level of initial MA was disappeared in the sera of all 6 chicks in 
the vaccinated group at 7 dpv, whereas most of the chicks in the control group still had 
detectable level of anti-CIAV antibodies at the same time. This might be due the 
interference of the vaccine virus by the MA which lead to partial neutralization of both 
vaccine virus and MA in the vaccinated chicks. This also might explain the fact that in 
the absence of immune disorders which were observed in the SPF chicks, the commercial 
chick’s immune system did not mount an effective humoral response at various times 
post-vaccination.  
4.5. Effects of CIAV and IBDV coinfection in commercial chicks 
Our findings indicate that IBDV inoculation in the CIAV vaccinated commercial 
chicks result in lymphocyte subpopulations alteration, extended persistence of both 
viruses in lymphoid organs and lack of humoral responses.  
Many features of the results obtained in the coinfection of commercial and SPF 
chicks are similar. The blood heterophil and lymphocyte percentages at 21 and 28 dpv, 
the thymic T cytotoxic and TCRγδ cells, spleen CD4+CD8+ and bursal T helper cells at 
all of the sampling times pv showed similar cell population pattern in the absence or 
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presence of MA, in the SPF and commercial chicks respectively. The presence of viral 
genomes of both viruses in the lymphoid organs also showed mostly similar results in the 
most cases. At the planned sampling times, there was not any residual of MA in the 
commercial chicks, therefore the persistent CIAV virus was able to replicate in a 
detectable level similar to those observed in the SPF chicks. The IBDV also had been 
injected at 14 days after CIAV vaccination in which the anti-IBDV MA was decreasing 
to a non-effective level while some immune disorders was already in process as a result 
of early CIAV inoculation. We suggest that this accumulated effects leaded to almost the 
same spread of IBDV and CIAV in the lymphoid organs of SPF and commercial chicks. 
The same trend was also observed in the ELISA results in which there were not effective 
humoral immune responses against CIAV and IBDV in the commercial chicks. 
Furthermore, the coinfected commercial chicks showed lower percentages of IgM-
bearing cells in their bursa at 18 and 21 dpv in compare to CIAV inoculated and even 
IBDV infected birds. 
It is known that MA can protect chickens against the clinical signs, severity of the 
disease and viral replication and persistence. Also, the age-related resistance to CIAV in 
mediated by antibodies (Schat and Woods, 2008) which means; it is extended in the 
absence of antibody response. As our results in the previous experiments demonstrated, 
the MA limited the presence of virus till 7 dpv, and thereafter there were some cases of 
viral presence in the tested commercial chicks. In addition, the CIAV induced immune 
disorders observed in lymphocyte subpopulations of SPF chicks were not created in the 
presence of MA. Therefore, in the commercial coinfected birds, the disorders observed in 
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the subpopulation of lymphoid organs are counted for the IBDV effects and synergetic 
effects of coinfection. 
Our results demonstrate that early inoculation of CIAV vaccine in broiler chicks 
induces subclinical infection associated with viral persistency, immune disorders in 
lymphocytes subpopulations of lymphoid organs and transient antibody responses.  
Infection of the CIAV vaccinated chicks by IBDV enhanced the effects in the presence or 
absence of maternal antibodies. 
 
 Conclusion 
The results obtained in the first part of this work strongly demonstrate the 
importance of growth rate and body weight on decline rate of residual anti-IBDV MA. 
We conclude that application of chicks weight in calculation of residual MA, leads to 
more exact timing of IBD vaccination and immediate administration of vaccine in the 
susceptible ages of chicken.  
In the second part, we conclude that early infection of in 1-day old SPF chicks 
with CIAV-vaccinal strain, induces a subclinical infection associated with viral 
persistency in lymphoid organs, transient humoral response and alterations of 
thymopoiesis. Infection of these chicks by other low-virulent agents, such as the strain of 
IBDV used in our experiment, may lead to more extended viral persistence, lack of 
humoral response, and immune disorders in the CIAV vaccinated chicks. Presence of 
MA may limit the viral persistence and disorders during the first week of age. 
Thereafter, the susceptibility of these immunocompromised chicks to coinfection and 
associated immune disorders is similar to SPF chicks. 
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SUMMARY. Growth rate in broiler birds has increased substantially in the last 
decade due to improvement in genetics, feed formulation, cleaner environment, and vaccine 
formulations. As a result, it has become necessary to review and revise prediction method 
for vaccination in chicks. This study was undertaken to determine the possible use of the 
rate of weight gain rather than age in predicting vaccination time. Two groups of 1-day-old 
broilers originating from old and young breeders, respectively, and with different levels of 
maternal antibodies against infectious bursal disease virus (IBDV) were used in this study. 
The chicks were divided into four groups and subjected to two feed regiments: groups A1 
and B1 were fed broiler feed for normal growth rate, and groups A2 and B2 were fed 
breeder feed for slower growth rate. At 1, 4, 8, 12, 16, 22, 29, and 36 days of age, 22 chicks 
in each group were weighed, and blood samples were collected. Serum samples were tested 
for antibodies against IBDV by enzyme-linked immunosorbent assay (ELISA) and virus 
neutralization test. Maternal antibody decline curves for each group were plotted according 
to chick age and chick weight. Fast-growing birds in groups A1 and B1 showed a faster rate 
of antibody decline, whereas slow-growing birds in groups A2 and B2 had a slower rate of 
antibody decline. Based on the effect of weight gain on maternal antibody decline, a new 
way of predicting vaccination time for IBDV based on measuring maternal antibody titers 
Vaccination time prediction by chick’s weight                                           A. Vaziry et al. 
at 4 days of age was proposed and tested. The predicted antibody decline was shown to 
correspond to the real ELISA titers measured in our experiments (R = 0.9889), whereas a 
lower correlation (R = 0.8355) was detected between real ELISA titers and the titers 
predicted by the current method using age-based Deventer formula.  
RESUMEN. Prediccio´n del momento ideal para la vacunacio´n contra la 
enfermedad infecciosa de la bolsa basa´ndose en el peso del ave.  
La tasa de crecimiento de los pollos de engorde se ha incrementado substancialmente 
en la u´ltima de´cada debido a las mejoras en gene´tica, la formulacio´n del alimento, un 
medio ambiente ma´s limpio y los planes de vacunacio´n. Debido a esto, se ha hecho 
necesario revisar y modificar el me´todo de prediccio´n del mejor momento para la 
vacunacio´n de aves dome´sticas. Este estudio se realizo´ para determinar el posible uso de 
la tasa de ganancia de peso en lugar de la edad para predecir el momento ideal para 
vacunar. Se utilizaron dos grupos de pollos de engorde de un dı´a de edad con diferentes 
niveles de anticuerpos maternales contra el virus de la enfermedad infecciosa de la bolsa 
provenientes de reproductoras jo´venes y viejas, respectivamente. Las aves se 
subdividieron en cuatro grupos y fueron sometidas a dos programas alimenticios: los 
grupos A1 y B1 fueron alimentados con alimento formulado para una tasa de crecimiento 
normal y los grupos A2 y B2 fueron alimentados con alimento formulado para una tasa de 
crecimiento ma´s lenta. A la edad de 1, 4, 8, 12, 16, 22, 29 y 36 dı´as, se pesaron y 
sangraron 22 aves en cada grupo. Las muestras de sangre se analizaron mediante la prueba 
de virus neutralizacio´n y la prueba de inmunoensayo asociado a enzimas para determinar 
los niveles de anticuerpos contra la enfermedad infecciosa de la bolsa. La curva del 
catabolismo de anticuerpos maternales se grafico´ de acuerdo con la edad y peso de las 
aves. Las aves con crecimiento ra´pido pertenecientes a los grupos A1 y B1 mostraron una 
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tasa de catabolismo de anticuerpos ma´sra´pida, mientras que las aves de crecimiento lento 
pertenecientes a los grupos A2 y B2 mostraron una tasa de catabolismo de anticuerpos ma´s 
lenta. Basa´ndose en el efecto de la ganancia de peso sobre el catabolismo de los 
anticuerpos maternales, se propuso y evaluo´ una nueva forma de predecir el momento 
ideal para la vacunacio´n contra el virus de la enfermedad infecciosa de la bolsa 
fundamentada en la determinacio´n de los tı´tulos de anticuerpos maternales a los cuatro 
dı´as de edad. Se demostro´ que la tasa predicha de catabolismo de anticuerpos 
correspondio´ a los tı´tulos reales detectados mediante la prueba de inmunoensayo asociado 
a enzimas en nuestro experimento (R = 0.9889), mientras que entre los tı´tulos reales de 
anticuerpos y los tı´tulos predichos por el actual me´todo utilizando la fo´rmula de 
Deventer basada en la edad, se observo´ una correlacio´n menor.  
Key words: infectious bursal disease, maternal antibody, vaccination timing, 
vaccination prediction formula, weight formula, chicken  
Abbreviations: ELISA = enzyme-linked immunosorbent assay; IBD = infectious 
bursal disease; IBDV = infectious bursal disease virus; MA = maternal antibody; MDA = 
malondialdehyde; TAC = total antibody content; VN = virus neutralization  
 
Infectious bursal disease (IBD), also known as Gumboro disease, is one of the major 
causes of economic loss in the chicken industry due to morbidity, mortality, and 
immunosuppression (17). Specific diagnostic measures, enforced sanitary programs, and 
vaccination schedule are required for successful control of the disease (6, 16).  
Since the late 1970s, medical prophylaxis of IBD has been largely based on the use of 
live attenuated vaccines to immunologically prime breeder pullets at an early age, followed 
by inactivated oil-adjuvant vaccines administered at around 10 and 18 wk of age. This 
vaccination protocol results in the generation of high antibody levels in the parent flocks, 
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and at the same time it provides maternal antibodies (MAs) to the progeny chicks to ensure 
their protection against IBD virus (IBDV) (3,6,16). High levels of neutralizing MAs protect 
chicks against early infection and immunosuppression, but they can also interfere with the 
development of active immunity to vaccine virus (12, 18).  
Since the appearance of variant strains and very virulent strains of the virus, it has 
become more difficult to formulate a successful vaccination program (21). Broiler chickens 
cannot be protected by MAs during the whole growing period; therefore, they should be 
vaccinated as soon as the level of MAs becomes low enough to allow the vaccine to break 
through (breakthrough titer) (21). The timing of vaccination in relation to MA levels is thus 
critical in ensuring adequate replication of the vaccine virus and efficacious protection of 
young chicks from disease (13). If the vaccine is administered too early, it will be 
neutralized by the residual MAs, and if it is administered too late, the birds might have 
already been infected by wild virus.  
Several formulas for estimating the optimal vaccination time are used in poultry 
production. The first and most frequently used formula was developed by Kouwenhoven 
(14) and revised and renamed as the Deventer formula (5). The formulas are based on the 
decline of antibody levels due to immunoglobulin half-life in the chicken. The 
breakthrough titer can thus be predicted by measuring the level of MAs at a young age, 
usually within the first week of life (5). Prediction of vaccination time can thus be made 
based on initial titer, immunoglobulin half-life, and breakthrough titer, depending on the 
vaccine strain used.  
In the past few decades, rapid improvements in genetics, feed and vaccine 
formulations, and management have lead to increased growth rate in chicks. Faster growth 
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can lead to a faster decline in MA levels due to a dilution effect. This study examines the 
effects of chick weight gain on MA decline and the use of weight rather than age in 
predicting Gumboro disease vaccination time.  
MATERIALS AND METHODS  
Experimental birds. Two groups of 500 Hubbard/Ross 1-day-old male broilers were 
used in this study. The chicks in group A, with an average initial enzyme-linked 
immunosorbent assay (ELISA) titer of 5333 originated from 27-wk-old breeders, whereas 
those in group B with a titer of 3799 were derived from 60-wk-old breeders. Each group 
was equally subdivided into two groups: group A1, group A2, group B1, and group B2. 
Birds in group A1 and group B1 were kept on broiler feed ration, whereas those in group 
A2 and group B2 were fed breeder ration, which normally has lower protein and energy 
contents.  
At 1, 4, 8, 12, 16, 22, 29, and 36 days of age, 22 chicks from each group were 
weighed, and blood was collected from the heart or wing-vein puncture. Birds sampled at 1, 
4, and 8 days of age were sacrificed during blood collection. Serum was prepared from 
clotted blood by centrifugation, labeled, and frozen at 220 C until used. The serum samples 
from each group were tested for antibodies to IBDV using ELISA and virus neutralization 
(VN) test.  
ELISA procedure. Titration of MAs in chick sera was carried out using commercial 
IBD kits provided by Synbiotics Corporation (San Diego, CA) according to the 
manufacturer’s protocol. Regular titers and sample to positive (SP) values calculated by 
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Synbiotics Corporation software were used for statistical analysis and prediction of 
vaccination age.  
VN test. VN test using constant-virus, dilute-serum (ß method) was conducted in 
VERO cell cultures. Serum was inactivated at 56 C for 30 min and serially diluted in 
twofold directly in 96-well tissue-culture microtiter plates. VERO cell adopted D78 strain 
of IBDV was added at 100 tissue culture infectious dose50 to the serially diluted serum 
samples in triplicates and incubated at 37 C for 1 hr before adding the cells. The cultures 
were incubated at 37 C for 5 days in a humid chamber, and the results, based on the 
absence of cytopathic effects, were recorded. Appropriate cell and virus controls were 
included in each test plate. Antibody titers were calculated based on the average of 
triplicate wells, determined after 5 days of incubation. The VN titer was expressed as a 
twofold serum dilution (e.g., 1/256 serum dilution was expressed as 256), and their 
geometric mean titers were calculated for age groups.  
Comparison of vaccination times: age vs. weight. For ELISA results, the averages 
of the measured MA titers were plotted out against corresponding bird ages and against 
bird weights. VN titers were also plotted against bird ages and bird weights. To determine 
the most suitable moment for vaccination of young birds based on the decline in MA titers, 
a target titer was considered for ELISA and VN. This target titer or breakthrough titer is 
determined by vaccine manufacturers, and it varies according to vaccine types (mild, 
intermediate, hot) and ELISA kit manufacturers. A breakthrough titer of 100 for VN, and 
500 for IBD ELISA (Synbiotics), was considered for the analysis of the results. Based on 
the measured titers, the time at which a breakthrough titer occurs was determined by 
comparing MA decline vs. age and vs. weight.  
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Prediction of vaccination age using ELISA titer and bird weight. ELISA titer, 
which is most commonly used by the industry, was used to establish a new IBD vaccination 
prediction formula. Bird weights and titers measured at 4 days of age were used to predict 
residual titer at any given targeted weight. The number of times the average chick weight 
increased compared with the weight at day 4 was used in calculating the effect of weight 
gain on the decreasing titer. Therefore, the following formula was devised to predict the 
residual MA titers at different chick weights:  
TiterghBreakthrou
DayatWeightDayatTiterTimenVaccinatioatWeight )4()4( ×=
 
The average of 75% lowest bird titers was used for vaccination prediction by the 
formula. This was done by eliminating 25% highest titers in computing the average titer of 
day 4 samples used for prediction.  
This formula was then used to predict the vaccination time for chicks using bird 
weight and the titers measured at day 4. The results were compared with the prediction 
made by current Deventer formula (5).  
Total antibody content (TAC). In this analysis, the effects of weight on the decline 
of MAs and the decline due to normal catabolic rate were studied. Total antibody content in 
birds at different ages post hatch was calculated by multiplying the average VN titer by 
respective bird weight. The value was assumed to represent the entire amount of antibody 
remaining in the bird at the specified age (TAC = titer × weight). The TACs were then 
plotted in a graph against bird ages.  
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Statistical analysis. The averages of body weights, ELISA titers, and VN titers, and 
correlation analysis were performed using Excel (Microsoft, Redmond, WA). Linear model 
analysis, with groups and time, were performed using SAS for Windows, version 9.1 (SAS 
Institute, Inc., Cary, NC).  
RESULTS  
Weight gains. Significant differences in weights between groups A1 and A2, and 
groups B1 and B2, were observed starting from day 12 (P ≤ 0.005), and they persisted 
throughout the experiment (P ≤ 0.0001). As expected, fast-growing birds in groups A1 and 
B1 had similar growth curves, even though they originated from two breeder flocks of 
different ages and the chicks differed in initial average weights (39.5 g vs. 44.8 g). 
Likewise, chicks from slow-growing groups A2 and B2 had similar growth curves (Fig. 1).  
MA titers and ages. Antibody titers monitored by VN and ELISA at different ages 
post hatch showed different decline patterns for each group (Fig. 2a,b). Among the chicks 
with higher initial MA titers, birds in group A1, with a faster growth, also had a faster 
antibody decline pattern compared with those in slow-growing group A2. Likewise, in the 
groups with lower initial titers, the faster growing group B1 showed a faster decline in MA 
titer compared with the slow-growing group B2. Based on the ELISA results, the antibody 
half-life for fast-growing chicks in groups A1 and B1 were thus 4.35 and 2.84 days, 
respectively, whereas slow-growing chicks in groups A2 and B2 showed higher half-life of 
6.91 and 4.02 days, respectively.  
MA titers and weights. MA titers showed two decline patterns when titers were 
plotted against weights. Chicks in fast-growing group A1 and slow-growing group A2 
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shared the same MA decline curve at the same given weights, whereas those in groups B1 
and B2 also had a similar titer curve (Fig. 3a,b). 
 
 
Fig. 1. Growth curves of broiler chicks treated with broiler feed (21.8% protein and 
4.4% fat) or breeder feed (18% protein and 2.4% fat). Groups A1 and B1 received broiler 
feed, and groups A2 and B2 received breeder feed.  
MA titers and weights. MA titers showed two decline patterns when titers were 
plotted against weights. Chicks in fast-growing group A1 and slow-growing group A2 
shared the same MA decline curve at the same given weights, whereas those in groups B1 
and B2 also had a similar titer curve (Fig. 3a, b). 
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Fig. 2. Decline of MA titers at different ages posthatch measured by ELISA (a) and 
VN test (b). Groups A1 and B1 were given broiler feed, and groups A2 and B2 were given 
breeder feed.  
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Fig. 3. Decline of MA titers at different weights post hatch measured by ELISA (a) 
and VN test (b). Groups A1 and B1 were given broiler feed, and groups A2 and B2 were 
given breeder feed.  
Comparison of vaccination times: age vs. weight. When a breakthrough ELISA 
titer of 500 was chosen as an ideal vaccination titer for an intermediate IBD vaccine, four 
different vaccination ages were predicted: 19 days for group A1, 24 days for group A2, 13 
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days for group B1, and 17 days for group B2 (Fig. 4a). When the same titer was chosen and 
plotted against weight rather than age, 630 6 20 g was determined to be the ideal 
vaccination weight for groups A1 and A2, whereas 380 6 20 g was the most appropriate 
vaccination weight for groups B1 and B2 (Fig. 4b). In VN studies using the same serum 
samples, a titer of 100 was detected at 18, 22, 12, and 15 days of age in groups A1, A2, B1, 
and B2, respectively (Fig. 4c). The same breakthrough titer was detected in chicks in 
groups A1 and A2 at 530 g of weight and in groups B1 and B2 at 260 g (Fig. 4d).  
Predicting vaccination time by the weight formula. An ELISA titer of 500 was 
assumed to be the breakthrough titer used in predicting vaccination time based on weight 
rather than age. The targeted weight for vaccination was then calculated as follows:  
500
)4()4*( DayatWeightDayatTiteronVaccoinatiatWeight ×=
 
 * indicates the average of the lowest 75% birds’ titer tested at day 4 was applied as 
the titer at day 4.  
The predicted vaccination weight for birds in groups A1 and A2 was 484 g and 433 
g, respectively, and for groups B1 and B2, 305 g and 313 g, respectively (Table 1). For 
comparison purposes, prediction of vaccination time based on age was also calculated using 
Deventer formula (5), and the results were compared with the measured real titers (Fig. 5). 
Although a breakthrough of 500 ELISA titer was targeted by both formulas, the birds’ 
weight predicted by weight formula corresponded to the ELISA titer of 700, 725, 300, and 
500 for groups A1, A2, B1, and B2, respectively. The vaccination ages predicted by 
Deventer formula corresponded to titers of 850, 1400, 490, and 1050 for groups A1, A2, 
B1, and B2, respectively (Table 1). When the predicted times by weight formula were 
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compared with the real measured titers in the experiment, a strong correlation between 
them was observed (R = 0.9889). The results indicated a lower correlation between real 
ELISA titers and the titers predicted by Deventer formula (R = 0.8355).  
 Total antibody content. Figure 6 represents the TAC and its decline based on VN 
titers and measured bird weights. The four curves are parallel, and they show a similar 
steady, declining pattern.  
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Fig. 4. Real vaccination times obtained by the ELISA (a and b) and VN test results (c 
and d) for a breakthrough ELISA titer of 500 and VN titer of 100. Arrows indicate the 
breakthrough titers at which point birds can be vaccinated. (a and c) Breakthrough titers 
according to age. (b and d) Breakthrough titers based on weight.  
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Table 1. Vaccination time predicted by the weight or the Deventer formulas compared 
with the real measured weights and age of vaccination for a breakthrough ELISA titer of 
500. For prediction by weight formula, the highest 25% titers measured at 4 days of age 
were eliminated, and the average titers were based on the remaining 75% of birds. In the 
Deventer formula, the bird titer next to the 75th percentile was used in the prediction. 
Corresponding weight, titer, and ages were determined by regression model analysis of the 
measured and predicted results.  
 
Breakthrough titer measured by 
ELISA at different weights and 
their corresponding age in days 
Predicted vaccination time by the weight 
formula and its corresponding age and 
titer 
Predicted vaccination age by the 
Deventer formula and its corresponding 
weight and titer  
 
Groups 
Targeted 
break-
through 
titter 
Weight at 
break-
through 
titer 
Age at 
break-
through 
titer* 
Titer at 
predicted 
weight 
Predicted 
vaccination 
Weight 
Age at 
corresponding 
vaccination 
weight 
Titer at 
predicted 
age 
Weight at 
corresponding 
vaccination 
age 
Predicted 
vaccination 
age* 
A1 500 590 18 700 484 17 850 340 14 
A2 500 510 22 725 433 20 1400 200 14 
B1 500 250 11 300 305 12 490 240 11 
B2 500 310 17 500 313 17 1050 180 11 
 
A
Vaccination ages were rounded up to the nearest day.  
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Fig. 5. Prediction of IBDV vaccination time, using current Deventer formula and 
weight-based formula for a breakthrough titer of 500. The two methods were compared with 
vaccination time based on real titers measured by ELISA at different ages in the experiment. 
Correlation between vaccination time determined by real ELISA titers and predicted by 
Deventer formula (R = 0.8355). Correlation between vaccination time determined by real 
ELISA titers and predicted by weight-based formula (R = 0.9889).  
DISCUSSION  
Success in genetic selection and improvement in feed quality have resulted in at least 
the doubling of the chicken growth rate and overall performance over the past few decades 
(11). A 1-day/year decrease in chicken marketing age was reported over the 35-yr period 
ending in 1991 (9), and the same trend has continued, albeit at a different rate until now (8). 
As a result, a shorter growing period is now required to produce the broiler chicken of a 
given body weight, and many management methods should be applied at an earlier stage of 
broiler growth (2). The increase in growth rate has also been accompanied by changes in 
body composition and yield (10), which, in turn, negatively influence adaptive immune 
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responses (19). MA, which has always been assumed to decline according the chick age, 
may also be affected by the dilution of blood serum due to rapid weight gain.  
To avoid IBDV infection, vaccination timing and vaccine choice are important factors 
in initiating active immunity in the chick (14,16). The timing is predicted based on MA 
decline rate, which is currently based on immunoglobulin half-life. It is generally accepted 
that flocks represent a mosaic of passive immunity; thus, the wider the coefficient of 
variation in mean antibody titer, the greater will be the possibility of infection (16). 
Differences in the MA decline rates have been reported (14, 15, 16). In studies on passive 
immunity and MA decline in chicks, greater rates of decline were observed in rapidly 
growing broiler chicks compared with slow-growing layer chicks (4, 7, 21). In contrast, 
different MA half-lives for IBDV in chickens were reported as 3 days (20), 4 days (23), 5.5 
days (1), 6.7 days (7), and 6–8 days (22). These differences in the calculated 
immunoglobulin half-life of the same chicken breed are not normal, and they indicate that 
there should be another important factor in calculation of antibody half-life.  
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Fig. 6. TAC of the chicks at various times posthatch, calculated by multiplying virus 
neutralization titer by corresponding chick weight. Values represent the mean TAC of 22 
chicks tested at each occasion. Groups A1 and B1 were given broiler feed, and groups A2 
and B2 were given breeder feed.  
In this study, in addition to initial antibody titer and age of the birds, their weight was 
taken into consideration and studied as another influencing factor in MA decline rate. This 
was then used to calculate the amount of residual MAs. The differences seen in the MA 
decline curves were minimized when the results were plotted according to the chick weight. 
The initial titer and the chick weight determined the antibody decline pattern regardless of 
their age. In other words, chicks of the same weight had the same level of residual MA even 
at different ages. The ELISA results, validated by VN, showed the effects of weight gain on 
the waning MAs, demonstrating the same antibody decline pattern for the groups with the 
same initial titers when they were plotted against bird weight. Analysis performed on the 
ELISA SP values (data not shown) also showed a similar pattern as regular ELISA titer and 
VN titer. Uniformity of the TAC curves, which are obtained by multiplying titer by weight, 
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shows the same linear antibody decline pattern and half-life, regardless of feed used. 
Because of the direct effects of weight in this index, we suggest its application in calculation 
of MA half-life.  
The results obtained by vaccination weight formula, and its comparison with 
measured breakthrough titer in chicks confirmed the importance of growth rate and body 
weight on residual IBD maternal antibodies. The vaccination times predicted by weight 
formula were closer to the targeted breakthrough titer under different growth conditions, 
more significantly so in slow-growing birds. The formula may also be used to calculate 
targeted weights for different vaccine types using appropriate breakthrough titer for each 
vaccine. Under field conditions, it is common that there are some high to very high titers in 
some chicks within a commercial broiler flock. These high titers can affect the overall 
average of the group, whereas the majority of birds in the group are MA negative or close to 
negative. The titer variation effects on vaccination prediction may be reduced using weight 
formula. The prediction results, obtained by the average of 75% lowest titers as the 
representative titer to be used in the formula, were more realistic and closest to the 
measured breakthrough titer compared with the average titers of all samples tested. This was 
also true when compared with the Deventer, which uses only one titer as the representative 
titer that is the titer equal to or next above the 75th percentile; in our case, this was the sixth 
highest titer of 22 samples tested. The application of the average of 75% lowest birds’ titers 
in the formula decreases the effects of high titers on the prediction value and targets mid-
range and lower titer birds within a flock. The chickens with higher MA titer that are missed 
by the vaccination will be contaminated by the others as the vaccine virus spreads for 
several days after the vaccination (5). It should be noted that the VN test presented in this 
study was for the purpose of validating ELISA results. For vaccination prediction, it is 
recommended to use ELISA because of its simplicity, rapidity, popularity, and cost-
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effectiveness. Also, commercial ELISA kits are available in most countries that have 
intensive poultry production.  
These findings strongly demonstrate the effects of weight gain rate on decline rate of 
MAs to IBDV in chickens and introduce the application of bird weight as an influencing 
factor in timing of IBD vaccination.  
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ABSTRACT  
The chicken infectious anemia virus (CIAV) infection may induce 
immunosuppression and persistent infection. The use of vaccination in young chicks is 
still controversial due to its low immune efficiency. In order to verify the viral 
persistency of a vaccinal strain of CIAV and its associated-lymphoid cell disorders, 
fifty-four one day-old specific pathogen free (SPF) chicks were vaccinated (CAV-VAC
® 
Intervet) and hematologic examination, expression of viral VP3 gene, humoral response 
and phenotyping of lymphoid cells were studied in lymphoid organs at various times 
 III
postvaccination (pv). No clinical signs were observed but light heteropenia was 
detected in CIAV-vaccinated chicks. The VP3 gene of CIAV was detected by PCR in 
the thymus and spleen from day 7 until 28 days pv. Thymic larger CD4+CD8+ cells 
increased only at 7 days pv while smaller CD4+CD8+ cells decreased after14 and 28 
days in CIAV-vaccinated birds. The CD4 expression, in contrast to that seen for CD8, 
decreased in thymocytes from CIAV-vaccinated group. In spleen and bursa, the 
percentage of CD8+ cells increased at 7 and 28 days pv only while CD4+ cells 
decreased simultaneously. The vaccinated chicks also exhibited a higher number of 
splenic CD3-CD8+ cells (NK cells). The anti-CIAV antibody responses, however, 
remained low in most of vaccinated chicks and did not persist up to 18 days pv. These 
results suggest that vaccinal virus strain is clinically attenuated but persists in thymus 
and spleen in some birds inducing a low humoral immune response and altering 
thymopoiesis.   
Key words: Chicken anemia virus, circovirus, viral persistency, CD4+ and CD8+ 
lymphocytes, humoral response  
INTRODUCTION  
Chicken infectious anemia virus (CIAV) was first isolated by Yuasa et al. (1983). 
The virus is a Gyrovirus belonging to the family Circoviridae with circular single 
stranded DNA genome (Gelderblom et al., 1989). The genome encodes for three viral 
proteins designated as VP1, VP2 and 4 VP3. These viral proteins are expressed in the 
infected cells, whereas only VP1 which is the capsid polyprotein is present in the 
 IV
purified virus particles (Todd et al., 1990). The disease is transmitted vertically and 
horizontally (Chettle et al., 1989; Hoop, 1992). It is characterized by aplastic anemia, 
heterophils decrease, generalized lymphoid atrophy, skin lesions, haemorrhages, 
immunosuppression, enhancement of the pathogenicity of secondary infectious agents, 
suboptimal antibody responses and mortality in chicks younger than 3 weeks-old (Goryo 
et al., 1985; Jeurissen et al., 1992; McNulty et al., 1988; Otaki et al., 1992; Taniguchi et 
al. 1982; Vielitz & Landgraf, 1988). In younger chicks, extensive lesions occurred in 
thymus and bone marrow between 10 to 17 days postinfection (Kuscu & Gurel, 2008).  
The clinical or subclinical features result from virus replication and apoptosis of 
hemacytoblasts in bone marrow and T cell precursors in thymus of infected chicks 
leading to the anemia, intramuscular hemorrhages and granulocytopenia, reduction in 
size of thymic cortex and immunosuppression (Noteborn, 2004; Noteborn et al., 1994; 
Kuscu & Gurel, 2008). In the thymus, it has been shown that the virus replication and 
cell destruction occur in immature cortical lymphocytes (Jeurissen et al., 1989; 
McNeilly et al., 1991).   
It has been reported that CIAV infection either destroys cells expressing CD4, 
CD8, and CT1 molecules on their surface or interferes with the expression of these 
molecules on thymic cells (Hu et al., 1993a, b). In addition to the infection of precursor 
T-cells in the thymus, Adair et al., (1993) demonstrated that mature T lymphocytes in 
the spleen are also affected by CIAV. In many experimental studies, a greater 
destruction of CD8+ cells than CD4+ cells was observed (Adair et al., 1993; Cloud et 
al., 1992), while in some other studies no selective decrease in cytotoxic T-cells (CTL) 
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were detected by flow cytometric analysis of CD4+ and CD8+ subpopulations (Hu et 
al., 1993b). However, impairment of CTL activity has also been reported (Cloud et al., 
1992; Bounos et al., 1995). VP3 gene presence in CIAV infected cells is shown to 
induce apoptosis in chicken lymphoblastoid T cells and myeloid cells, which are 
susceptible to the infection, but not in chicken embryo fibroblasts, which are not 
susceptible to CIAV (Noteborn et al., 1994). The B cells are not susceptible to the 
infection (Markowski-Grimsrud & Schat, 2001). After infection with CIAV, antibodies 
are produced in immunologically mature chickens which prevent lesions development. 
Therefore, the age-related resistance to CIAV is antibody-mediated since older birds can 
develop lesions or persistent viremia when the antibody system is compromised by 
embryonal bursectomy (Hu et al., 1993a). In addition, it was proposed that CIAV can 
persist as a latent virus in spite of occurrence of neutralizing antibodies (McNulty, 1991; 
Miller & Schat, 2004).  
Considering ubiquitous and contagious nature of CIAV, some attenuated viral 
strains have been studied or used as vaccine strains. It was demonstrated that attenuated 
viral strains may induce lower T-cell depletion in thymus and reduced severity of lesions 
in one-day old chicks than those induced by a pathogenic viral strain (McKenna et al., 
2003). However, the current vaccines cannot be used for younger birds because of the 
age-dependent susceptibility to CIAV (Miller & Schat, 2004). No information is 
available on viral persistency of vaccinal strains in younger birds.  
In this study, the viral persistency of CAV-VAC
® 
vaccine virus and T-cell 
disorders were investigated in one-day-old SPF chicks.   
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MATERIAL AND METHODS  
Chicken and experimental design. Embryonated pathogen free eggs were 
obtained from the Veterinary Laboratories Agency (Nepean, Ont., Canada) and 
incubated, hatched and reared in the Faculty of Veterinary Medicine facilities (St-
Hyacinthe, Canada). All procedures were approved by the Université de Montréal 
animal care committee. Thirty six 1-day-old SPF chicks were divided in two groups and 
housed separately in isolators with chickens under sterile condition in room under 
negative pressure. Eighteen chicks of the vaccinated group received intraperitoneally 
(i.p.) 5 µl of CIA vaccine (CAV-VAC
®
, Intervet, Millsboro, DE) while eighteen chicks 
in the control group were inoculated with PBS. At 7, 14 and 28 days postvaccination 
(pv), six chicks from each group were weighed, blood-sampled by cardiac puncture and 
euthanized by CO2 chamber. Eighteen more chicks were vaccinated by i.p, injection, as 
indicated above, kept under the same conditions and euthanized at 18, 21 and 28 days pv 
for additional antibody assay and virus genome detection by PCR.    
Sampling and cell extraction. The blood samples were collected directly into 
heparinised micro-hematocrit tubes for packed cell volume (PCV) determinations and 
also for white blood cells counts (WBC) and differential analysis. Thymus, spleen, bone 
marrow and bursa were collected under sterile conditions and subjected to lymphocyte 
extraction procedure. Samples of sera and cecal tonsils were also collected and kept 
frozen until tested. Isolation of lymphocytes from spleen, thymus and bursa was 
conducted by mincing each tissues into fragments in RPMI 1640 media (GIBCO, 
Laboratories, Grand Island, NY) supplemented with 20% fetal bovine serum (FBS) and 
antibiotic anti-mycotic solution (GIBCO Laboratories), and then pushing it through a 70 
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µm cell strainer (Falcon Scientific Co, Montreal, Qc, Canada). Lymphocytes from 
the spleen and thymus cell suspensions were further enriched by centrifugation at 2500 
RPM for 20 min on a Lymphoprep gradient (Cedarlane, Hornby, Ont., Canada). The 
recovered lymphocyte layer from spleen and thymus and the original cell suspension 
from bursa samples were washed in fresh media by centrifugation at 1300 RPM for 10 
min. Bone marrow cells were collected from femur in RPMI 1640 with 5% FBS after 
cutting the 2 epiphysis and pushing the media through the medular cavity using a one ml 
insulin syringe. The suspensions were placed on FBS cushion and incubated on ice for 
10 min to remove the debris. The top layer from each bone marrow cell suspension was 
recovered in a fresh tube. The cell suspensions of thymus, spleen, bursa and bone 
marrow suspensions have been enumerated in a hemacytometer with trypan blue 
(Fischer Scientific, Montréal, Qué. Canada), adjusted at 10
6
 viable cells per 1 ml and 
used for different assays.  
Hematology. Peripheral leukocyte analyses such as PCV, WBC and differential 
percentages of heterophils, monocytes, lymphocytes, eosinophils, and basophils were 
performed by May-Grunwald's staining and light microscopic examination.  
Immunolabeling of lymphocyte subsets. The phenotype of lymphocyte 
subpopulations such as CD4+CD8-, CD4-CD8+, CD4+CD8+, CD3-CD8+, CD3-IgM+, 
CD3+TCRγδ+ cells was determined by double immunolabelings (CD4 and CD8, CD3 
and CD8, CD3 and IgM or CD3 and TCRγδ markers) using fluorescein isothiocyanate 
(FITC)-conjugated-anti-CD4, anti-IgM, anti-CD3 or anti TCR-γδ, and phycoerythrine 
(PE)-conjugated-anti-CD8a or anti-CD3 monoclonal antibodies (mAb) (Southern 
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Biotech, Anaheim, CA). For double-staining, for each double staining 1x10
6 
cells 
from thymic, splenic and bursal lymphocyte suspensions were incubated with 1 µg of 
anti-chicken mAbs labelled with FITC or PE for 30 min at 4
o
C. Cells were then washed 
gently three times in RPMI-1640 and cells were fixed overnight at 4oC in PBS, pH 7.2, 
containing 1% formaldehyde (Fischer 21 Scientific). Cytofluorometric analysis of 
positive FITC and PE stained cells was performed on a FACScan cytofluorometer 
(Becton Dickinson, Mountain View, CA) using CellQuest software (Becton Dickinson, 
San Jose, CA). Analysis was done on 10,000 events and discrete viable lymphoid cell 
populations were gated according to forward scatter (FSC) versus 90
o 
angle scatter (SSC) 
parameters. Percentages of different lymphoid cell subpopulations in thymus, spleen and 
bursa, were determined by multiparametric analysis.  
Viral VP3 DNA of CIAV detection by nested PCR. Total DNA was extracted 
from thymus, spleen and bursa, cecal tonsils, bone marrow and liver using Trizol_LS 
Reagent (Life Technologies, Grand Island, NY) according to the manufacturer 
procedure. Bursa tissues were homogenized by beads previous to Trizol extraction. To 
detect the viral genome in the samples, fragments of 374 bp situated between 
nucleotides 472 and 846, and 203 bp situated between nucleotides 588 and 791, were 
targeted to be amplified in conventional and nested PCR respectively. A set of primers 
were designed and used as follow: 
Forward (5’-CTCTCCAAGAAGATACTCCAC-3’), 
Reverse (5’-GCTCGTCTTGCCATCTTA-3’),  
Forward nested (5’-ATCACTCTATCGCTGTGTGG-3’) 
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Reverse nested (5’-GGAGTAGTGGTAATCAAGC-3’). 
PCR program consisted of an initial denaturation at 94˚ C for 5 min, and 35 cycles 
of 94˚ C for 35 sec, 58˚ C for 55 sec, and 72˚C for 1 min followed by a final extension at 
72˚C for 5 min. PCR products were analyzed by electrophoresis on 1.4% agarose gel in 
TAE buffer (40 mM of Tris and 2 mM of EDTA, pH 8.0) containing 0.5 mg/ml of 
ethidium bromide for 60 min at 100 volts and visualized under an ultraviolet light 
transilluminator.   
Specific anti-CIAV antibodies. Specific anti-CIAV antibodies were quantified in 
serum by ELISA using the IDEXX FlockChek* CIAV test Kit and according to the 
manufacturer procedure (IDEXX Laboratories, Inc., Westbrook, MA).  
Statistical analysis. Percentages of blood cells and lymphocytes subsets in 
lymphoid organs from CIAV-vaccinated young birds were compared to those from sham 
birds using Student’s t test. Values of P ≤ 0.05 were considered significant.  
RESULTS  
Hematologic evaluation of CIAV-vaccinated SPF chicks. Thirty-six one-day old 
CIAV vaccinated SPF birds or controls were euthanized at 7, 14 and 28 days pv. Birds in 
both CIAV vaccinated and control groups did not show any clinical signs and anemia 
following vaccination. No weight losses were observed between vaccinated and control 
groups. No thymic atrophy, as revealed by gross examination, was observed in vaccinated 
chicks at various times. The PCV, WBC counts and percentages of lymphocytes in blood of 
CIAV-vaccinated birds did not show any significant variations up to 28 days pv when 
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compared with chicks in control group (Figs 1A, B and D). However, percentage of blood 
heterophils slightly decreased at 14 days pv only in vaccinated chicks (p< 0.05) (Fig. 1C). 
Bone marrow cell numbers were not altered in these chicks (results not shown).  
Persistency of CIAV vaccinal strain in lymphoid organs. The presence of the 
viral VP3 gene of the CIAV vaccinal strain was detected by PCR in thymus, spleen, 
bursa, and cecal tonsils. As shown in Table 1, viral VP3 gene was expressed in the 
thymus of 5 (out of 6) vaccinated birds at day 7 pv. There were not any viral VP3 
positive cases in the thymus samples at 14, 18 and 21 days pv, whereas presence of viral 
genome in thymus was revealed at 28 days pv in 2 of the 12 tested vaccinated chicks. In 
the spleen, the vaccine virus was detected in one chick at 7 days pv and persisted in 
some vaccinated birds until 28 days pv. All other specimens collected from bursa and 
cecal tonsils remained negative for viral DNA. In addition, bone marrow, sera and liver 
were also negative in the carried out nested-PCR (results not shown).  
Analysis of thymic cell subpopulations. To verify whether the viral persistency 
of CIAV genome of vaccinal strain in thymus induces disorders in lymphoid cell 
populations, percentages of the different lymphoid subsets in thymus from CIAV-
vaccinated chicks were compared with control group birds at various time pv. The 
lymphoid cells were isolated from the thymus and double immunolabelled with 
fluorescent antibodies against CD4, CD8, CD3, TCR-γδ and IgM, and analyzed by 
cytofluorometry by comparing the co-expression of markers among the gated cells.   
As shown in Figure 2, percentages of thymic CD4+CD8-, CD4-CD8+ or TCRγδ+ 
cells were not altered in vaccinated chicks and the values were similar to those from 
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control birds (Figs 2A, B and D). The percentages of CD4+CD8+ thymic cells, 
however, slightly decreased after 14 and 28 days in CIAV-vaccinated group (p<0.05) 
(Fig. 2C). No significant modification in percentages of thymic CD3-CD8+, 
corresponding to NK cells, was detected in vaccinated chicks (results not shown).  
To verify if the thymopoiesis was altered by CIAV-vaccination, thymocytes were 
analyzed according to FSC/SSC parameters. Thymocytes were separated in smaller (G1) 
and larger (G2) cells, as shown in the Figure 3. The G1/G2 ratio of thymic cells did not 
significantly differ between CIAV vaccinated or control birds (results not shown). The 
multiparametric analysis of cells within the G1 region revealed the presence of 
CD4+CD8-, CD4+CD8+ and CD4-CD8+ cell subsets (Fig. 3 sect. I, B and E) whereas 
the cells located in G2 area were mostly double positive (CD4+CD8+) cells (Fig.3 sect. 
I, C and F). Percentages of small CD4+CD8+ cells (in G1 area) decreased at 14 and 28 
days pv in the thymus of CIAV-vaccinated birds (p<0.05) (Fig.3 sect. II, A) whereas the 
large CD4+CD8+ cells increased only at 7 days pv (p<0.05) (Fig.3 sect. II, B). 
Percentages of small CD4-CD8+ cells increased at 14 and 28 days pv in CIAV-
vaccinated chicks (p<0.05) (Fig. 3 II, A). Large CD4+CD8- cells transiently decreased 
at 7 days pv (p<0.05) (Fig.3-II-B).  
The intensity of CD4 or CD8 molecules expression in thymocytes may reflect their 
maturation level. Cytofluorometric analysis of CD4 and CD8 expression on thymocytes 
is presented in Figure 4. It revealed that the CD4 expression on thymocytes increased at 
7 days pv (p<0.001) while it decreased at 28 days pv (p<0.05) (Figs 4 A and C). The 
CD8 expression on the thymocytes surface, however, strongly increased in CIAV-
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vaccinated group at 7 days pv (p<0.01) and remained variable until 28 days pv in the 
group of CIAV-vaccinated chicks (Figs 4 B and D).  
Analysis of splenic and bursal lymphocyte subpopulations. In spleen, the 
percentage of CD4 CD8+ cells increased at 28 days pv only (p<0.05) (Fig. 5A) while 
CD4+CD8-cells decreased simultaneously (p<0.05) (Fig.5B) in CIAV-vaccinated 
chicks. The subpopulation of CD4+CD8+ spleen cells exhibited a paramount elevation 
only 7 days after vaccination (p<0.05) (Fig. 5C). The splenic IgM+ B-cells as well as 
TCRγδ cells were not significantly altered following CIAV vaccination (Figs. 5D and 
F). The vaccinated chicks, however, exhibited a higher number of CD3- CD8+ cells 
(corresponding to NK cells) in the spleen at 7 days pv (p<0.05) (Fig. 5E). Nevertheless, 
at 28 days pv, the number of NK cells increased less in CIAV-vaccinated birds than that 
of control group (p<0.05) (Fig. 5E), in spite of the fact that NK cells increased in older 
control birds.  
In the bursa of Fabricius, percentages of CD4-CD8+ cells increased at 7 and 28 
days pv (p<0.05) (Fig.6A) whereas percentages of CD4+CD8-cells simultaneously 
decreased (p<0.05) (Fig. 6B). The number of double positive (CD4+CD8+) bursal cells 
were slightly lowered in CIAV vaccinated group only at 28 days pv (p<0.05) (Fig.6C). 
Percentages of IgM+ bursal lymphocytes were relatively steady until day 28 where the 
percentage of these cells was lower in CIAV-vaccinated chicks (p<0.05) (Fig. 6 D). 
Humoral immune response. The efficiency of the vaccine virus to induce anti-
CIAV antibodies in 1-day old SPF chicks was monitored by ELISA assay. As shown in 
figure 7, the vaccination with the CIAV-VAC
® 
did not produce a notable humoral 
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response in the majority of the vaccinated chicks when administered at hatch. 
Among the 30 vaccinated birds sampled at 5 different times pi, the anti CIAV titers were 
detected in 1, 3 and 1 chicks at 7, 14 and 18 dpi respectively. The anti-CIAV antibodies 
did not persist up to 18 days pv in seropositive chicks.   
DISCUSSION  
In this work, we report that commercial CIAV-vaccinal strain induces a subclinical 
infection in one-day old chicks associated with viral persistency in spleen and thymus, 
transient humoral response and alterations in thymopoiesis.  
Clinical signs of CIAV infection in very young chicken are characterized by 
anorexia, depression, pallor, and decrease of weight gain, hematocrit and white blood 
cells especially blood lymphocytes and heterophils. Pale bone marrow and atrophy of 
thymus, spleen and bursal reflect depletion of T and B cells predisposing the birds to 
secondary infections (reviewed in Todd, 2004). CIAV-infection in one-day-old SPF 
chicks rendered them anaemic with depleted bone marrow and thymus at 14 days post-
infection (Yuasa & Imai, 1986).  
The attenuated CIAV strains are commercially used as vaccine but some technical 
and practical problems affect the widespread use of vaccines (reviewed in Schat, 2009). 
In this work, we addressed whether a commercial vaccinal strain may retain the ability 
to induce disorders in percentages of thymus and spleen cells and on thymopoiesis as the 
pathogenic CIAV strain. We have shown that a commercial attenuated CAV-VAC
® 
did 
not induce clinical signs in one-day old chicks, did not significantly decrease total white 
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blood cells in spite of low significant decrease of heterophil percentage at 14 days 
only, and induced no significant cell depletion in thymus, spleen, bursa and bone 
marrow. The transient decrease in percentage of heterophils may reflect either cell 
recruitment in infected organs or a low decrease in myelopoiesis. However, the absence 
of anemia and no bone marrow cell depletion do not support the second hypothesis. 
These observations are in agreement with those reported by McKenna et al. (2003), who 
have shown that some attenuated CIAV strains may induce subclinical infection with no 
anemia and no or low mild lesions. 
Replication of the vaccinal virus strain tested in our work was detected in thymus 
in most of vaccinated chicks, at 7 days pv only, indicating that viral replication rapidly 
aborted in the thymus, reflecting the attenuation of this viral strain. Kaffashi et al. (2006) 
have demonstrated that pathogenic CIAV can replicate in many organs, both in one-day 
old or 6 week-old infected chicks, up to day 18 pi and reached a peak in the thymus, 
spleen and liver at 18 or 20 days p.i. At 28 days pv, however, VP3 gene was still 
observed in the thymus of some birds, indicating a viral persistency. Hu et al. (1993a) 
showed that persistent viremia occurs in CIAV-infected birds in the absence of antibody 
production. The viral persistency of pathogenic CIAV was confirmed by Imai et al. 
(1999) who suggested that CIAV can induce persistent infection in infected birds. The 
detection of VP3 gene in total DNA cannot permit to clearly distinguish between viral 
replication or integrated viral DNA in cellular genome. However, porcine circoviruses 
can persist in infected cells but they are not endogeneous as retroviruses (Victoria et al. 
2010).  
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The replication of vaccinal strain in thymus and its persistency in some birds 
suggest the occurrence of thymopoiesis disorders, as previously reported in the thymus 
of pathogenic CIAV- infected birds (Jeurissen et al., 1989; Kuscu & Gurel, 2008). The 
cytofluorometric analysis of thymocytes subsets from CIAV-vaccinated birds revealed 
that larger CD4+CD8+ thymic cells and he expression levels of CD4 and CD8 on 
thymocytes increased but were followed by a relative decrease of CD4+CD8+ cells in 
spite of no significant decrease in total thymic cells, suggesting that replication of 
vaccinal strain slightly alter the thymocyte maturation process or that mature antiviral 
CD4+CD8- and CD4-CD8+ cells were recruited in the thymus from blood and spleen. 
The absence of significant changes in percentages of CD4+CD8-or TCR-γδ cells and the 
slight increase of CD4- CD8+ cells do not support the second hypothesis. On the other 
hand, the discrimination between dividing cells and resting cells by the FSS/SCC 
parameters revealed that smaller thymic CD4+CD8+ cells were depleted in vaccinated 
chicks, suggesting that viral infection can block the cell mitosis. Infection of T cell 
precursor in the thymus and inhibition of anaphase-promoting complex/cyclosome by 
the viral apoptin which leads to G2/M arrest and apoptosis has already been reported in 
pathogenic CIAV infection (Teodoro et al. 2004).   
The analysis of the expression intensity of CD4 and CD8 markers revealed that 
CD4 expression, but not CD8, was diminished in thymocytes suggesting that vaccinal 
strain of CIAV may specifically interfere with CD4+ expression leading to decrease in 
percentage of small CD4+CD8+ cells. The specific decrease of CD4 expression on 
thymocytes by CIAV viral infection has never been reported. However, the T helper 
subset is known to be a target cells in spleen for the CIAV (Adair et al., 1993). Hu et al. 
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(1993b) demonstrated that percentages of both CD4+ and CD8+ thymic cells 
similarly decreased in the thymus of one-day-old chicks infected with the pathogenic 
CIAV (CIA-1 strain) due to cell destruction by viral infection or interference with CD4+ 
and CD8+ expression. The CD4+CD8+ cell subset, however, represents the most 
important population in the thymus, and a decrease of CD4+ cells would involve also a 
decrease in CD8+ cells. The decrease of CD4 expression only in thymic cells induced by 
the attenuated vaccinal CIAV strain rather revealed a discrimination between the 
thymocyte subsets expressing CD4 and/or CD8. It is well-known that the thymic CD4 
CD8+ cell subset occurs earlier than the CD4+CD8-or CD4+CD8+ cell subsets during 
the avian thymopoiesis (Davidson et al. 1992). In consequence, the lower expression of 
CD4+ in presence of higher expression of CD8 may reflect the accumulation of CD4-
CD8+ cells rather than a differential decrease in CD4+ expressing thymocytes. The 
decreases in CD4+CD8+ cells observed at 14 and 28 days pv indicate that thymocyte 
precursors can support the replication of the CIAV vaccinal strain, as confirmed by VP3 
gene presence in the thymus of some birds at 28 days pv, such as seen with pathogenic 
CIAV (reviewed in Schat, 2009). 
Contrary to that seen in thymus, VP3 gene is gradually expressed in spleen of 
vaccinated-one-day old chicks with time. The percentage of splenic CD4-CD8+ cells 
increased while CD4+ CD8-cells decreased at 28 days pv only, such as seen in the 
thymus, suggesting the occurrence of a delayed cytotoxic T lymphocyte (CTL) immune 
response. However, the CTL response cannot favour totally the viral elimination. 
Markowski-Grimsrud and Schat (2003) have demonstrated that CIAV-infected chicks 
without anti-CIAV maternal antibodies have lost the ability to mount a CTL response at 
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7 days post-infection (pi) against secondary viral infections, suggesting that CIAV 
can impair the CTL functions. Adair et al. (1991) have shown that IFN-γ production 
decreased after up to 43 days pi in CIAV infection, indicating a suppression of CTL 
response. We have not observed any increase in the IFNγ production in CIAV-
vaccinated chicks (results not shown), suggesting that CD8+-dependent cytotoxic 
function is not strongly stimulated by viral vaccination. In addition, no significant 
stimulation of lymphocytes to ConA has been detected in thymic or splenic cells from 
CIAV vaccinated chicks (results not shown); supporting the hypothesis that vaccination 
did not strongly stimulate the lymphocyte activity. Depressed responsiveness of 
lymphocytes to mitogens following CIAV infection has been well-documented (Adair et 
al., 1991; Bounous et al., 1995; McConnell, 1993; Otaki et al., 1988).  
Transient increase of CD3-CD8+ (NK cells) suggests the occurrence of an innate 
antiviral immune response. It was previously demonstrated that pathogenic CIAV did 
not alter the NK cell activity (Markowsi-Grimsrud & Schat, 2001).  
Finally, the percentage increases of CD4-CD8+ cells in the bursa of Fabricius 
correlated with concurrent decreases of CD4+CD8-cells suggesting that these 
modifications reflect the thymus disorders rather than a specific viral replication. No 
VP3 gene presence was detected in bursa or cecal tonsils. However, the late decrease of 
IgM+ cells and low and transient humoral immune responses following the CIAV-VAC
® 
administration suggest disorders in B cell-dependent immunity. It is well-known that the 
infection with pathogenic CIAV strain triggers antibody production in immunologically 
mature chicken which mediates the age-related resistance to the virus. It was previously 
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reported that pathogenic CIAV was recovered from blood cells or lymphoid 
organs of infected birds at different days pi even in the presence of low or high viral 
neutralizing antibodies (Imai et al., 1999; Yuasa et al., 1983). We can hypothesize that 
incompetent immune system of the very young chicks favours decrease of the CD4+ 
cells in the thymus and spleen, decrease in percentage of IgM+ B cells, low antibody 
response and persistency of vaccinal strain in thymus and spleen.  
The virus persistence and the lymphoid disorders induced by the CIAV vaccine 
virus in very young birds lead to practical consequences and may potentially play an 
important role in the sub clinical infections and decreased responsiveness to other avian 
pathogens in the poultry industry.  
Work is in progress to determine the effects of infection with vaccinal CIAV strain 
on efficiency of bursal viral disease vaccination in young chicks.  
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Table 1. Detection of CIAV vaccinal virus genome in thymus, spleen, bursa of 
Fabricius and cecal tonsils in CIAV-vaccinated and control groups of chicks at 7 to 28 
days postvaccination. 
 
a
Groups of 6 chicks were inoculated by CIAV-VAC
® 
or PBS at hatch, euthanized at various 
times postvaccination and organs were sampled. VP3 gene expression was detected by 
polymerase chain reaction (PCR).  
b
Number positive/number tested  
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Figure 1: Hematological examination of blood from CIAV-vaccinated SPF chicks at 
hatch. Hematocrit (PCV) (A), white blood cell count (WBC) (B), percentages of 
heterophils (C) and lymphocytes (D) in the blood of CIAV-vaccinated () and control 
birds () were determined at 7, 14 and 28 days post-vaccination. The mean of each 
value for vaccinated and control birds (n=6) were calculated and compared. * p≤ 0.05  
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Figure 2: Percentages of lymphocyte subpopulations in thymus of SPF chicks at 7, 14 
and 28 days following CIAV vaccination at hatch. Thymocytes from CIAV-vaccinated 
() and control birds () were double labeled with anti-CD4, anti-CD8, anti-TCRγδ 
conjugated to FITC or PE and analyzed in cytofluorometry.  The mean percentage of 
thymic CD4+CD8- (A), CD4-CD8+ (B), CD4+CD8+ (C) and TCRγδ+ (D) 
subpopulations for CIAV-vaccinated and control groups (n=6) were calculated and 
compared. * p≤ 0.05.  
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Figure 3: Analysis of small and large lymphocyte subpopulations in thymus of SPF 
chicks at 7, 14 and 28 days following CIAV vaccination at hatch. Thymocytes from 
CIAV-vaccinated () and control birds () were double labeled with anti-CD4, anti-
CD8, anti-TCRγδ conjugated to FITC or PE and analyzed in cytofluorometry.  
I. Thymocytes were separated in small (G1 area) and large (G2 area) cells according to 
FSC/SSC parameters: In control (A) and CIAV-vaccinated (D) groups of birds; 
multipparametric analyysis of CD4/CD8 small (Band E) and largger (C and F) 
thymocytes are shown.  
II. Percentages of small (A) and large (B) cell subpopulations in thymus from control 
and CIAV-vaccinated groups at various days postvaccination.  
* p≤ 0.05.  
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 Figure 4: Analysis of relative expression of CD4 and CD8 molecules on thymocytes 
from CIAV-vaccinated and control groups at various times postvaccination. The lines 
illustrate the intensity of CD4 (A) or CD8 (B) molecules on thymocytes of one control 
and CIAV-vaccinated bird. Thymocytes from CIAV-vaccinated () and control birds 
() were double labeled with anti-CD4 and anti-CD8, conjugated to FITC and PE, and 
analyzed in cytofluorometry. The relative expression levels of CD4 (C) and CD8 (D) 
were compared on thymocytes from each groups (n=6) of birds at 7, 14 and 28 days 
postvaccination. * p≤ 0.05,  ** p≤ 0.01.  
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Figure 5: Percentages of lymphocyte subpopulations in spleen of SPF chicks at 7, 14 
and 28 days following CIAV vaccination at hatch. Splenic cells from CIAV-vaccinated 
() and control birds () were double labeled with anti-CD4, anti-CD8, anti-TCRgd, 
anti-IgM, and anti-CD3 conjugated to FITC or PE and analyzed in cytofluorometry.  The 
mean percentage of splenic CD4-CD8+ (A), CD4+CD8-(B), CD4+CD8+ (C), IgM+ 
(D), CD3-CD8+ (E) and TCRγδ+ (D) subpopulations for CIAV-vaccinated and control 
groups (n=6) were calculated and compared. * p≤ 0.05.  
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Figure 6: Percentages of lymphocyte subpopulations in bursa of Fabricius of SPF chicks 
at 7, 14 and 28 days following CIAV¸vaccination at hatch. Lymphoid cells from CIAV-
vaccinated () and control birds () were double labeled with anti-CD4, anti-CD8, 
anti-IgM conjugated to FITC or PE and analyzed in cytofluorometry.  The mean 
percentage of bursal CD4-CD8+ (A), CD4+CD8- (B), CD4+CD8+ (C) and IgM+ (D) 
subpopulations for CIAV-vaccinated and control groups (n=6) were calculated and 
compared.  * p≤ 0.05;  ** p≤ 0.01.  
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Figure 7: Anti-CIAV antibody titers after vaccination of one-day-old SPF chicks by 
CIAV-VAC®. Serum samples from CIAV-vaccinated and control group were tested for 
anti-CIAV antibodies at 7, 14, 18, 21 and 28 days postvaccination by ELISA test.  
Each point represents the ELISA titer of one chick tested. The line corresponds to the 
negative threshold .tested. 
 
 
 
   
  
Other results of this work including “effects of a low-virulent IBDV infection on 
immune responses and viral persistency of CIAV-vaccinated SPF and commercial 
chicks” are in preparation process and will be published soon.   
  
